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A B S T R A C T
Background
Axillary surgery is an established part of the management of primary breast cancer. It provides staging information to guide adjuvant
therapy and potentially local control of axillary disease. Several alternative approaches to axillary surgery are available, most of which
aim to spare a proportion of women the morbidity of complete axillary dissection.
Objectives
To assess the benefits and harms of alternative approaches to axillary surgery (including omitting such surgery altogether) in terms of
overall survival; local, regional and distant recurrences; and adverse events.
Search methods
We searched the Cochrane Breast Cancer Group Specialised Register, MEDLINE, Pre-MEDLINE, Embase, CENTRAL, the World
Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov on 12 March 2015 without language
restrictions. We also contacted study authors and checked reference lists.
Selection criteria
Randomised controlled trials (RCTs) including women with clinically defined operable primary breast cancer conducted to compare
axillary lymph node dissection (ALND) with no axillary surgery, axillary sampling or sentinel lymph node biopsy (SLNB); RCTs
comparing axillary sampling with SLNB or no axillary surgery; RCTs comparing SLNB with no axillary surgery; and RCTs comparing
ALND with or without radiotherapy (RT) versus RT alone.
Data collection and analysis
Two review authors independently assessed each potentially relevant trial for inclusion. We independently extracted outcome data, risk
of bias information and study characteristics from all included trials. We pooled data according to trial interventions, and we used
hazard ratios (HRs) for time-to-event outcomes and odds ratios (OR) for binary outcomes.
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Main results
We included 26 RCTs in this review. Studies were at low or unclear risk of selection bias. Blinding was not done, but this was only
considered a source of bias for outcomes with potential for subjectivity in measurements. We found no RCTs of axillary sampling versus
SLNB, axillary sampling versus no axillary surgery or SLNB versus no axillary surgery.
No axillary surgery versus ALND
Ten trials involving 3849 participants compared no axillary surgery versus ALND. Moderate quality evidence showed no important
differences between overall survival of women in the two groups (HR1.06, 95%confidence interval (CI) 0.96 to 1.17; 3849 participants;
10 studies) although no axillary surgery increased the risk of locoregional recurrence (HR ranging from 1.10 to 3.06; 20,863 person-
years of follow-up; four studies). It was uncertain whether no surgery increased the risk of distant metastasis compared with ALND
(HR 1.06, 95% CI 0.87 to 1.30; 946 participants; two studies). Low-quality evidence indicated no axillary surgery decreased the risk
of lymphoedema compared with ALND (OR 0.31, 95% CI 0.23 to 0.43; 1714 participants; four studies).
Axillary sampling versus ALND
Six trials involving 1559 participants compared axillary sampling versus ALND. Low-quality evidence indicated similar effectiveness
of axillary sampling compared with ALND in terms of overall survival (HR 0.94, 95% CI 0.73 to 1.21; 967 participants; three studies)
but it was unclear whether axillary sampling led to increased risk of local recurrence compared with ALND (HR 1.41, 95% CI 0.94
to 2.12; 1404 participants; three studies). The relative effectiveness of axillary sampling and ALND for locoregional recurrence (HR
0.74, 95% CI 0.46 to 1.20; 406 participants; one study) and distant metastasis was uncertain (HR 1.05, 95% CI 0.74 to 1.49; 406
participants; one study). Lymphoedema was less likely after axillary sampling than after ALND (OR 0.32, 95% CI 0.13 to 0.81; 80
participants; one study).
SLNB versus ALND
Seven trials involving 9426 participants compared SLNB with ALND. Moderate-quality evidence showed similar overall survival
following SLNB compared with ALND (HR 1.05, 95% CI 0.89 to 1.25; 6352 participants; three studies; moderate-quality evidence).
Differences in local recurrence (HR 0.94, 95% CI 0.24 to 3.77; 516 participants; one study), locoregional recurrence (HR 0.96, 95%
CI 0.74 to 1.24; 5611 participants; one study) and distant metastasis (HR 0.80, 95% CI 0.42 to 1.53; 516 participants; one study)
were uncertain. However, studies showed little absolute difference in the aforementioned outcomes. Lymphoedema was less likely after
SLNB than ALND (OR ranged from 0.04 to 0.60; three studies; 1965 participants; low-quality evidence). Three studies including
1755 participants reported quality of life: Investigators in two studies found quality of life better after SLNB than ALND, and in the
other study observed no difference.
RT versus ALND
Four trials involving 2585 participants compared RT alone with ALND (with or without RT). High-quality evidence indicated that
overall survival was reduced among women treated with radiotherapy alone compared with those treated with ALND (HR 1.10, 95%
CI 1.00 to 1.21; 2469 participants; four studies), and local recurrence was less likely in women treated with radiotherapy than in those
treated with ALND (HR 0.80, 95% CI 0.64 to 0.99; 22,256 person-years of follow-up; four studies). Risk of distant metastasis was
similar for radiotherapy alone as for ALND (HR 1.07, 95% CI 0.93 to 1.25; 1313 participants; one study), and whether lymphoedema
was less likely after RT alone than ALND remained uncertain (OR 0.47, 95% CI 0.16 to 1.44; 200 participants; one study).
Less surgery versus ALND
When combining results from all trials, treatment involving less surgery was associated with reduced overall survival compared with
ALND (HR 1.08, 95% CI 1.01 to 1.17; 6478 participants; 18 studies). Whether local recurrence was reduced with less axillary surgery
when compared with ALND was uncertain (HR 0.90, 95% CI 0.75 to 1.09; 24,176 participant-years of follow up; eight studies).
Locoregional recurrence was more likely with less surgery than with ALND (HR 1.53, 95% CI 1.31 to 1.78; 26,880 participant-
years of follow-up; seven studies). Whether risk of distant metastasis was increased after less axillary surgery compared with ALND was
uncertain (HR 1.07, 95% CI 0.95 to 1.20; 2665 participants; five studies). Lymphoedema was less likely after less axillary surgery than
with ALND (OR 0.37, 95% CI 0.29 to 0.46; 3964 participants; nine studies).
No studies reported on disease control in the axilla.
Authors’ conclusions
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This review confirms the benefit of SLNB and axillary sampling as alternatives to ALND for axillary staging, supporting the view that
ALND of the clinically and radiologically uninvolved axilla is no longer acceptable practice in people with breast cancer.
P L A I N L A N G U A G E S U M M A R Y
Surgical removal of underarm lymph nodes in breast cancer
Review question
This review aimed to compare the benefits of surgical removal of underarm lymph nodes with the potential harms associated with this
surgical procedure. The review also aimed to learn whether complete removal of all underarm nodes could be replaced by procedures
that remove only a small number of lymph nodes.
Background
Surgical removal of underarm (axillary) lymph nodes is often part of the initial surgical treatment for patients with operable breast
cancer. If cancer has spread to these lymph nodes, patients are advised to undergo additional treatments, such as chemotherapy or
radiotherapy, to help treat their disease. If cancer has not spread to these lymph nodes, patients are spared extra treatments (with extra
side effects). Surgical removal of lymph nodes can lead to short-term surgical complications (such as infection and wound healing
problems) and long-term problems (such as shoulder stiffness, pain and arm swelling (lymphoedema)) when fluid accumulation causes
restricted function and discomfort.
Modern strategies use a stepwise approach by first removing a small number of nodes and removing the others only if cancer is found
at the first stage. This first stage can consist of ‘random’ axillary sampling, whereby the surgeon removes a small number of nodes
(typically four) that can be felt. Alternatively, surgeons can use sentinel node techniques to identify those nodes most likely to contain
cancer, leading to removal of as few nodes as possible. For patients with cancer in the sentinel nodes (or sample), complete removal of
all underarm lymph nodes (axillary lymph node dissection) is usually recommended; however, radiotherapy to the axilla can also be
given to obliterate any cancer cells in the lymph nodes. Some studies have explored alternative approaches such as no surgical treatment
to the underarm nodes.
Study characteristics
The evidence is current to March 2015. The review identified 26 randomised controlled trials that compared axillary lymph node
dissection (ALND) with alternative approaches involving less axillary surgery. Patients in these trials had operable primary breast cancer,
and some trials included patients with palpably enlarged axillary lymph nodes. Ten trials including 3849 patients compared ALND
with no axillary surgery. Six trials including 1559 patients compared ALNDwith axillary sampling. Seven trials including 9426 patients
compared ALND with sentinel lymph node biopsy (SLNB). Four trials including 2585 patients compared ALND (with or without
radiotherapy) with radiotherapy alone.
Key results
Moderate-quality evidence suggests that patients treated with approaches involving lesser axillary surgery (such as axillary sampling
or SLNB) do not have a reduced chance of survival compared with those treated with ALND. Moderate-quality evidence indicates
that overall survival is slightly reduced in patients who receive radiotherapy (but no axillary surgery) when compared with ALND. If
survival is assumed to be 81% five years after surgery with ALND, then the evidence suggests it would be between 77% and 81% after
treatment with radiotherapy alone.
Moderate-quality evidence suggests that patients who have no axillary lymph nodes removed at all are at increased risk of locoregional
recurrence (regrowth of cancer, in the breast, mastectomy scar area or underarm glands). If it is assumed that 86% of patients receiving
ALND are free of locoregional recurrence five years after surgery, evidence suggests that the corresponding figure for patients who have
no lymph nodes removed at all would be between 66% and 76%. For patients treated with axillary sampling, low-quality evidence
suggests that between 73% and 87% would be free of locoregional recurrence at five years.
Axillary recurrence rates were reported only in SLNB versus ALND trials, and researchers remain uncertain about the best treatment
for this outcome because rates were very low (occurring in less than 1% of patients).
Low-quality evidence suggests that patients treated with ALND are at increased risk of lymphoedema compared with those treated
with SLNB or no axillary surgery. On the basis of this evidence, we would expect that out of every 1000 patients receiving ALND, 132
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would experience lymphoedema at one year after surgery, compared with between 22 and 115 of those receiving SLNB. Other long-
term harms such as pain, impaired arm movement and numbness were also more likely with ALND than with SLNB.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
No axillary surgery compared with full axillary surgery for operable primary breast cancer
Patient or population: women with operable primary breast cancer
Settings: hospital
Intervention: no axillary surgery
Comparison: f ull axillary surgery
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Full axillary surgery No axillary surgery
All- cause mortality 92% overall survival at 5
yearsa
92% overall survival at 5
years
(91% to 93%)
HR 1.06
(0.96 to 1.17)
3849
(10 studies)
⊕⊕⊕©
moderateb
Locoregional recurrence 86% locoregional recur-
rence- free survival at 5
yearsc
71% locoregional recur-
rence- free survival at 5
years
(66% to 76%)
HR 2.35
(1.91 to 2.89)
20,863d
(5 studies)
⊕⊕⊕©
moderatee
Lymphoedema
Increase in arm circumfer-
ence
Follow-up: 1 or more years
236 per 1000 87 per 1000
(66 to 117)
OR 0.31
(0.23 to 0.43)
1714
(4 studies)
⊕⊕©©
lowe,f
Arm or shoulder movement
impairment
Follow-up: 1 or more years
91 per 1000 67 per 1000
(47 to 95)
OR 0.72
(0.49 to 1.05)
1495
(5 studies)
⊕©©©
very lowf,g
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HR: hazard rat io; OR: odds rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aAssumed risk is taken f rom full axillary surgery arm of Inst itut Curie.
bConf idence interval around the ef fect est imate includes both no ef fect and appreciable harm associated with no axillary
surgery.
cAssumed risk is taken f rom full axillary surgery arm of Inst itut Curie, local or axillary recurrence rates.
dPerson-years of follow-up.
eSubstant ial heterogeneity (I2 > 50%).
f Unclear blinding of outcome assessment.
gConsiderable heterogeneity (I2 > 75%).
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B A C K G R O U N D
Description of the condition
Invasive breast cancer occurswhenuncontrolled, abnormal growth
and division of cells in the lobules or ducts of the breast spreads to
surrounding tissue. The Union Internationale Contre le Cancer
staging system for breast cancer (UICC 1987) reflects how, when
left untreated, cancer cells may spread locally to breast tissue and
lymph glands in the axilla (stages I to III) and through the blood-
stream and lymphatic system to other parts of the body (stage IV).
Description of the intervention
Removal of regional lymph nodes during attempts to achieve a cu-
rative excision for management of most cancers has a long history
(Halsted 1895). Its aim consists of both local control of axillary
disease and determination of stage to permit appropriate adju-
vant therapy. Axillary surgery is a key component of breast cancer
management, with UK clinical guidelines specifying that minimal
surgery (preferably sentinel lymph node biopsy (SLNB)) should
be performed to stage the axilla for patients with early invasive
breast cancer and clinically negative axillary lymph nodes (NICE
2009).
Several alternative approaches to axillary surgery may be used.
1. Axillary clearance - removal of all nodal tissue in the axilla
by dissection up to the level of the axillary vein (Craig 1998) -
was previously the standard practice in many units. Full axillary
clearance carries increased morbidity when compared with breast
surgery alone, with 10% to 15% incidence of chronic arm
lymphoedema (Kissin 1986), 9% incidence of late seroma, 2.2%
infection rate, 12% breast oedema and 0.3% risk of damage to
the long thoracic nerve (Senofski 1991). Other problems include
shoulder stiffness (“frozen shoulder”), which can be severe
(Kissin 1986). Immediate axillary node clearance is not
considered appropriate in the absence of evidence of cancer
spread determined by biopsy before surgery.
2. Axillary node sampling - removal of four or five axillary
nodes from the lower axilla (Craig 1998) - involves removal of
individual nodes, leaving axillary fat and most nodes and
lymphatics intact. As a result, virtually none of the complications
listed for axillary clearance are associated with this procedure.
Women whose sampled axillary nodes contain cancer may need
subsequent axillary clearance or radiotherapy. This previously
popular approach was once considered appropriate.
3. Sentinel lymph node biopsy (Kelley 1998) - a procedure in
which the lymphatic pathway from the site of breast cancer is
tracked with the use of a radio-isotope or blue lymphatic dye -
allows biopsy of the first lymph node or nodes (sentinel node).
Sentinel nodes are most likely to involve spread of cancer, and
this approach allows accurate assessment of whether the cancer
has spread along with removal of a small number of nodes
(typically three or fewer).
4. In some patients who are not candidates for adjuvant
therapies, surgeons may omit axillary surgery altogether to avoid
additional morbidity (EBCTCG 1998, Walsh 1989). This has
led some surgeons to spare some frail women with breast cancer
from undergoing staging of the clinically uninvolved axilla by
means of sentinel node biopsy or full clearance (Yancik 1989).
How the intervention might work
Removal of axillary nodes can improve local control of axillary
disease while providing information on cancer stage that can be
used to guide adjuvant therapy.
Why it is important to do this review
Arguments for and against each of these procedures are compli-
cated and, as a result, practice is variable. Statistical synthesis of
outcomes for these procedures will offer surgeons and patients a
more reliable evidence base on which they can make difficult de-
cisions concerning treatment.
O B J E C T I V E S
To assess the benefits and harms of alternative approaches to axil-
lary surgery (including omitting such surgery altogether) in terms
of overall survival; local, regional and distant recurrences; and ad-
verse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials.
Types of participants
Women with clinically defined operable primary breast cancer,
that is, primary tumour not fixed to underlying structures (in-
cludes tumour-node-metastasis (TNM) classifications T1-3 and
T4b with only minor skin involvement, N0-1 and M0) nor to
mobile lymph nodes (UICC 1987).
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Types of interventions
1. Axillary lymph node dissection (ALND) versus no axillary
surgery at the time of primary surgery
i) With the following subgroups for both arms:
a) Radiotherapy
b) No radiotherapy
2. ALND versus axillary sampling at the time of primary
surgery
i) With the following subgroups for both arms:
a) Radiotherapy
b) No radiotherapy
ii) And the following subgroups for the limited axillary
staging arm:
a) Further treatment for histologically node-positive
cases
b) No further treatment for histologically node-
positive cases
3. ALND versus SLNB at the time of primary surgery
i) With the following subgroups for both arms:
a) Radiotherapy
b) No radiotherapy
ii) And the following subgroups for the limited axillary
staging arm:
a) Further treatment for histologically node-positive
cases
b) No further treatment for histologically node-
positive cases
4. Axillary sampling versus sentinel node biopsy at the time of
primary surgery
i) With the following subgroups for both arms:
a) Radiotherapy
b) No radiotherapy
ii) And the following subgroups for both arms:
a) Further treatment for histologically node-positive
cases
b) No further treatment for histologically node-
positive cases
5. Axillary sampling versus no axillary surgery at the time of
primary surgery
i) With the following subgroups for both arms:
a) Radiotherapy
b) No radiotherapy
ii) And the following subgroups for the limited axillary
staging arm:
a) Further treatment for histologically node-positive
cases
b) No further treatment for histologically node-
positive cases
6. SLNB versus no axillary surgery at the time of primary
surgery
i) With the following subgroups for both arms
a) Radiotherapy
b) No radiotherapy
ii) And the following subgroups for the limited axillary
staging arm:
a) Further treatment for histologically node-positive
cases
b) No further treatment for histologically node-
positive cases
7. ALND with no radiotherapy versus no axillary surgery with
radiotherapy
i) With no subgroups
For all studies involving full axillary surgery or axillary sampling,
the number of nodes removed and the method of node analysis
used were recorded when available, to indicate whether an ade-
quate sampling or clearance procedure was performed.
Types of outcome measures
Primary outcomes
1. Survival - overall (interval between start of treatment or
randomisation and death)
2. Disease control in the axilla (interval between start of
treatment and the need for second-line treatment or palliative
treatment or regional recurrence in the axilla)
3. Breast cancer recurrence, either locally within the breast
(local recurrence) or distantly as metastatic disease (distant
recurrence), with time to recurrence and site of recurrence
recorded
4. Adverse events (surgical complications) including acute
local surgical complications, such as haematoma, infection,
wound dehiscence or seroma, and acute systemic complications,
such as chest infection, deep venous thrombosis, pulmonary
embolism, cardiac failure, cardiac ischaemia and cerebrovascular
accident
5. Long-term complications including lymphoedema,
shoulder stiffness, paraesthesia, pain, loss of functional capacity,
winging of scapula and wound contracture or scarring
Secondary outcomes
1. Quality of life (measured on a validated scale)
2. Psychological and psychosocial variables (measured on
validated scales)
Search methods for identification of studies
Electronic searches
The Trials Search Co-ordinator for the Cochrane Breast Cancer
Review Group searched the Specialised Register of the Group on
16 March 2015. Details of sources and search strategies used to
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populate this register are provided in the Group module in the
Cochrane Library (http://onlinelibrary.wiley.com/o/cochrane/
clabout/articles/BREASTCA/frame.html) . We have extracted for
consideration studies coded as “AXILLARY NODE(S)”, “EARLY
BREAST CANCER”, “LOCALLY ADVANCED BREAST
CANCER”, “PSYCHOSOCIAL” or “SURGERY” on the Spe-
cialised Register.
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL; Issue 2) in the Cochrane Library on 16March 2015.
See Appendix 1 for the search strategy used.
In addition, an information specialist searched the following
databases while using the search terms and strategy identified in
Appendix 2: MEDLINE via OvidSP (2007 to 12 March 2015),
PreMEDLINE via OvidSP (12 March 2015) and Embase via
OvidSP (2002 to 12 March 2015). We used a validated fil-
ter to identify reports of RCTs in our initial search of MED-
LINE (Lefebvre 2001), and for updated searches, we used the re-
vised filter (Lefebvre 2011). We used the Scottish Intercollegiate
Guidelines Network RCT filter in our search of Embase (http://
www.sign.ac.uk/methodology/filters.html).
We also searched on 16 March 2015 the World Health Organiza-
tion International Clinical Trials Registry Portal (WHO ICTRP)
(Appendix 3) and ClinicalTrials.gov (Appendix 4), for prospec-
tively registered and ongoing trials.
Searching other resources
We searched (on 12 March 2015) conference proceedings from
the American Society of Clinical Oncology (ASCO) 41st to 50th
Annual Meetings (2005 to 2014) via Journal of Clinical Oncol-
ogy (http://jco.ascopubs.org/site/meetings). We also searched (on
12 March 2015) conference proceedings from the San Anto-
nio Breast Cancer (SABCS) 29th to 37th Annual Symposium
Meetings (2006 to 2014) via the Cancer Research website (http://
cancerres.aacrjournals.org/).
We contacted the authors of included and ongoing trials by email
and asked them if they knew of any relevant studies. This yielded
no additional studies. We also checked the reference lists of in-
cluded studies and published reviews to look for relevant studies.
Data collection and analysis
Selection of studies
Two review authors (NB, MSH or MA) screened the titles and
abstracts of references identified by electronic searches to identify
publications of potentially eligible trials. We obtained a copy of
the full-text article for each reference reporting a potentially el-
igible trial, and we applied the review selection criteria to each
trial. We reported all exclusions of potentially eligible trials in
the PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) diagram (Figure 1) and, in some cases, in the
Characteristics of excluded studies table. We used trial publica-
tions to assess each trial’s eligibility, and for unpublished trials, we
obtained information from the trial protocol or the next best avail-
able resource. When necessary and possible, we sought additional
information from the principal investigator. Two review authors
(NB, MSH or MA) independently assessed each potentially eligi-
ble trial for inclusion in the review and resolved discrepancies in
eligibility judgements by discussion.
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Figure 1. Study flow diagram.
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Data extraction and management
We extracted data from published trial reports and entered them
onto an electronic form (using Microsoft Word). Two review au-
thors (NB, MSH or MA) independently extracted data from each
trial and resolved disagreements regarding data extraction by dis-
cussion. The Early Breast Cancer Trialists’ Collaborative Group
(Clarke 2005) has published a meta-analysis based on individual
participant data formany of the included trials.We used thismeta-
analysis as an additional source of outcome data for trials included
in this review.
We contacted the authors of included and ongoing trials by email
and asked them to share unpublished data from their trials and to
clarify details about their trial that were unclear or missing from
the published reports.
Assessment of risk of bias in included studies
We assessed the risk of bias of included studies by applying
standard Cochrane methods for randomised trials as outlined in
Higgins 2011. We assessed selection bias (random sequence gen-
eration, allocation concealment; two items) and reporting bias
(selective reporting; one item) at study level, and detection bias
(blinding of outcome assessment; one item) and attrition bias (in-
complete outcome data; one item) at outcome level. We did not
assess detection bias for the outcome of survival because this in an
objective outcome, and we did not assess performance bias (one
item) because blinding of healthcare personnel and participants is
not possible for the interventions considered in this review.
Measures of treatment effect
For dichotomous data, we used odds ratio (OR) as the measure
of treatment effect. For continuous data, we used the standard-
ised mean difference (SMD). For time-to-event (survival) data,
we used the hazard ratio (HR). For our meta-analysis of time-to-
event outcomes in Review Manager 5.3 (RevMan), we used ’O-E’
(observed minus expected) and ’V’ (variance) statistics or hazard
ratios for each trial. If these values were not reported for a given
trial, we calculated them from available statistics, if possible, using
the methods described in Tierney 2007.
Unit of analysis issues
Some trials performed serial measurements of arm volume and/
or function over the first months and years after surgery. For our
analysis, we used themeasurement at one year post operation (or at
the nearest time point after one year for trials not reporting data at
the one-year time point). One trial (NSABP B-04) included three
treatment comparison groups. This presented an issue only for
analysis of less versus more axillary surgery (Analysis 5.1); to avoid
double-counting of the ALND group, we omitted the comparison
of radiotherapy versus ALND in clinically node negative study
participants.
Dealing with missing data
We analysed only data available in trial reports or obtained through
contact with trial authors. We did not attempt data imputation.
Assessment of heterogeneity
We assessed statistical heterogeneity (variability in intervention ef-
fects) in meta-analyses by using the I2 statistic, which we inter-
preted alongside magnitude and direction of effects. We regarded
an I2 value of 30% to 60% as indicating potentially important
heterogeneity and downgraded the overall quality of evidence for
that outcome (owing to inconsistency) in the summary of findings
tables. If heterogeneity was greater than 50%, we did not pool
effect estimates but instead used the range of effects reported by
individual studies.
Assessment of reporting biases
We checked reporting bias by using funnel plots and checked
that outcomes measured in individual trials were reported in trial
publications. If we suspected reporting bias for a given outcome,
we downgraded the overall quality of the evidence in the summary
of findings table owing to reporting/publication bias.
Data synthesis
We statistically synthesised time-to-event outcomes that were en-
tered into RevMan as ‘O-E’ and ’Variance’ outcomes by using a
fixed-effect model (the random-effects model is not an option for
this analysis in RevMan). We analysed dichotomous outcomes by
using fixed-effect (Mantel-Haenszel method) and random-effects
(DerSimonian and Laird) models (Sensitivity analysis).
For summary of findings tables (Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4), we used the GRADE approach to as-
sign an overall assessment of the quality of the evidence. In addi-
tion to the risk of bias assessment, the GRADE quality rating in-
cludes assessments of inconsistency, indirectness and imprecision
of results, and of the likelihood of publication bias. We prioritised
Primary outcomes for inclusion in summary of findings tables and
organised them according to Types of interventions.
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Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses.
1. Radiotherapy versus no radiotherapy.
2. Further treatment versus no further treatment for
histologically node-positive participants.
3. Age groups (18 to 49 years; 50 to 69 years; 70 to 79 years;
80 years and older).
We were not able to analyse results by age group. When evidence
suggested potentially important between-study statistical hetero-
geneity (I2 value of 30% to 60%), we compared fixed-effect and
random-effects estimates to check whether the intervention effect
was sensitive to the type ofmodel used, although it should be noted
that such comparisons were not possible for analyses of time-to-
event outcomes, as already outlined in the Data synthesis section.
Sensitivity analysis
To examine the robustness of our results, we performed sensitivity
analyses that included only studies with low risk of bias for allo-
cation concealment. Moreover, we planned to undertake sensitiv-
ity analyses to examine short-term and long-term morbidity out-
comes only for studies with low risk of bias for blinded assessment
of these outcomes. However, we considered none of the studies
to be at low risk of bias for these items, so we could not perform
these analyses.
R E S U L T S
Description of studies
Results of the search
In total, we screened 7436 references for inclusion in this re-
view (Figure 1). We retrieved full-text articles for 163 refer-
ences to potentially relevant publications to check inclusion
eligibility. Of these,13 full-text articles reported on eight tri-
als that appeared relevant but did not meet all of the inclu-
sion criteria (AATRM-048-13-2000; ACOSOG Z0011; Buenos
Aires; Copenhagen; Edinburgh SES; IBCSG-23-01; IPO-P;
OTOASOR). See Excluded studies section.
We identified six articles reporting on eight possibly eligible
ongoing trials (AMAROS; GF-GS 01; KiSS; NCT01717131;
NCT02167490; NCT02271828; SNAC2; SOUND). Two stud-
ies (ISRCTN88463711; Semiglazov 2003) await classification.
We excluded 45 other full-text articles for the following reasons:
23 used ineligible Types of interventions, four included ineligible
Types of participants and 18 were the wrong Types of studies.
The remaining 97 articles were reports of 26 eligible RCTs in-
cluded in this review. We contacted the authors of included stud-
ies by email to ask about other relevant trials for inclusion in the
review, but this yielded no additional studies.
Included studies
This review includes 26 studies that performed 27 treatment com-
parisons.
Full axillary surgery versus no axillary surgery
Ten studies compared axillary lymph node dissection (ALND)
versus no axillary surgery (N = 3849; Addenbrookes; Guy’s;
Hammersmith; IBCSG-10-93; Institut Curie; Institut Bergonie;
Malmo; Milan 2; Milan 3; NSABP B-04).
The Malmo trial compared ALND plus radiotherapy (RT) ver-
sus no ALND and no RT. In one trial (IBCSG-10-93), only
those treated with conservative breast surgery received RT. In
Addenbrookes; Guy’s; Hammersmith; Institut Curie; Institut
Bergonie; Milan 2; and Milan 3, all study participants received
RT. NSABP B-04 reported a three-group comparison of ALND,
no ANLD plus RT and no ALND for patients with clinically neg-
ative axillary nodes. Patients in the ALND arm received limited
RT to the chest wall. We included the ALND and no ALND arms
of NSABP B-04 for this comparison.
Five studies excludedpatientswith clinically involved lymphnodes
(Institut Bergonie; Institut Curie; Malmo; Milan 2; Milan 3),
whereas the remaining five studies included these patients only
when clinically involved nodes were mobile and were not fixed
to underlying structures (Addenbrookes; Guy’s; Hammersmith;
IBCSG-10-93; NSABP B-04).
Seven studies (Addenbrookes; Guy’s; Hammersmith; IBCSG-10-
93; Malmo; Milan 2; NSABP B-04) did not provide extra treat-
ment for participants with histologically positive axillary lymph
nodes. In Institut Curie, Institut Bergonie and Milan 3, such in-
dividuals could receive chemotherapy or hormone therapy.
Full axillary surgery versus axillary sampling
Six trials compared ALND versus axillary sampling (N = 1559;
Cape Town; Cardiff; E’dburgh Sample/Clear; Edinburgh 1;
Ostersund; Xu 2003). Of these trials, only Cape Town did not
provide RT as part of the randomised treatment.
In Cardiff, E’dburgh Sample/Clear, Edinburgh 1 and Ostersund,
participants with histologically positive sampled axillary lymph
nodes received additional RT. In Xu 2003, RT was provided only
for participants withmore than three positive axillary lymph nodes
and for those with a primary tumour in the central quadrant.
In Cape Town, participants with histologically positive sampled
nodes did not receive additional treatment.
Four trials (Cape Town; Cardiff; E’dburgh Sample/Clear;
Edinburgh 1) included patients with clinically involved axillary
nodes, provided such nodes were mobile. In the Ostersund and
Xu 2003 trials, inclusion criteria were unclear.
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Full axillary surgery versus sentinel node biopsy
Seven trials compared ALND versus sentinel lymph node biopsy
(SLNB) (N = 9426; Addenbrookes 2; ALMANAC; Genoa;
GIVOM Sentinella; Milan; NSABP B-32; SNAC).
In three studies (Genoa; GIVOM Sentinella; Milan), only par-
ticipants treated with breast-conserving surgery received RT,
which meant that some of the participants in Genoa and
GIVOM Sentinella did not receive RT. In the remaining trials
(Addenbrookes 2; ALMANAC; NSABP B-32; SNAC), partici-
pants received RT according to local treatment protocols, which
meant that in practice, most participants received RT.
In all of these trials, participants with histologically positive
sentinel lymph nodes received further treatment. Treatment
for histologically positive lymph nodes consisted of ALND (
Addenbrookes; Genoa; GIVOMSentinella; NSABPB-32;Milan;
SNAC) or the choice of ALND or RT to the axilla (ALMANAC).
Addenbrookes 2; ALMANAC; Genoa; GIVOM Sentinella;
NSABPB-32 andSNACexcludedpatientswith clinically involved
axillary nodes, but it was unclear whether theMilan trial excluded
such individuals.
Axillary sampling versus SLNB
We identified no studies for this comparison.
Axillary sampling versus no axillary surgery
We identified no studies for this comparison.
SLNB versus no axillary surgery
We identified no studies for this comparison.
Full axillary surgery with no RT versus no axillary surgery
with RT
Four trials compared ALND without RT versus RT alone (N =
2585; Manchester; NSABP B-04; SE Scotland; WSSA Glasgow).
One of these trials (NSABP B-04) performed a three-group com-
parison of ALND, no ANLD plus RT and no ALND with clini-
cally negative axillary nodes. Participants in the ALND arm of this
trial did receive limited RT to the chest wall. We included in this
review the ALND and no ALND plus RT arms of NSABP B-04.
This trial randomised participants with clinically positive nodes
to ALND or no ANLD plus RT; we analysed these results sepa-
rately. All of these trials included patients with clinically involved
axillary nodes provided such nodes were mobile. None of these
trials specified that they provided extra treatments for participants
with histologically positive axillary nodes.
Excluded studies
We excluded eight trials from this review (see Excluded studies
table for full details). We excluded two otherwise relevant trials
because treatment allocation was not randomised; instead, inves-
tigators decided treatment group on the basis of month of birth
(Buenos Aires) or order of entry into the trial (Copenhagen). We
excluded the Edinburgh South East Scotland trial (Edinburgh
SES) because it did not involve axillary surgery or lymph node
biopsy.
We excluded five trials comparing ALND versus no further
axillary surgery because trial entry or inclusion depended on
the results of SLNB (AATRM-048-13-2000; ACOSOG Z0011;
IBCSG-23-01; IPO-P; OTOASOR). All of these trials excluded
patients with clinically involved axillary nodes before their pri-
mary surgery. The IPO-P trial included only those with negative
SLNB. Remaining trials included only patients with a positive
SLNB (AATRM-048-13-2000; ACOSOG Z0011; IBCSG-23-
01; OTOASOR). AATRM-048-13-2000 included only patients
with sentinel lymph node micrometastases.
Risk of bias in included studies
We summarised in Figure 2 the risk of bias of included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
In all, 17 trials clearly reported random sequence generation
(Addenbrookes; Addenbrookes 2; ALMANAC; Cape Town;
Cardiff; Edinburgh 1; Genoa; GIVOM Sentinella; Guy’s;
Hammersmith; IBCSG-10-93; Malmo; Milan; Milan 2; Milan
3; NSABP B-32; SNAC), and the remaining nine trials provided
unclear information on this (E’dburgh Sample/Clear; Institut
Bergonie; Institut Curie; Manchester; NSABP B-04; Ostersund;
SE Scotland; WSSA Glasgow; Xu 2003).
Allocation concealment was adequate in 15 trials (Addenbrookes;
ALMANAC; Cape Town; Cardiff; E’dburgh Sample/Clear;
Edinburgh 1; Genoa; GIVOM Sentinella; IBCSG-10-93; Milan;
Milan 2;Milan 3; NSABPB-32; SE Scotland; SNAC) and unclear
in the other 11 trials (Addenbrookes 2; Guy’s; Hammersmith;
Institut Bergonie; Institut Curie; Malmo; Manchester; NSABP
B-04;Ostersund;WSSAGlasgow; Xu 2003). In trials with unclear
risk of selection bias, we did not observe obvious differences in
the baseline characteristics of treatment groups, although Malmo,
Ostersund and WSSA Glasgow poorly reported baseline charac-
teristics.
Blinding
Two studies were at high risk of detection bias due to lack of
blinding of outcome assessment or disease recurrence and adverse
event outcomes (Addenbrookes 2; SNAC2). All other studies were
at unclear risk of detection bias due to poor reporting.
Incomplete outcome data
Seventeen trials had low risk of incomplete overall survival
data (ALMANAC; Cape Town; Cardiff; E’dburgh Sample/Clear;
Edinburgh 1; Genoa; Guy’s; IBCSG-10-93; Institut Bergonie;
Malmo; Manchester; Milan; Milan 3; NSABP B-32; SE Scotland;
WSSA Glasgow; Xu 2003). The remaining trials were at unclear
risk of bias due to incomplete outcome data because they did not
report overall survival or the completeness of their reporting was
uncertain. We observed a similar pattern for outcomes related to
breast cancer recurrence and disease control in the axilla (Figure
2).
We judged five trials to be at low risk of bias because they provided
incomplete data for short-term adverse events (Addenbrookes 2;
ALMANAC; NSABP B-32; SNAC; Xu 2003); all of these trials
involved SLNB. Three trials were at high risk (IBCSG-10-93;
Ostersund; SE Scotland), and the remainder were at uncertain
risk. We noted a similar pattern for long-term adverse events, with
three trials at low risk of bias (Addenbrookes 2; Hammersmith;
Xu 2003), seven trials at high risk (E’dburgh Sample/Clear; Guy’s;
IBCSG-10-93; Milan; NSABP B-32; Ostersund; SE Scotland)
and the remainder at uncertain risk.
Selective reporting
Three trials were at low risk of bias due to selective reporting
(Addenbrookes; ALMANAC; Edinburgh 1). Addenbrookes 2 and
Milan 3 were at high risk of bias due to selective reporting of some
outcomes on the basis of statistical significance. The remaining
trials were at uncertain risk of bias due to selective reporting.
Other potential sources of bias
Trials typically reported intention-to-treat analyses, but in four
trials it was unclear whether such analyses were performed (Cape
Town; NSABP B-04; Ostersund; WSSA Glasgow). We included
two trials that performed per-protocol analysis (Malmo; Milan)
because study authors stated that per-protocol results were similar
to intention-to-treat results (Malmo), or because protocol viola-
tions were few (Milan).
Effects of interventions
See: Summary of findings for the main comparison No
axillary surgery compared with full axillary surgery for operable
primary breast cancer; Summary of findings 2 Axillary sampling
compared with full axillary surgery for operable primary breast
cancer; Summary of findings 3 Sentinel node biopsy compared
with full axillary surgery for operable primary breast cancer;
Summary of findings 4 Radiotherapy alone compared with full
axillary surgery for operable primary breast cancer
We recorded in Table 1 time-to-event statistics extracted for each
trial.We listed in Table 2 the definitions of adverse event outcomes
used in each study, and we summarised in Table 3 adverse events
at various time points after treatment.
We reported relative effects of treatments on time-to-event out-
comes and noted that HRs less than 1.0 favour the ’less axillary
surgery’ arm, and HRs greater than 1.0 favour the ’more axillary
surgery’ arm. Similarly, for adverse event rates, ORs less than 1.0
favour the ’less axillary surgery’ arm, and ORs greater than 1.0
favour the ’more axillary surgery’ arm.
No axillary surgery versus full axillary surgery
Overall survival
All 10 trials comparing ALND versus no axillary surgery reported
overall survival. The HR for death from any cause was 1.06 (95%
confidence interval (CI) 0.96 to 1.17; 3849 participants; 10 stud-
ies; Analysis 1.1) with no statistically significant heterogeneity (I2
= 26%; P = 0.20).We downgraded evidence for this outcome from
high to moderate quality owing to imprecision: The confidence
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interval of the effect estimate includes both no difference between
treatment groups and appreciable harm associated with no axillary
surgery (Summary of findings for the main comparison). For the
single trial that did not use RT (NSABP B-04), the HR was 0.96
(95% CI 0.80 to 1.15; 773 participants; one study; Analysis 1.1).
For trials that used RT, the HR was 1.11 (95% CI 0.98 to 1.25;
3076 participants; nine studies; Analysis 1.1) with no statistically
significant heterogeneity (I2 = 24%; P = 0.23).
For the subgroup of studies that provided additional treatment
to participants with histologically positive axillary nodes (Institut
Bergonie; Institut Curie; Milan 3), no axillary surgery was asso-
ciated with increased risk of overall mortality (HR 1.51, 95% CI
1.09 to 2.09; 1174 participants; three studies; Analysis 1.2.1) with
no statistically significant heterogeneity (I2 = 25%; P = 0.27).
For the subgroup of studies that did not provide additional treat-
ment to participants with histologically positive axillary nodes
(Addenbrookes; Guy’s; Hammersmith; IBCSG-10-93; Malmo;
Milan 2; NSABP B-04), the HR for overall mortality was 1.02
(95% CI 0.92 to 1.13; 2675 participants; seven studies; Analysis
1.2.2) with no statistically significant heterogeneity (I2 = 0%; P =
0.59).
For the subgroup of studies with adequate allocation concealment
(Addenbrookes; IBCSG-10-93; Milan 2; Milan 3), the HR for
death from any cause was 0.98 (95% CI 0.81 to 1.18; 1442 par-
ticipants; four studies; Analysis 1.13.1) with no statistically signif-
icant heterogeneity (I2 = 0%; P = 0.81).
Disease control in the axilla
Trials comparing full axillary surgery with no axillary surgery did
not report disease control in the axilla.
Breast cancer recurrence
Local recurrence
Included studies not separately report time to local recurrence.
Locoregional recurrence
Wewere able to extract locoregional recurrence time-to-event data
for four of the nine included trials. No axillary surgery was as-
sociated with increased risk of locoregional recurrence (with HR
ranging from 1.10 to 3.06; 20,863 person-years of follow-up; four
studies; Analysis 1.3) but heterogeneity was substantial (I2 = 71%;
P = 0.007); for this reason, we downgraded evidence for this out-
come to moderate quality (Summary of findings for the main
comparison).
For the single trial that provided additional treatment to partic-
ipants with histologically positive axillary nodes (Institut Curie),
the HR for locoregional recurrence was 1.10 (95% CI 0.69 to
1.75; 4171 person-years of follow-up; one study; Analysis 1.4.1).
For the remaining trials (Addenbrookes; Guy’s; NSABP B-04),
which provided no specific additional treatment to participants
with histologically positive axillary nodes, no axillary surgery was
associatedwith increased risk of locoregional recurrence (HR2.83,
95% CI 2.25 to 3.57; 16,692 person-years of follow-up; three
studies) with no statistically significant heterogeneity (I2 = 0%; P
= 0.74).
In subgroup analyses of trials according to use of RT (Analysis 1.3),
no axillary surgery was associated with increased risk of locore-
gional recurrence (HR ranging from 1.10 to 3.06; 13,579 person-
years of follow-up; three studies; Analysis 1.3.2) but heterogeneity
was substantial (I2 = 75%; P = 0.008). For the single trial that
did not use RT (NSABP B-04), no axillary surgery was associated
with increased risk of locoregional recurrence (HR 2.94, 95% CI
2.05 to 4.23; 7284 person-years of follow-up; one study; Analysis
1.3.1).
We judged allocation concealment as adequate in only one of the
trials reporting locoregional recurrence (Addenbrookes). We were
uncertain about whether no axillary surgery was associated with
increased risk of locoregional recurrence in this trial (HR 1.84,
95% CI 0.79 to 4.28).
Distant metastasis
We were able to extract distant metastasis time-to-event data for
two trials (Milan 2; NSABP B-04). The HR for distant metastasis
was 1.06 (95% CI 0.87 to 1.30; 946 participants; two studies;
Analysis 1.5) with moderate heterogeneity (I2 = 40%; P = 0.20).
One of the trials (Milan 2) had adequate allocation concealment,
but its results indicate uncertainty about the relative rates of distant
metastasis with the two treatment options (HR 0.64, 95%CI 0.28
to 1.42; 219 participants; one study).
Institut Curie reported the rate of metastases but provided insuffi-
cient detail for extraction of time-to-event outcomes. In this trial,
at 15 years of follow-up, the rate of metastasis was 24.9% for no
axillary surgery versus 25.8% for axillary lymph node dissection
(P reported as not significant).
Long-term adverse events
Lymphoedema
Four of the included trials reported the rate of lymphoedema, de-
fined as an increase in arm circumference, at 12 or more months
after surgery (Addenbrookes; Guy’s; Institut Bergonie; NSABP
B-04). The Addenbrookes, Guy’s and Institut Bergonie trials used
RT. NSABP B-04 was a three-arm trial, but we included the two
“no radiotherapy” arms for this comparison. No axillary surgery
was associated with decreased risk of lymphoedema at 12 or more
months post surgery (OR 0.31, 95% CI 0.23 to 0.43; fixed-effect
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model; 1714 participants; four studies; Analysis 1.6). We down-
graded evidence for this outcome to low quality owing to sub-
stantial heterogeneity (I2 = 69%; P = 0.02) and unclear blinding
of the outcome assessment (Summary of findings for the main
comparison). A random-effects model yielded a similar result (OR
0.22, 95% CI 0.08 to 0.57; random-effects model; 1714 partici-
pants; four studies; I2 = 69%; P = 0.02; Analysis 1.7).
Subgroup analysis of trials that did not provide additional treat-
ment to participants with histologically positive axillary lymph
nodes (Addenbrookes; Guy’s, NSABP B-04) revealed that no ax-
illary surgery was associated with decreased risk of lymphoedema
(OR 0.40, 95% CI 0.28 to 0.55; 1182 participants; three studies)
and showed no important heterogeneity (I2 = 0%; P = 0.54).
We judged allocation concealment as adequate in only one of
the trials reporting lymphoedema (Addenbrookes). Its results were
consistent with results of the pooled analysis (HR 0.35; 95% CI
0.12 to 1.03; 98 participants).
Arm or shoulder movement impairment
Five trials (Addenbrookes; Guy’s; Hammersmith; IBCSG-10-93;
Institut Bergonie), involving 1495 participants, reported impair-
ment of arm or shoulder function at 12 or more months after
surgery (Analysis 1.8). Results show considerable heterogeneity (I
2 = 78%; P = 0.001), with the OR for any impairment of func-
tion ranging from 0.24 to 3.26. We downgraded evidence for this
outcome to very low quality owing to heterogeneity and unclear
blinding of outcome assessment (Summary of findings for the
main comparison).
Differences between trials in the definitions of arm and shoulder
impairment are a possible source of this heterogeneity. All trials
provided RT, but in both Guy’s and Hammersmith trials, the no
axillary surgery group receivedmore extensive RT than the ALND
group.
Analysis restricted to trials with adequate allocation concealment
(Addenbrookes; IBCSG-10-93) suggests fewer participants with
arm or shoulder movement impairment in the no axillary surgery
than in the ALND group (HR 0.46, 95% CI 0.23 to 0.93) but
with potentially important heterogeneity (I2 = 59%; P = 0.12).
Arm pain
One study reported arm pain. In IBCSG-10-93, the OR for arm
pain at 12 or more months was 0.60 (95% CI 0.24 to 1.47; 379
participants; Analysis 1.9).
Paraesthesia
One study reported on paraesthesia. In Institut Bergonie, paraes-
thesia at 12 or more months after surgery was less likely in the
no axillary surgery group (OR 0.14, 95% CI 0.06 to 0.32; 532
participants; Analysis 1.10).
Short-term adverse events
One trial (Addenbrookes) reported acute adverse events (surgical
complications).
Delayed healing
Delayed healing was less likely in the no axillary surgery group
(OR 0.27, 95% CI 0.11 to 0.67; 204 participants; one study;
Analysis 1.11).
Skin grafts
Skin grafts were less likely in the no axillary surgery group (OR
0.39, 95% CI 0.07 to 2.19; 204 participants; one study; Analysis
1.12).
Quality of life
IBCSG-10-93 was the only trial that measured quality of life out-
comes; investigators reported no statistically significant differences
in quality of life, bother and coping scores between treatment
groups during the two years of postoperative follow-up.
Psychological and psychosocial outcomes
The included studies did not report on these outcomes.
Axillary sampling versus full axillary surgery
Overall survival
Five trials (Cape Town; Cardiff; E’dburgh Sample/Clear;
Edinburgh 1; Xu 2003) reported time to death from any cause,
but we excluded Cardiff data from the meta-analysis owing to
non-proportionality of hazard rates (i.e. survival curves cross at 12
years’ follow-up) and the published report provided insufficient
detail to include Xu 2003. In the remaining three trials (Cape
Town; E’dburgh Sample/Clear; Edinburgh 1), heterogeneity in
the HR for overall mortality was substantial (HR 0.94, 95% CI
0.73 to 1.21; 967 participants; three studies; I2 = 45%; P = 0.16;
Analysis 2.1). We downgraded this evidence to low quality owing
to substantial heterogeneity and serious imprecision (Summary of
findings 2).
Subgroup analysis of the two trials that provided RT (E’dburgh
Sample/Clear; Edinburgh 1) yielded an HR of 0.84 (95% CI
0.64 to 1.11; 872 participants; two studies; Analysis 2.1) with no
significant heterogeneity (I2 = 0%; P = 0.44), and for the trial that
did not use RT (Cape Town), an HR of 1.47 (95% CI 0.84 to
2.56; 85 participants).
We conducted no sensitivity analysis for this outcome because all
trials were at low risk of bias owing to allocation concealment.
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Disease control in the axilla
Included studies did not report disease control in the axilla, but
two trials reported axillary recurrence (see below).
Breast cancer recurrence
Local recurrence
Five trials that performed six treatment comparisons reported lo-
cal recurrence (Cape Town (1) and (2); Cardiff; Edinburgh 1;
Ostersund; Xu 2003), but we could not extract time-to-event
data from Ostersund and Xu 2003. The HR for local recurrence
was 1.41 (95% CI 0.94 to 2.12; 1404 participants; three studies;
Analysis 2.2) with no heterogeneity (I2 = 0%; P = 0.91). In the
Ostersund trial, one out of 54 participants in the axillary sampling
arm experienced local recurrence compared with four of 57 partic-
ipants in the ALND arm. In Xu 2003, local recurrence rates were
3.2% and 2.3% in the axillary sampling and ALND arms, respec-
tively (181 participants; P value reported as greater than 0.05). We
downgraded evidence for local recurrence to low quality on the
basis of few events and serious imprecision (Summary of findings
2). We performed no sensitivity analysis for this outcome because
all trials were at low risk of bias owing to allocation concealment.
Axillary recurrence
Two trials reported axillary recurrence rates (Cape Town;
Edinburgh 1), but we were able to extract time-to-event data only
from Edinburgh 1, yielding an HR for axillary recurrence of 0.99
(95% CI 0.58 to 1.69; 466 participants; Analysis 2.3) with axil-
lary lymph node sampling versus dissection. In Cape Town, rates
of axillary recurrence were 8/52 for axillary lymph node sampling
and 2/43 for ALND.
Locoregional recurrence
Two trials (Cape Town; E’dburgh Sample/Clear) reported locore-
gional recurrence, but we could extract time-to-event data only
from E’dburgh Sample/Clear, yielding an HR for locoregional re-
currence of 0.74 (95% CI 0.46 to 1.20; 406 participants; one
study; Analysis 2.4). In the Cape Town trial, 19 of 52 participants
in the axillary sampling group experienced locoregional recurrence
compared with 11 of 43 in the ALND group.
Distant metastasis
Four trials reported distant metastasis (Cape Town; Cardiff;
E’dburgh Sample/Clear; Xu 2003). We were able to extract time-
to-event data only extracted from the Cardiff and E’dburgh
Sample/Clear trials, but we did not include data from Cardiff in
the meta-analysis owing to the non-proportionality of HRs. In
E’dburgh Sample/Clear, the HR for distant metastasis was 1.05
(95%CI 0.74 to 1.49; 406 participants; Analysis 2.5). In the Cape
Town trial, distant metastasis occurred at a rate of 13 of 52 par-
ticipants in the axillary sampling group compared with 11 of 43
participants in the ALND group. In Xu 2003, distant metastasis
rates were 19/93 and 15/88 in the axillary sampling and ALND
arms, respectively (181 participants; P value reported as greater
than 0.05).
Long-term adverse events
Lymphoedema
Two trials reported on lymphoedema. In the Cardiff trial, lym-
phoedema at 12 or more months after surgery (defined as an in-
crease in arm circumference) was less likely in the axillary sam-
pling group than in the ALND group (OR 0.32, 95% CI 0.13
to 0.81; 85 participants; one study; Analysis 2.6). In Xu 2003,
postoperative lymphoedema occurred in 3/93 participants in the
axillary sampling group compared with 7/88 in the ALND group,
but it was unclear at what time this measurement was taken.
Arm or shoulder movement impairment
One trial (Edinburgh 1) reported shoulder lateral rotation at 12-
months follow-up, noting a relatively small decrease in range of
movement when compared with baseline in both the axillary sam-
pling and ALND groups (mean difference (MD) -0.05 cm, 95%
CI -1.50 to 1.40; 191 participants; one study; Analysis 2.7).
Short-term adverse events
Seroma
One trial collected data on seroma formation. In the Ostersund
trial, seroma occurred at a rate of 10 of 50 participants in the
axillary sampling group comparedwith 17 of 50 participants in the
ALND group (OR 0.49, 95% CI 0.20 to 1.20; 100 participants;
one study; Analysis 2.8).
Quality of life
The included studies did not report this outcome.
Psychological and psychosocial outcomes
The included studies did not report these outcomes.
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Sentinel node biopsy versus full axillary surgery
Overall survival
Five trials reported overall mortality (ALMANAC; Genoa;
GIVOM Sentinella; Milan; NSABP B-32), but we were able to
extract time-to-event data from only three studies (Genoa; Milan;
NSABP B-32). The HR for overall mortality was 1.05 (95% CI
0.89 to 1.25; 6352 participants; three studies; Analysis 3.1) with
minimal heterogeneity (I2 = 28%; P = 0.25). We rated evidence
for overall mortality as moderate quality owing to imprecision.
The confidence interval of the effect estimate included both no
differences between treatment groups and appreciable harm asso-
ciated with SLNB (Summary of findings 3). In the ALMANAC
trial, the overall mortality rate for the year after surgery was seven
out of 478 women (1.5%) in the sentinel node group versus seven
out of 476 women (1.5%) in the full axillary surgery group. In
the GIVOM Sentinella trial, the overall mortality rate over the
five years after surgery was 21 out of 345 women (6.1%) in the
sentinel node group versus 14 out of 352 women (4.0%) in the
full axillary surgery group.
We conducted no sensitivity analysis for this outcome because all
trials were at low risk of bias owing to allocation concealment.
Disease control in the axilla
The included studies did not report disease control in the axilla,
although five trials reported axillary recurrence (see below).
Breast cancer recurrence
Local recurrence
Data reveal uncertainty about the relative effectiveness of SLNB
and ALND in terms of local recurrence (HR 0.94, 95% CI 0.24
to 3.77; 516 participants; one study; Milan; Analysis 3.2).
Axillary recurrence
Five trials, involving 7487 participants, reported axillary recur-
rence (ALMANAC; GIVOM Sentinella; Genoa; NSABP B-32;
Milan), but event rates were low, and we were able to extract time-
to-event data only fromMilan. Results derived fromMilan suggest
uncertainty about whether axillary recurrence is more likely with
SLNB than with ALND (HR 6.96, 95% CI 0.44 to 111.25; 516
participants; one study; Analysis 3.3). In ALMANAC, the rate of
axillary local recurrence during the first year after surgery was 1/
478 (0.2%) in the SLNB group versus 4/476 (0.8%) in the ALND
group. In GIVOM Sentinella, axillary recurrence rates over the
five years after surgery were 1/345 (0.3%) in the SLNB group ver-
sus 0/352 (0%) in the ALND group. In Genoa, axillary recurrence
rates were 0/110 (0%) in the SLNB group versus 1/115 (0.8%) in
the ALND group. In NSABP B-32, axillary recurrence rates were
14/2804 (0.5%) in the SLNB group versus 6/2807 (0.2%) in the
ALND group.
We conducted no sensitivity analysis for this outcome because all
trials were at low risk of bias owing to allocation concealment.
Locoregional recurrence
Two trials reported locoregional recurrence (GIVOM Sentinella;
NSABP B-32), but we were able to extract time-to-event data only
fromNSABP B-32. Data reveal uncertainty about whether SLNB
or ALND was more effective in terms of locoregional recurrence
(HR 0.96, 95% CI 0.74 to 1.24; 5611 participants; one study;
Analysis 3.4). In GIVOMSentinella, locoregional recurrence rates
were 16/345 (4.6%) in the SLNB group versus 3/352 (0.9%) in
the ALND group.
Distant metastasis
Two studies reported distant metastases (GIVOM Sentinella;
Milan), but we were able to extract time-to-event data only from
Milan. The relative effectiveness of SLNB and ALND in terms of
distant metastasis was uncertain (HR 0.80, 95% CI 0.42 to 1.53;
516 participants; one study; Analysis 3.5). In GIVOM Sentinella,
distant metastasis rates were 11/3345 (3.2%) in the SLNB group
versus 16/352 (4.5%) in the ALND group.
Long-term adverse events
Lymphoedema
Four studies reported objectively measured lymphoedema at 12
or more months after surgery (ALMANAC; GIVOM Sentinella;
Milan; SNAC). Investigators measured lymphoedema by using
arm circumference (GIVOM Sentinella; Milan) or arm volume
(ALMANAC; SNAC). Increased arm circumference at 12 months
after surgery was less likely with SLNB than with ALND (OR
0.48, 95% CI 0.26 to 0.92; 677 participants - Analysis 3.6 OR
0.04, 95%CI 0.00 to 0.60; 200 participants - Analysis 3.6 andOR
0.60, 95% CI 0.37 to 0.96, 1088 participants - Analysis 3.6) for
the GIVOM Sentinella, Milan and SNAC trials, respectively. We
did not pool results owing to heterogeneity (I2 = 51%; P = 0.13),
and we conducted no sensitivity analysis for this outcome because
all trials were at low risk of bias owing to allocation concealment.
The ALMANAC trial reported the mean ratio in arm volume at
baseline compared with 12 months after surgery. In the sentinel
lymph node group, this was 1.03 (95%CI 1.02 to 1.04) compared
with 1.06 (95% CI 1.05 to 1.07) in the ALND group (P = 0.096;
two sided t-test).
In ALMANAC, Addenbrookes 2 and SNAC, patient-reported
lymphoedema (of any severity) was less likely in the SLNB group
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than in the ALND group (OR 0.33, 95% CI 0.23 to 0.47; fixed-
effect model; 1903 participants; three studies; Analysis 3.7) with
no heterogeneity (I2 = 0%; P = 0.96). The random-effects model
produced the same result. We downgraded evidence on patient-
reported lymphoedema to moderate quality owing to incomplete
follow-up (Summary of findings 3). Restricting this analysis to
trials with adequate allocation concealment (ALMANAC and
SNAC) yielded a similar result (OR 0.33, 95% CI 0.22 to 0.48;
fixed-effect model).
Shoulder or arm movement impairment
The Addenbrookes 2, ALMANAC and SNAC trials measured
change in the range of shoulder movement from baseline to 12
months after surgery. Results showed no statistically significant
differences between SLNB and ALND groups when change in the
range of movement was compared from baseline to 12 months
post surgery, for flexion (MD1.55°, 95%CI -0.19° to 3.29°; 2257
participants; three studies; Analysis 3.8), abduction (MD -1.02°,
95% CI -2.79° to 0.75°; 2252 participants; three studies; Analysis
3.9), internal rotation (MD 0.50°; 95% CI -1.10° to 2.09°; 1227
participants; two studies; Analysis 3.10) or external rotation (MD
-0.56°; 95% CI -2.21° to 1.09°; 1227 participants; two studies;
Analysis 3.11). Except for external rotation, heterogeneitywas sub-
stantial or considerable for all shoulder movement comparisons.
In two trials (GIVOM Sentinella and Milan), subjective arm
movement impairment was less likely with SLNB than with
ALND. This difference was statistically significant in the Milan
trial (OR 0.02, 95% CI < 0.00 to 0.31; 200 participants; Analysis
3.12) but not in the GIVOM Sentinella trial (OR 0.74, 95% CI
0.39 to 1.41; 677 participants; Analysis 3.12), and heterogeneity
in the pooled estimate was considerable (I2 = 88%; P = 0.004).
We downgraded evidence on subjective arm movement impair-
ment to low quality owing to heterogeneity and lack of blinding
(Summary of findings 3). We conducted no sensitivity analysis for
this outcome because all trials were at low risk of bias owing to
allocation concealment.
The SNAC trial reported subjective arm disability rated on a scale
from 0 (no trouble at al) to 10 (the worst I can imagine). At
one year postoperatively, mean arm disability ratings were low in
both groups: 0.65 (standard error (SE) 0.1) in the ALND group
compared with 0.45 (SE 0.1) in the SLNB group.
Pain
Two trials reported pain at 12 or more months after surgery
(GIVOM Sentinella; Milan). Pain was less likely to be reported
in the sentinel lymph node group than in the axillary dissection
group. This difference was statistically significant in theMilan trial
(OR 0.14, 95% CI 0.06 to 0.31; 200 participants; Analysis 3.13)
but not in the GIVOM Sentinella trial (OR 0.76, 95% CI 0.46
to 1.25; 677 participants; Analysis 3.13), and heterogeneity was
considerable in the pooled estimate (I2 = 92%; P = 0.0005). We
downgraded evidence on pain to low quality owing to heterogene-
ity and lack of blinding (Summary of findings 3).
Paraesthesia
Two trials reported paraesthesia at 12 ormoremonths after surgery
(Addenbrookes 2; Milan). Both trials found that paraesthesia was
less likely in the sentinel lymph node group than in the axillary
dissection group. For the Milan trial (OR < 0.00, 95% CI <0.00
to 0.04; 200 participants; Analysis 3.14) and the Addenbrookes 2
trial (OR 0.37, 95% CI 0.21 to 0.64; 295 participants; Analysis
3.14), heterogeneity was considerable in the pooled estimate (I2 =
95%; P < 0.00001). We downgraded evidence on paraesthesia to
low quality owing to heterogeneity and lack of blinding (Summary
of findings 3).
Numbness
Three trials reported numbness or sensory deficit at 12 or more
months after surgery (Addenbrookes 2; ALMANAC; GIVOM
Sentinella). All found that numbness was less likely in the SLNB
group than in the ALND group (OR 0.43, 95% CI 0.34 to 0.54;
1799 participants; Analysis 3.15) with limited heterogeneity (I2 =
20%; P = 0.29). Restricting this analysis to trials with adequate al-
location concealment (ALMANAC; GIVOM Sentinella) yielded
a similar result (OR 0.47, 95% CI 0.36 to 0.61).
Short-term adverse events
Seroma
The Addenbrookes 2 and SNAC trials reported that seroma was
less likely with SLNB than with ALND (OR 0.60, 95% CI 0.33
to 1.11; 298 participants; Analysis 3.16; OR 0.36; 95% CI 0.27
to 0.48; 1083 participants; Analysis 3.16 respectively) but with
considerable heterogeneity (I2 = 53%; P = 0.14).
Wound infection
The ALMANAC and SNAC trials reported that wound infection
was less likely with SLNB than with ALND (OR 0.65, 95% CI
0.50 to 0.85; 2074 participants; Analysis 3.17).
Brachial plexus injury
The ALMANAC trial reported the rate of brachial plexus injury
at six months postoperatively (OR 0.38, 95% CI 0.12 to 1.22;
804 participants).
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Quality of life
We did not conduct statistical meta-analysis because of differences
in the scales used, but results from three trials (Addenbrookes
2; ALMANAC; GIVOM Sentinella) suggested that SLNB was
associated with better quality of life, at least in the immediate
postoperative period.
Addenbrookes 2 reported that quality of life scores were usually
higher (better) in the SLND group than in the ALND group, and
significantly so in the immediate postoperative period (P < 0.01).
ALMANAC measured a trial outcome index (TOI, derived from
the sum of scores on physical and well-being subscales and on
breast cancer concerns subscales of the FACT-B+4 (Functional
Assessment of Cancer Therapy, Breast, for patients with lym-
phoedema questionnaire) before surgery and repeatedly in the fol-
lowing 18 months. Participants in the SLND group recovered
more quickly to their baseline TOI value than those in the ALND
group. This occurred at 12 months for the SLND group com-
pared with 18 months for the ALND group (P < 0.01). Global
quality of life (measured with the total FACT-B+4 score) was sig-
nificantly better in the SLND group than in the ALND group at
most time points following surgery (at one month, P < 0.001; at
three months, P = 0.04; at six months, P = 0.059; at 12 months,
P = 0.024; at 18 months, P = 0.019). .
GIVOM Sentinella reported no significant differences between
SLNB and ALND groups on the physical and health-related qual-
ity of life components of the Short Form (SF)-36 measure.
Psychological and psychosocial outcomes
Although three trials reported psychological outcomes, we did not
pool their results owing to insufficient detail in reporting and
differences in measurement scales used.
The Addenbrookes 2 trial reported no significant differences be-
tween SLND and ALND groups inMental Adjustment to Cancer
scores, depressive symptoms (measured on the Beck Depression
Inventory) or state anxiety (measured by the Spielberger State/
Trait Anxiety Inventory) during the first year after surgery.
ALMANAC reported that Spielberger State/Trait Anxiety Inven-
tory scores were slightly lower (better) in the SLNB group than
in the ALND group during the first year after surgery, but this
difference was not statistically significant.
GIVOM Sentinella reported no significant differences between
SLNB and ALND groups on the mental health-related quality of
life components of the SF-36. Participants in the SLNB group
scored significantly better than those in the ALND group in gen-
eral and anxiety domains of the psychological well-being measure
within the first 12 months after surgery, but this difference was no
longer statistically significant at two years after surgery.
Full axillary surgery with no radiotherapy versus no
axillary surgery with radiotherapy
Overall survival
Four studies involving seven treatment comparisons reported that
overall survival was reduced among participants treated with RT
compared with those treated with ALND (HR 1.10, 95% CI 1.00
to 1.21; 2469 participants; Analysis 4.1) with no heterogeneity (I2
=0%;P=0.63).We graded this evidence as high quality (Summary
of findings 4). Only one of the trials (SE Scotland) was at low risk
of bias owing to allocation concealment; this trial was consistent
with the pooled analysis showing reduced overall survival among
patients treated with RT compared with those treated with ALND
(HR 1.27, 95% CI 1.04 to 1.54).
Disease control in the axilla
Trials included in this comparison did not report disease control
in the axilla.
Breast cancer recurrence
Local recurrence
Four studies involving seven treatment comparisons reported that
local recurrence was less likely among participants treated with RT
compared in those treated with ALND (HR 0.80, 95% CI 0.64
to 0.99; 22256 person-years of follow-up; four studies; Analysis
4.2) with no heterogeneity (I2 = 0%; P = 0.63). We graded this
evidence as high quality (Summary of findings 4). Only one trial
(SE Scotland) was at low risk of bias owing to allocation conceal-
ment; results showed uncertainty about whether local recurrence
was less likely in patients treated with RT compared with those
treated with ALND (HR 0.85, 95% CI 0.56 to 1.30).
Locoregional recurrence
The trials included for this comparison did not report locoregional
recurrence.
Distant metastasis
One trial (NSABP B-04) that performed two treatment compar-
isons reported that the HR for distant metastasis for RT alone
versus ALND alone was 1.07 (95% CI 0.93 to 1.25; 1313 partic-
ipants; Analysis 4.3).
Long-term adverse events
Lymphoedema
One trial (SE Scotland) reported lymphoedema at 12 or more
months after treatment and used a definition of 2 cm or greater
increase in arm circumference. In the RT group, 5 out of 100
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participants had lymphoedema compared with 10 out of 100 in
the axillary surgery group (OR 0.47, 95% CI 0.16 to 1.44; 200
participants; Analysis 4.4).
Short-term adverse events
Delayed healing, wound infection and skin graft
One trial (SE Scotland) involving 200 participants reported that
acute adverse events - delayed healing (OR 0.24, 95% CI 0.10 to
0.55; Analysis 4.5), wound infection (OR 0.65, 95% CI 0.22 to
1.89; Analysis 4.6), skin graft (OR 0.04, 95% CI 0.00 to 0.74;
Analysis 4.7) and haematoma (OR 0.20, 95% CI 0.08 to 0.52;
Analysis 4.8) - were less likely with radiotherapy than with axillary
surgery.
Quality of life
The trials included for this comparison did not report quality of
life.
Psychological and psychosocial outcomes
The trials included for this comparison did not report psycholog-
ical and psychosocial outcomes.
Less axillary surgery versus axillary lymph node
dissection
Overall survival
When all trials were combined, the HR for overall mortality was
1.08 (95% CI 1.01 to 1.17, when HR > 1 favours ALND; 12,089
participants; 18 studies; Analysis 5.1) with no significant hetero-
geneity (I2 = 16%; P = 0.25). Trials comparing no axillary surgery
(with or without RT) versus ALND reported increased mortality
with less axillary surgery (HR 1.11, 95% CI 1.02 to 1.21; 4770
participants; 13 studies; I2 = 20%; obtained by combining anal-
yses 5.1.1 and 5.1.4), but trials comparing axillary sampling or
SLNB versus ALNDdid not report increased mortality (HR 0.90,
95% CI 0.72 to 1.14; 1708 participants; seven studies; obtained
by combining analyses 5.1.2 and 5.1.3).
We performed subgroup analysis that was based on use of radio-
therapy. Trials using RT in both treatment groups reported no dif-
ference in overall survival between less axillary surgery and more
axillary surgery groups (HR 1.06, 95% CI 0.96 to 1.16; 10,075
participants; 13 studies; Analysis 5.2.1) with no important het-
erogeneity (I2 = 28%; P = 0.15). Similarly, results showed no dif-
ferences between groups for trials that did not use RT in either
group (HR 1.00, 95% CI 0.85 to 1.19; 1093 participants; three
trials; Analysis 5.2.3) with no important heterogeneity (I2 = 8%;
P = 0.34). Trials that used RT only in the less axillary surgery arm
reported reduced overall survival for the less axillary surgery arm
compared with the ALND arm (HR 1.10, 95% CI 1.00 to 1.21;
2469 participants; four trials; Analysis 5.2.2) with no heterogene-
ity (I2 = 0%; P = 0.52).
We conducted subgroup analysis according to whether additional
treatment was given to participants with histologically positive
nodes and excluded trials in which one of the treatment arms re-
ceivedno axillary staging.Trials that provided additional treatment
to participantswith histologically positive axillary nodes (E’dburgh
Sample/Clear; Edinburgh 1; Genoa; Milan) reported uncertainty
whether less axillary surgery was the more effective treatment in
terms of overall survival (HR 0.82, 95% CI 0.64 to 1.05; 1613
participants; four trials; Analysis 5.3) with no heterogeneity (I2 =
0%; P=0.61). They also described uncertainty about relative ef-
fectiveness in the only trial (Cape Town) that did not provide ad-
ditional treatment to those with histologically positive nodes (HR
1.47, 95% CI 0.84 to 2.56; 95 participants; Analysis 5.3).
Breast cancer recurrence
Local recurrence
Study results show uncertainty about whether local recurrence was
reduced with less axillary surgery when compared with ALND
(HR 0.90, 95% CI 0.75 to 1.09, when HR > 1 favours ALND;
24,176 participants; eight studies; Analysis 5.4).
Locoregional recurrence
Locoregional recurrence was more likely with less surgery than
with ALND (HR 1.53, 95% CI 1.31 to 1.78, when HR > 1
favours ALND; 26,880 participant years of follow-up; seven stud-
ies; Analysis 5.5).
Distant metastasis
Results reveal uncertainty about whether distant metastasis was
more likely in patients treated with less axillary surgery than in
those receiving ALND (HR 1.07, 95%CI 0.95 to 1.20, whenHR
>1 favours ALND; 2665 participants; five studies; Analysis 5.6).
Long-term adverse effects
Lymphoedema (defined as an increase in arm circumference at 12
or more months postoperatively) was less likely with less axillary
surgery than with ALND (OR 0.37, 95% CI 0.29 to 0.46; fixed-
effect model; 3964 participants; nine studies; I2 = 52%; Analysis
5.7). The random-effects model produced a similar result (OR
0.35, 95% CI 0.23 to 0.53; random-effects model; 3964 partici-
pants; nine studies; I2 = 52%).
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Paraesthesia
Three trials reported paraesthesia at 12 or more months after
surgery (Institut Bergonie; Addenbrookes 2; Milan). All trials
found paraesthesia less likely in the less axillary surgery group than
in themore axillary surgery group. For Institut Bergonie (OR0.14,
95% CI 0.06 to 0.32; 532 participants; Analysis 5.8), for Milan
(OR < 0.00, 95% CI <0.00 to 0.04; 200 participants; Analysis
5.8) and for Addenbrookes 2 (OR 0.37, 95% CI 0.21 to 0.64;
295 participants; Analysis 5.8); heterogeneity was considerable in
the pooled estimate (I2 = 91%; P < 0.0001).
Pain
Three trials reported pain at 12 or more months after surgery
(IBCSG-10-93; GIVOM Sentinella; Milan). Pain was less likely
to be reported in the less surgery group than in the more surgery
group. This difference was statistically significant in theMilan trial
(OR 0.14, 95% CI 0.06 to 0.31; 200 participants; Analysis 5.9)
but not in the GIVOM Sentinella trial (OR 0.76, 95% CI 0.46
to 1.25; 677 participants; Analysis 5.9) or the IBCSG-10-93 trial
(OR 0.60 95% CI 0.24 to 1.47; 379 participants; Analysis 5.9),
and heterogeneity was considerable in the pooled estimate (I2 =
84%; P < 0.0001).
Short-term side effects
Delayed healing
TheAddenbrookes and SE Scotland trials reported delayedwound
healing was less likely with less surgery than with more surgery
(OR 0.25, 95% CI 0.13 to 0.46; 404 participants; fixed-effect
model; two studies; I2 = 0%; Analysis 5.10). The random-effects
model produced a similar result (OR 0.25, 95% CI 0.13 to 0.47;
404 participants; random-effects model; two studies; I2 = 0%).
Seroma
Seroma was less likely with less axillary surgery than with ALND
(OR 0.40, 95% CI 0.32 to 0.52; 1481 participants; fixed-effect
model; three studies; I2 =14%;Analysis 5.11). The random-effects
model produced a similar result (OR 0.42, 95% CI 0.31 to 0.56;
1481 participants; random-effectsmodel; three studies; I2 = 14%).
Wound infection
Wound infection was less likely with less axillary surgery than with
ALND (OR 0.65, 95% CI 0.50 to 0.84; fixed-effect model; 2274
participants; three studies; I2 = 0%; Analysis 5.12). The random-
effects model yielded the same result.
Skin graft
Data reveal uncertainty about whether skin graft was less likely
with less axillary surgery than with ALND (OR 0.15, 95% CI
0.04 to 0.57; fixed-effect model; 404 participants; two studies;
I2 = 49%; Analysis 5.13). The random-effects model suggested
that skin graft was less likely with less axillary surgery than with
ALND (OR 0.17, 95% CI 0.02 to 1.64; random-effects model;
404 participants; two studies; I2 = 49%).
Haematoma
The SNAC and SE Scotland trials reported haematoma. In the
SNAC trial there were similar rates of haematoma in the less
surgery group than more surgery group (OR 1.27, 95% CI 0.78
to 2.09; 1083 participants; Analysis 5.14). In the SE Scotland trial
haematoma was less likely in the less surgery group than the more
surgery group (OR 0.20, 95% CI 0.08 to 0.52; 200 participants;
Analysis 5.14. There was considerable heterogeneity in the pooled
estimate (I2 = 91%; P = 0.0007).
Quality of life, psychological and psychosocial outcomes
Only trials comparing SLND versus ALND reported these out-
comes, so we could perform no additional analyses.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Axillary sampling compared with full axillary surgery for operable primary breast cancer
Patient or population: women with operable primary breast cancer
Settings: hospital
Intervention: axillary sampling
Comparison: f ull axillary surgery
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Full axillary surgery Axillary sampling
All- cause mortality 82% overall survival at
5 yearsa
83% overall survival at
5 years
(79% to 87%)
HR 0.94
(0.73 to 1.21)
967
(3 studies)
⊕⊕©©
lowb,c
Local recurrence 85% local recurrence-
free survival at 5 years
d
80% local recurrence
free survival at 5 years
(71% to 86%)
HR 1.41 (0.94 to 2.12) 1404
(3 studies)
⊕⊕©©
lowe,f
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HR: hazard rat io; OR: odds rat io.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aAssumed risk is taken f rom full axillary surgery arm of E’dburgh Sample/ Clear.
bSubstant ial heterogeneity.
cConf idence interval for the ef fect includes both appreciable benef it and harm with axillary sampling.
dAssumed risk taken f rom full axillary surgery arm of Cardif f .24
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eNo blinding of outcome assessment or blinding not reported.
f Conf idence interval for ef fect includes both no dif ference and appreciable harm with axillary sampling. Low number of
events.
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Sentinel node biopsy compared with full axillary surgery for operable primary breast cancer
Patient or population: women with operable primary breast cancer
Settings: hospital
Intervention: sent inel node biopsy
Comparison: f ull axillary surgery
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Full axillary surgery Sentinel node biopsy
All- cause mortality 96% overall survival at 5
yearsa
96% overall survival at 5
years
(95% to 96%)
HR 1.05
(0.89 to 1.25)
6352
(3 studies)
⊕⊕⊕©
moderateb
Lymphoedema
Patient-reported lym-
phoedema of any severity
Follow-up: 12 months
132 per 1000 48 per 1000
(22 to 115)
OR 0.33
(0.15 to 0.86)
815
(3 studies)
⊕⊕©©
lowb,c
Subjective arm movement
impairment
Follow-up: 12 months
100 per 1000 40 per 1000
(24 to 69)
OR 0.38
(0.22 to 0.67)
877
(2 studies)
⊕©©©
very lowb,d,e
Paraesthesia
Follow-up: 12 months
776 per 1000 343 per 1000
(238 to 444)
OR 0.15
(0.09 to 0.23)
495
(2 studies)
⊕⊕©©
lowd,e
Pain
Follow-up: 12 months
177 per 1000 86 per 1000
(61 to 126)
OR 0.44
(0.3 to 0.67)
877
(2 studies)
⊕⊕©©
lowd,e
Numbness
Follow-up: 12 months
346 per 1000 185 per 1000
(152 to 222)
OR 0.43
(0.34 to 0.54)
1799
(3 studies)
⊕⊕⊕©
moderatef
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* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HR: hazard rat io; OR: odds rat io.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aAssumed risk taken f rom the full axillary surgery arm of Milan.
bLow number of events.
cIncomplete follow-up for pat ient-reported lymphoedema in ALMANAC. Event rates not reported in Addenbrookes 2.
dModerate or substant ial heterogeneity.
eNo blinding or blinding not reported.
f No explanat ion provided.
2
7
A
x
illa
r
y
tre
a
tm
e
n
t
fo
r
o
p
e
ra
b
le
p
rim
a
ry
b
re
a
st
c
a
n
c
e
r
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Radiotherapy alone compared with full axillary surgery for operable primary breast cancer
Patient or population: women with operable primary breast cancer
Settings: hospital
Intervention: radiotherapy alone
Comparison: f ull axillary surgery
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Full axillary surgery Radiotherapy alone
All- cause mortality 81% overall survival at 5
yearsa
79% overall survival at 5
years
(77% to 81%)
HR 1.1
(1 to 1.21)
2469
(4 studies)
⊕⊕⊕⊕
high
Local recurrence 90% local recurrence- free
survival at 5 yearsb
92% local recurrence- free
survival at 5 yearsa
(90% to 93%)
HR 0.8
(0.64 to 0.99)
22,256c
(4 studies)
⊕⊕⊕⊕
high
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HR: hazard rat io.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aAssumed risk f rom full axillary surgery arm of NSABP B-04 using mean 5-year overall survival in combined N+ and N- groups.
bAssumed risk f rom full axillary surgery arm of NSABP B-04, using mean 5-year risk for local or regional recurrence in
combined lymph node-posit ive and -negat ive groups.
cPerson-years of follow-up.
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D I S C U S S I O N
Summary of main results
Risk of overall mortality was not increased when participants
were treated with axillary sampling or sentinel lymph node biopsy
(SLNB) versus axillary lymphnode dissection (ALND).Treatment
omitting all axillary surgery was associated with increased risk of
overall mortality compared with ALND, but this was noted only
in trials comparing radiotherapy (RT) alone versus ALND.
Axillary lymph node dissection was associated with increased risk
of lymphoedema and surgical adverse events compared with less
axillary surgery.
Overall completeness and applicability of
evidence
We found no trials that performed the following comparisons:
sentinel node biopsy versus axillary sampling, no axillary surgery
versus axillary sampling and no axillary surgery versus sentinel
node biopsy.
Adverse event data were limited, particularly for older trials com-
paring no surgery, RT or axillary sampling versus ALND. Quality
of life data were limited to three trials. Sentinel lymph node trials
provided limited data on long-term overall survival and breast can-
cer recurrence; these trials were often designed to compare qual-
ity of life and adverse effects. Substantial heterogeneity in adverse
event trial results was often due to differences among adverse event
definitions between trials.
Some trials reported data in a way that precluded inclusion in
the time-to-event meta-analysis, and although we contacted study
authors, we obtained no additional data.
Applicability of some of the comparisons in this review to current
breast cancer practice is questionable, particularly for comparisons
involving no axillary surgery. Use of adjuvant therapies differs
between current practice and many of the included trials - more
effective adjuvant systemic therapies are available today. Similarly,
RT regimens used in the older trials are most likely less effective
and are associated with more side effects:
Patients with breast cancer today are likely to differ from those
who participated in older trials, and breast cancer is more likely to
be detected at an earlier stage.
Quality of the evidence
The included studies were at low or unclear risk of selection bias.
Selection bias was typically unclear because trial publications did
not fully report methods of random sequence generation or allo-
cation concealment used and study authors did not reply when we
contacted them to request additional information about conduct
of the trial. We performed sensitivity analyses for trials with ade-
quate allocation concealment and found that these results gener-
ally were consistent with findings of the main analyses.
Risk of attrition bias tended to be lower for survival and for breast
cancer recurrence than for adverse events. This sometimes oc-
curred because adverse event assessments were done for a subset
of the trial population. This subgroup of participants assessed for
adverse events could be systematically different from the trial pop-
ulation as a whole, especially in the case of assessment for long-
term adverse events when patients may have died or may have
been too sick to participate.
The included trials did not include blinding (and it was proba-
bly infeasible), but this was considered a source of bias only for
outcomes with potential subjectivity in measurement (i.e. breast
cancer recurrence and adverse events). Detection bias could lead
to overestimation of adverse events in patients with more extensive
axillary surgery. Similarly, patients receiving less extensive axillary
surgery could be checked more carefully for breast cancer recur-
rence.
For these reasons, we downgraded the quality of the evidence for
adverse effects (Summary of findings for the main comparison;
Summary of findings 2; Summary of findings 3; Summary of
findings 4).
Potential biases in the review process
The meta-analyses of time-to-event outcomes conducted for this
review used the fixed-effect model because only fixed-effect meta-
analytical methods are available in RevMan for ‘O-E’ and ’Vari-
ance’ outcomes. This could affect interpretation of results by yield-
ing narrower confidence intervals for the pooled hazard ratio in the
presence of heterogeneity than would be obtained with a random-
effects model. This is particularly the case for Analysis 5.1 (which
compares overall survival with more surgery vs less surgery), in
which the underlying assumption of the fixed-effect model is un-
likely to be true, given the different types of interventions and
patient populations included.
Agreements and disagreements with other
studies or reviews
Kell 2010 reported a meta-analysis of seven trials of SLNB ver-
sus axillary clearance (Addenbrookes 2; ALMANAC; GIVOM
Sentinella; Milan; SNAC; ACOSOG Z0011; NSABP B-32).
Compared with axillary clearance, SLNB was associated with re-
duced risk of postoperative wound infection (odds ratio (OR)
0.58, 95% confidence interval (CI) 0.42 to 0.80), of postoperative
seroma (OR 0.40, 95%CI 0.31 to 0.51) and of arm swelling at six
months postoperatively (OR 0.30, 95% CI 0.14 to 0.66). These
results are consistent with findings of the current review.
Wang 2011 also analysed trials examining the sentinel lymph node
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versus axillary clearance (Addenbrookes 2; ALMANAC; GIVOM
Sentinella; Genoa; Milan; SNAC; ACOSOG Z0011; NSABP B-
32). Comparison of SLNB with ALND revealed no statistically
significant difference in overall survival (hazard ratio (HR) 1.07,
95% CI 0.90 to 1.27) or regional lymph node recurrence (OR
1.65, 95% CI 0.77 to 3.56). Postoperative complications were less
likely with SLNB than with ALND, including lymphoedema (OR
0.24, 95% CI 0.11 to 0.53), numbness (OR 0.19, 95% CI 0.11
to 0.33), infection (OR 0.50, 95% CI 0.36 to 0.70) and seroma
(OR 0.39, 95% CI 0.31 to 0.49). These results are consistent with
findings of the current review.
In the Early Breast Cancer Trialists Group, meta-analysis of indi-
vidual participant data (Clarke 2005) revealed that axillary clear-
ance versus effective axillary RT involved little absolute difference
(< 10%) in five-year risk of local recurrence, as well as little differ-
ence in breast cancer mortality (when combined with other local
treatment comparisons). The current review observed an increase
in overall mortality with RT with no axillary surgery compared
with axillary clearance, but the absolute difference at five years was
on the order of a few percent (Summary of findings 4), and had
a random-effects model been possible, greater uncertainty would
surround this estimate.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review confirms the evidence base for the current widespread
approach to staging of disease and treatment of the axilla in pa-
tients with operable early breast cancer. Evidence showing a small
but significant survival benefit with ALND (when compared with
no axillary surgery) and the impact that this procedure has on sys-
temic therapy planning and provision of prognostic information
is balanced against increased incidence of harmful side effects, par-
ticularly lymphoedema. Full axillary clearance of the clinically and
radiologically uninvolved axilla is no longer considered acceptable
practice. In the absence of any direct comparisons, both sentinel
node biopsy and axillary node sampling are considered appropri-
ate choices for axillary staging followed by treatment with surgery
or RT.
Implications for research
Emerging evidence (ACOSOG Z0011) suggests that overall sur-
vival is not improved by further surgical lymph node clearance
of the axilla in a subset of patients undergoing breast conserva-
tion with surgery and RT to the breast, and systemic therapy
has resulted in revised American Society of Clinical Oncology
(ASCO) guidelines pertaining to treatment when one or two sen-
tinel nodes contain metastases (Lyman 2014). These guidelines
state that women without sentinel lymph node metastases should
not undergo ALND, and that most women with one to two
metastatic sentinel lymph nodes planning to receive breast-con-
serving surgery with whole breast RT should not undergo ALND.
However, evidence from ACOSOGZ0011 has not yet resulted in
awidespread change in practice outside theUSA. Further evidence
is required to confirm this finding - trials are under way (e.g. Goyal
2014) to address some of the issues raised by ACOSOG Z0011
(such as inclusion of patients with micrometastases and exclusion
of patients undergoing mastectomy) and will be included in future
reviews.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Addenbrookes
Methods Study design: RCT
Country: UK
Study period: 1958-1965
Inclusion criteria: clinical stage II breast cancer (a tumour of any size but confined to the
breast tissue with mobile axillary nodes present on the same side, no skin infiltration or
muscle involvement) and judged by the surgeon to be suitable for treatment allocation
including postoperative radiotherapy
Exclusion criteria: none listed, but somepatientswere excluded owing to age, poor general
condition or the surgeon’s opinion that their tumour was unsuitable for treatments
provided in the trial
Length of follow up: 5-12 years
Participants No. in trial arms: simple: N = 113; ALND: N = 91
Age: simple: mean = 54 years; ALND: mean = 54 years
Stage distribution: stage II (entry requirement)
Proportion node positive: simple: 47/113 (42/113 were negative and 24/113 were nil -
no node histopathology - possibly because no nodes were removed); ALND: 51/91 (39/
91 were negative and 1/91 was nil - no node histopathology)
Pathological type of breast cancer: not reported
Interventions Modified simple mastectomy (removal of breast tissue without removal of the pectoral
muscle. This might include removal of accessible axillary glands with no block dissection
of the axilla) + x-ray therapy vs radical mastectomy (removal of breast tissue and sternal
head of the pectoralis-majormuscle and the pectoralis-minormuscle, together with block
dissection of the axilla. The surgeon might remove the internal mammary nodes if he
wished) + x-ray therapy
Outcomes Survival, recurrence-free survival, oedema of the arm, shoulder stiffness, skin graft, de-
layed healing
Axillary node surgery Minimum no. nodes to be removed according to protocol: no minimum for the simple
mastectomy arm - accessible nodes were optionally removed, and some participants had
no nodes removed for histopathology
Nodes removed radical mastectomy arm: not reported
Nodes removed simple mastectomy arm: not reported
Method of node pathological analysis: not reported
Further treatment for node-positive cases: no
Radiotherapy Both arms: X-ray therapy was administered as soon after surgery as possible, typically
within 3-4 weeks. Two 30 × 10 cm longitudinal fields were used to treat the whole
pectoral area, axilla and supraclavicular and internal-mammary-node regions in a single
block. Bolus was used and aminimum tumour dose of 3250r was given, during an overall
time of 18 days, by means of 250 kV rays of h.v.l. 2.7 mm Cu. If wide separation of the
fields was necessary, an extra direct field was used to build up the dose centrally and over
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Addenbrookes (Continued)
the supraclavicular area
RT same in all trial arms? yes
Hormone and chemotherapy Both arms: no details reported
Notes N = ≥ 3 ALND patients had tumours > 5 cm in diameter (i.e. stage III by the 1961
international scheme of clinical staging)
Baseline differences? ALND group included a larger proportion with inner quadrant
tumours
Intention to treat analyses? No details were provided, and for long-term adverse events,
data are missing from N = 106
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Once entered into the trial, the drawing
of an odd or even number from a random
number table decided the type of treat-
ment. This procedure was performed by
personnel who were not in any way con-
cerned with clinical examination or treat-
ment of participants
Allocation concealment (selection bias) Low risk See cell above.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided. Outcome might
have been affected by blinding
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk No details were provided. Outcome might
have been affected by blinding
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were provided. Outcome might
have been affected by blinding
Incomplete outcome data (attrition bias)
Survival
Unclear risk Patients entered into the trial were not re-
ported in Brinkley et al (1966) - only those
who received treatment were reported
Incomplete outcome data (attrition bias)
Axillary recurrence
Unclear risk Outcome was not reported.
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Addenbrookes (Continued)
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk Patients entered into the trial were not re-
ported in Brinkley et al (1966) - only those
who received treatment were reported
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Patients entered into the trial were not re-
ported in Brinkley et al (1966) - only those
who received treatment were reported
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Patients entered into the trial were not re-
ported in Brinkley et al (1966) - only those
who received treatment were reported. In
the 1971 paper, results were reported for
98/114 participants who were still alive
Selective reporting (reporting bias) Low risk Major outcomes were reported.
Addenbrookes 2
Methods Study design: RCT
Country: UK
Study period: 1999-2003
Inclusion criteria: Tumour diameter < 3 cm, histological diagnosis of invasive breast
cancer
Exclusion criteria: prior treatment for breast cancer, pregnancy, clinically involved axillary
nodes, multi-focal breast cancer or previous diagnostic excision biopsy
Length of follow-up (median and range): All participants were reviewed at 3-monthly
intervals for the first year after surgery. The study planned to observe participants yearly
until 5 years
Participants No. in trial arm: ALND: N =155; SLNB: N = 143
Age: ALND: mean (SD) = 58 (10.6) years; SLNB: mean (SD) = 57 (9.5) years
Stage distribution: not reported
Proportion node positive: ALND: 26%; SLNB: 34%
Pathological type of breast cancer: not reported
Interventions Wide local excision/mastectomy + ALND (level 2 axillary node dissection) vs SLNB
(sentinel lymph node biopsy was done via a combined method of blue dye and radioiso-
tope - then, mastectomy/wide local excision was done as planned. ALND was done as a
second procedure if the sentinel node was positive)
Outcomes Arm volume change, subjective lymphoedema, seroma, sensory findings (numbness,
loss of pinprick sensation, loss of light touch sensation, paraesthesia), range of shoulder
movement, psychological morbidity
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed ALND arm: not reported
Nodes removed SLNB arm: not reported
Method of node pathological analysis: combined method of blue dye and isotope with
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Addenbrookes 2 (Continued)
intraoperative detection by gamma probe. All SLNs < 5 mm diameter were bisected,
and both halves were histologically examined. Nodes > 5 mm were sliced into 3 or
more sections and examined histologically. Blocks were sectioned at 3 levels of 100 µm
and stained with hematoxylin and eosin. If no metastases were found in H&E-stained
sections, serial sections from all levels of all blocks were stained with low-molecular-
weight cytokeratin antibody CAM5.2 to identify micrometastases. Nodes > 5 mm were
cut into 3 mm sections; those < 5 mm were embedded as a whole
Further treatment for node-positive cases: yes (ALND)
Radiotherapy RT ALND only arm: Participants received radiotherapy according to local protocols. N
= 137/88% received radiotherapy
RT SLND arm: Participants received radiotherapy according to local protocols. N =
132/92% received radiotherapy
RT same in all trial arms?unclear
Hormone and chemotherapy Participants received chemotherapy and endocrine therapy according to local protocols.
ALND: 23% received chemotherapy and 74% endocrine therapy; SLNB: 30% received
chemotherapy and 80% endocrine therapy
Notes Baseline differences? Table 1 shows comparable baseline characteristics. Text reports no
significant differences between groups
Intention to treat analyses? Short-term and long-term adverse events: Main analysis was
done on an intention-to-treat basis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer random number generator was
used.
Allocation concealment (selection bias) Unclear risk Sealed envelopes. Study does not mention
whether they were opaque
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Short term adverse events
High risk No blinding was reported - and it is un-
likely that treating clinicians would have
been blinded to the degree of surgery
Blinding of outcome assessment (detection
bias)
Long term adverse events
High risk No blinding was reported - and it is un-
likely that treating clinicians would have
been blinded to the degree of surgery
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Incomplete outcome data (attrition bias)
Survival
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Axillary recurrence
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Short term adverse events
Low risk Most participants were analysed for pri-
mary endpoints (134/143 in SLNB and
143/155 in ALND groups)
Incomplete outcome data (attrition bias)
Long term adverse events
Low risk Most participants were analysed for pri-
mary endpoints (134/143 in SLNB and
143/155 in ALND groups)
Selective reporting (reporting bias) High risk Some quality of life outcomes were
reported only if statistically significant
(QOL, BIS and MAC scale)
ALMANAC
Methods Study design: RCT
Country: UK
Study period: 1999-2003
Inclusion criteria: patients of either sex who were younger than 80 years and were sched-
uled to have a wide local excision or mastectomy for clinically node-negative invasive
breast cancer regardless of tumour size
Exclusion criteria: multi-centric cancer, previous ipsilateral breast or axillary surgery
other than benign excision biopsy, previous irradiation of the ipsilateral axilla or breast,
preexisting limb disease causing swelling, known allergy to human albumin or Patent
Blue V, pregnancy or breast feeding, inability to complete quality of life questionnaires
in English
Length of follow-up: 12 months
Participants No. in trial arms: SLNB: N = 495 (4 male); ALND: N = 496 (1 male)
Age: SLNB: mean (SD) = 57.4 (9.9) years; ALND: mean (SD) 57.9 (9.8) years
Stage distribution: not reported, but tumour size was as follows: SLNB: ≤ 20 mm, N =
354; 20.1-50 mm, N = 125; > 50 mm, N = 10. ALND: ≤ 20 mm, N = 378; 20.1-50
mm, N = 99; > 50 mm, N = 9
Proportion node positive: SLNB: N = 127/495; ALND: N = 116/496
Pathological type of breast cancer: SLNB: invasive ductal, N = 360; invasive lobular, N
= 40; other, N = 95. ALND: invasive ductal, N = 356; invasive lobular, N = 43; other,
N = 97
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Interventions Sentinel lymph node biopsy (SLNB; using a pharmaceutical compound and a blue dye
with preoperative lymphoscintigraphy) + breast-conserving procedure/mastectomy vs
standard axillary lymph node dissection (ALND; level I-III or 4-node axillary sampling)
+ breast-conserving procedure/mastectomy
Participants with metastatic disease in SNL were offered delayed ALND or axillary
radiotherapy. When no SLN could be identified, ALND was performed
Outcomes Arm morbidity, quality of life, state and trait anxiety, axillary recurrence rate, survival
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed clearance arm: participants (N = 123) who received 4-node sampling:
median (range) = 5 (2-25) nodes per participant; participants (N = 373) who received
ALND: median (range) = 15 (1-42) nodes per participant
Nodes removed SNLB: median (range) = 2 (1-11) per participant
Method of node pathological analysis: All lymph nodes were examined by standard
hematoxylin-eosin staining. Nodes smaller than 5 mm were bisected and stained; larger
nodes were sectioned at 3 mm intervals, and single sections H&E stained. No intraop-
erative histopathology or immunohistochemistry was used
Further treatment for node positive cases: yes (ALND or radiotherapy)
Radiotherapy Both arms: Participants were treated with adjuvant radiotherapy according to standard
institutional protocols.
RT same in all trial arms? not reported
Hormone and chemotherapy Both arms: Participants were treated with adjuvant systemic therapy according to stan-
dard institutional protocols.
Notes N = 37 were excluded because of substantial protocol deviation, or because they dropped
out of the study (i.e. no datawere available for analysis), leaving 954 participants available
for intention-to-treat analyses of efficacy outcomes
Baseline differences? The paper states that the 2 groups of participants were similar with
respect to participant and tumour characteristics
Intention-to-treat analyses? Paper states that intention-to-treat analysis was employed.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
was used.
Allocation concealment (selection bias) Low risk Central allocation was performed by fax.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
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Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were provided.
Incomplete outcome data (attrition bias)
Survival
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Short term adverse events
Low risk Data appear to be available for the vast ma-
jority/all participants
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Follow-up was incomplete (e.g. for lym-
phoedema self-assessment at 3 months in
ALND arm, only 395/476 participants
were included; see Table 2, Mansell 2006)
Selective reporting (reporting bias) Low risk All major outcomes within the stated fol-
low-up period appear to be reported
Cape Town
Methods Study design: RCT
Country: South Africa
Study period: 1968-1971
Inclusion criteria: female patients aged < 76 years with clinical T1-2, N0-1 and M0
breast cancer and fit for surgery
Exclusion criteria: patients with breast cancer with any of the following features: (1)
lump > 5 cm, (2) palpable/fixed/atypical nodes, (3) deep fixation, (4) skin infiltration or
ulceration, (5) any form of oedema of the skin of the breast, (6) metastases
Length of follow-up: 40 months-10 years
Participants No. in trial arms: simple: N = 51 or 52; ALND: N = 43 or 44 (see notes below)
Age: simple: median (range) = 54 (23-75) years; ALND: median (range) = 53 (31-69)
years
Stage distribution: simple: T1: N = 8; T2: N = 39; T3: N = 4. ALND: T1: N =5; T2:
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Cape Town (Continued)
N = 37; T3: N = 1
Proportion node positive: simple: 16/51 or 52; ALND: 22/43 or 44
Pathological type of breast cancer: not reported
Interventions Simple mastectomy alone if nodes were not clinically palpable or with local excision
of enlarged nodes vs radical mastectomy (ALND; mastectomy, axillary clearance and
excision of pectoral muscles)
Outcomes Locoregional recurrence, distant metastases, survival
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed clearance arm: not reported
Nodes removed simple arm: not reported
Method of node pathological analysis: not reported
Further treatment for node-positive cases: no
Radiotherapy Both arms: none initially, but a combination of RT and dromostanolone was given on
relapse
RT same in all trial arms: yes, none
Hormone and chemotherapy Both arms: See cell above.
Notes Helman (1992) states that 51 participants received simple mastectomy and 44 received
ALND; however, Dent (1996) states that 52 participants received simple mastectomy
and 43 received ALND
Trial was terminated early owing to relatively high local recurrence rate after simple
mastectomy
Baseline differences? very limited number of participant characteristics reported. Dent
(1996): Table 1 shows stage and pathological N1, possible excess of T3 and N0 in simple
group?
Intention to treat analyses? Helman (1992) states that 51 participants received simple
mastectomy and 44 received ALND; however, Dent (1996) states that 52 participants
received simple mastectomy and 43 received ALND.No additional details were provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by drawing
lots (Dent, 1996, page 870)
Allocation concealment (selection bias) Low risk Selection of lots was blinded (Dent, 1996,
page 870).
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were reported.
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Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were reported.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Survival
Low risk Outcomes appear to be reported for all par-
ticipants (although the Clarke 2005 paper
describes 3 additional participants in the
simple mastectomy arm)
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Outcomes appear to be reported for all par-
ticipants (although the Clarke 2005 paper
describes 3 additional participants in the
simple mastectomy arm)
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Outcomes appear to be reported for all par-
ticipants (although the Clarke 2005 paper
describes 3 additional participants in the
simple mastectomy arm)
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Outcome was not reported.
Selective reporting (reporting bias) Unclear risk Long-term and short-term adverse events
were not reported.
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Cardiff
Methods Study design: RCT
Country: UK
Study period: 1967-1973
Inclusion criteria: patients with primary breast cancer with tumours of TNM (1958)
stages I and II (T1, T2, N0, N1, M0)
Exclusion criteria: locally advanced or metastatic. No further criteria were reported, but
see also ‘Notes’
Length of follow up: median (range) = 20.6 (17-24) years
Participants No. in trial arms: sampling: N = 103; ALND: N = 97
Age: sampling: median (range) = 55 (31-85) years; ALND: median (range) = 55 (28-81)
years
Stage distribution (clinical): sampling: T1: N = 10; T2: N = 93. ALND: T1: N = 11;
T2: N = 86
Proportion node positive: sampling: N = 37/74, N = 29 ‘not known’; ALND: N = 34/
94, N = 3 ‘not known’
Pathological type of breast cancer: not reported, but Site of tumour was as follows:
sampling: medial: N = 54; other: N = 49. ALND: medial: N = 54; other: N = 43
Interventions Total mastectomy (preserving both pectoral muscles) + dissection of the axillary tail of
the breast to the level of the axillary fat, at which point those lower axillary nodes lying
close to the upper border of the axillary tail were removed for biopsy. In the protocol,
it was stated that the surgeon was responsible for defining lymph nodes for histological
examination, if necessary extending the dissection by removal of a portion of fat from
the lower axilla. If sampled nodes were free of tumour, or if the surgeon had failed to
identify any nodes for histological examination, no further treatment was given vs radical
mastectomywith total removal of the breast and in continuity dissection of axillary nodes
at levels I, II and III (which could include removal of the pectoralis major and minor
muscles (Halsted operation) or preservation of the pectoralis major (Patey operation))
Outcomes Local recurrence-free rates, distant disease-free rates, event-free survival, overall survival
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed clearance arm: not reported
Nodes removed sampling arm: not reported
Method of node pathological analysis: not reported
Further treatment for node-positive cases: yes (radiotherapy)
Radiotherapy Sampling: For those with histopathological involvement of these lower axillary nodes,
the axilla was irradiated to ‘eradicate residual disease’. Treatment consisted of 40 Gy
delivered from a 60Co source in 10 fractions over 4 weeks.
ALND: Radical postoperative radiotherapy was given if axillary node involvement was
histologically confirmed. The dose of radiation was 40 Gy to the chest wall (from a 60Co
source), 35 Gy to supraclavicular and internal mammary regions and 40 Gy to the axilla
by 300 Kv photons, each delivered in 10 fractions over 4 weeks
RT same in all trial arms? no
Hormone and chemotherapy None reported
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Notes N = 1 participant who emigrated in 1982 was lost to follow-up. Sampling: N = 5/103
patients were ineligible (N = 3 were over 75 years of age, N = 1 had previous cancer
of the cervix and N = 1 had non-invasive DCIS [?]). ALND: N = 8/97 patients were
ineligible (N = 3 were over 75 years of age, N = 3 had previous cancer of the breast and
N = 2 had non-invasive DCIS [?])
Baseline differences? The 2 groups of participants appear to be similar with respect to
reported participant and tumour characteristics
Intention to treat analyses? Paper states that intention-to-treat analysis was employed.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas completedwith the use
of sealed cards supplied by the Medical
Computing Unit in Cardiff
Allocation concealment (selection bias) Low risk See cell above.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Survival
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
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Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Outcome was not reported.
Selective reporting (reporting bias) Unclear risk Short-term and long-term adverse events
were not reported.
E’dburgh Sample/Clear
Methods Study design: RCT
Country: Scotland
Study period: 1980-1983
Inclusion criteria: patients with clinically operable invasive breast cancer (T1, T2, oper-
able T3; N0, N1; M0). Fit enough for surgery and radiotherapy
Exclusion criteria: those not available for continuous follow-up, with in situ cancer,
Paget’s disease of the nipple, multiple ipsilateral or contralateral breast cancer
Length of follow-up (median and range): 11.0 (2-13) years
Participants No. in trial arms: sampling: N = 203; ALND: N = 203
Age: sampling: median (range) = 58.7 (25.7-77.1) years; ALND: median (range) = 57
(29.6-76) years
Stage distribution: not reported (most had T1 or T2 tumour and N0 or N1 nodes, some
with operable T3 tumours were also enrolled)
Proportion node positive: sampling: N = 88/203; ALND: N = 80/203
Pathological type of breast cancer: not reported
Interventions Radical mastectomy with axillary node clearance (ALND; via the Patey technique, fat
and nodal tissue were dissected to the level of the first rib) vs mastectomy with axillary
node sample (sampling; the breast was dissected from the underlying chest wall from
medial to lateral and the axillary tail mobilised). Nodes were identified by inspection
and palpation of the axillary tail and connected fat, and 4 were removed for histological
examination
Outcomes Overall survival, distant recurrence, locoregional recurrence, reduced armmobility, severe
interference with daily activities, persistent arm swelling
Axillary node surgery Minimum no. nodes to be removed according to protocol: 4 nodes for axillary sample
Nodes removed sampling arm: mean 6, median 4 (range, 0-19)
Nodes removed clearance arm: mean 20, median 20 (range, 5-46)
Method of node pathological analysis: sampling: Samples of the axillary tail of breast
and related fat were palpated, and additional nodes dissected out, then fixed. ALDN:
Specimenswere assessed radiologically for determinationof node distribution. Specimens
then were placed on a cork board, and the nodes dissected out; these were then labelled
separately or in groups and were fixed. Sections of all nodes were examined by histology
Further treatment for node positive cases: yes (radiotherapy)
Radiotherapy RT node sampling arm: Postoperative radiotherapy (6-MeV) was given to 82/86 partic-
ipants with positive nodes, and to 2 with no identified nodes. Dose ranged from 4000
cGy to 4250 cGy; number of fractions ranged from 10 to 20 in 4 weeks (the radiotherapy
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protocol was modified over the course of the trial)
RT node clearance arm: none
RT same in all trial arms?no
Hormone and chemotherapy Sampling: endocrine therapy (tamoxifen or oophorectomy) 84/203, chemotherapy
(CMF) 10/203, no endocrine or chemotherapy 109/203
ALND: endocrine therapy (tamoxifen or oophorectomy) 96/203, chemotherapy (CMF)
8/203, no endocrine or chemotherapy 99/203
Notes Protocol violations: sampling: N = 16, ALND: N =7
Baseline differences? Groups appear to be comparable at baseline.
Intention-to-treat analyses? Survival, disease control in the axilla, breast cancer recur-
rence: Paper states that data were analysed according to the intention-to-treat principle.
Long-term adverse events: Arm morbidity was reported for only 33.2% of included par-
ticipants chosen alphabetically from those known to be free of local and systemic disease;
therefore, we have not included them
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details were provided.
Allocation concealment (selection bias) Low risk Central randomisation was performed by
telephone from Scottish Cancer Trials Of-
fice (except for first 8 weeks, when partici-
pants were randomised in theatre with se-
quentially numbered cards)
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were reported.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were reported.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were reported.
Incomplete outcome data (attrition bias)
Survival
Low risk Data appear to be available for all partici-
pants.
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Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
High risk Arm morbidity was reported for only 33.
2% of included patients chosen alphabeti-
cally from those known to be free of local
and systemic disease; therefore, we have not
included these data
Selective reporting (reporting bias) Unclear risk Data on short-term and long-term adverse
event outcomes are missing
Edinburgh 1
Methods Study design: RCT
Country: Scotland
Study period: 1987-1995
Inclusion criteria: < 70 years old, unilateral invasive breast cancer of clinical size≤ 4 cm,
no evidence of metastatic disease, considered suitable for either study intervention
Exclusion criteria: clinically multi-centric tumour or considered locally inoperable (T4),
fixed axillary nodes (N2), history of previous invasive carcinoma at any site (except skin
basal cell carcinoma)
Length of follow up: median = 4.1 years
Participants No. in trial arms: axillary clearance: N = 232; axillary sampling: N = 234
Age: axillary clearance: median = 54 years; axillary sampling: median = 54 years
Stage distribution: not reported
Proportion node positive: axillary clearance: N = 78/232; axillary sampling: N = 66/234
Pathological type of breast cancer: axillary clearance: no special type, N = 177; lobular, N
= 11; tubular, N = 16; non-invasive, N = 5; other, N = 23. Axillary sampling: no special
type, N = 176; lobular, N = 11; tubular, N = 13; non-invasive, N = 3; other, N = 31
Interventions Axillary node clearance (level III) vs axillary node sampling (obtain ≥ 4 palpable lymph
nodes from the axilla, starting at the axillary tail and working upwards)
Outcomes Survival, recurrence, range of shoulder movement (6, 12, 24 and 36 months), shoulder
muscle power (6, 12, 24 and 36 months), arm swelling (6, 12, 24 and 36 months)
Axillary node surgery Minimum no. nodes to be removed according to protocol: axillary clearance: level III;
axillary sampling: ≥ 4 palpable lymph nodes
Nodes removed clearance arm: median (range) = 15 (4-36)
Nodes removed sampling arm: median (range) = 5 (2-12)
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Method of node pathological analysis: not reported
Further treatment for node-positive cases: yes (radiotherapy)
Radiotherapy RTnode clearance arm: RT to the breast (45Gy/20 fractions/4wk or 45Gy/25 fractions/
5 wk for larger breasts + a boost to tumour bed by interstitial implant (20 Gy to 85%
reference isodose) or electrons (15 Gy at 100% isodose/5 daily fractions/1 wk, but not
to the axilla (all adjuvant))
RT node sampling arm: RT to the breast (as above) and regional lymphatics (45 Gy/20
fractions/4 wk) and to the axilla when sampling revealed involved nodes (apart from in
N = 5, who were also included in another trial and did not receive RT). N = 39 with
node-negative axilla receiving RT to the axilla (all adjuvant)
RT SNB arm: NA
RT same in all trial arms? no
Hormone and chemotherapy Axillary clearance: tamoxifen N = 163, chemotherapy N = 26, ovarian suppression N =
11, chemotherapy + tamoxifen N = 10, none N = 22 (all adjuvant)
Axilla sampling: tamoxifen N = 174, chemotherapy N = 28, ovarian suppression N = 6,
chemotherapy + tamoxifen N = 9, none N = 17 (all adjuvant)
Notes Participants in both groups received postoperative adjuvant hormone or chemotherapy,
depending on the results of pathology, including axillary node histology and oestrogen
receptor status
Baseline differences? probably, but no statistical analyses compared groups at baseline
Intention-to-treat analyses? survival, disease control in the axilla and breast cancer recur-
rence: stated in paper that intention-to-treat analyses were employed. Long-term adverse
events: stated in paper that analysis was performed per actual treatment received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk List was derived via randomised permuted
blocks of 8.
Allocation concealment (selection bias) Low risk Central allocation was conducted by the
Scottish Cancer Trials Office
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
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Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were provided.
Incomplete outcome data (attrition bias)
Survival
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Data were reported for N = 126-132 in the
axillary clearance group, and for N = 114-
123 in the axilla sampling group
Selective reporting (reporting bias) Low risk All major outcomes appear to have been
reported apart from short-term adverse
events
Genoa
Methods Study design: RCT, non-inferiority
Country: Italy
Study period: 1998-2001
Inclusion criteria: 18-75 years, primary invasive breast cancer as revealed by mammog-
raphy and cytohistology, clinically negative axillary lymph nodes, unifocal tumour ≤ 3
cm as estimated by echography
Exclusion criteria: previous surgery on the same breast or on the ipsilateral axilla, chronic
life-threatening disease possibly preventing adjuvant therapy
Length of follow-up: event-free survival: median = 5.5 ± 1.4 years. Overall survival:
median = 5.6 ± 1.3 years
Participants No. in trial arms: SLNB: N = 110; ALND: N = 115
Age: SLNB: median (range) = 60 (35-75) years; ALND: median (range) = 59 (28-75)
years
Stage distribution: SLNB: pTis N = 1, pT1mic N = 2, pT1a N = 11, pT1b N = 24,
pT1c N = 59, pT2 N = 13; pN0 N = 77, pN1mic N = 5, pN1a N = 21, pN2a N = 6,
pN3a N = 1. ALND: pTis N = 1, pT1mic N = 0, pT1a N = 10, pT1b N = 18, pT1c N
= 57, pT2 N = 29; pN0 N = 79, pN1mic N = 11, pN1a N = 17, pN2a N = 5, pN3a N
= 3
Proportion node positive: SLNB: N = 33/110; ALND: N = 36/115
Pathological type of breast cancer: SLNB: ductal NOS, N = 107; lobular, N = 1; in situ,
N = 1; other, N = 1. ALND: ductal NOS, N = 110; lobular, N = 2; in situ, N = 1; other,
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N = 2
Interventions Breast surgery (mastectomy or conservative quadrantectomy carried out according to
standard criteria) + sentinel lymph node biopsy (SLNB; identified by breast lym-
phoscintigraphy and lymphatic dye mapping) + axillary lymph node dissection (ALND)
vs breast surgery + SLNB + ALND only if SLN was found to be positive at the intraop-
erative evaluation. Any participant whose SLNs could not be identified received ALND
independently of the treatment assigned
Outcomes 5-Year event-free survival and 5-year overall survival, axillary recurrence in those who did
not undergo axillary lymph node dissection, sensitivity and predictive value of SLNB in
ALND arm
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed clearance arm: N = 211, mean = 1.83 per participant
Nodes removed SNB + clearance: N = 194, mean 1.76 per participant
Method of node pathological analysis: SLN bisected on major axis, and 5 pairs of frozen
sections, each 4 µm thick, were cut every 10 µm in each half of the node. The first,
third and fifth sections were stained with hematoxylin-eosin. If negative, then second
and fourth sections were tested with immunohistochemistry for cytokeratins, via cytok-
eratin mAb and horseradish peroxidase. Remaining tissue was embedded in paraffin for
postoperative evaluation
Further treatment for node-positive cases: yes (ALND and/or adjuvant therapy)
Radiotherapy ALND or SLNB: Only participants who received conservative surgery were given radio-
therapy (50 Gy/8 wk) to the ipsilateral breast. No RT was given to the axilla
RT same in all trial arms? yes
Hormone and chemotherapy Both arms: The choice of adjuvant chemotherapy and/or hormone therapy regimen,
when given, was based on the main prognostic factors of the primary tumour (nodal
status, tumour size, tumour grading, hormonal receptor status)
Notes No SLN was found in 3 patients who had ALND (1 control/2 research). Study was pow-
ered for 2570 participants; only 248 were recruited, and the trial was interrupted when
participants became aware of promising SLNB procedure and refused randomisation to
ALND
Baseline differences? No statistically significant differences between groups were noted
at baseline
Intention-to-treat analyses? Paper stated that intention-to-treat analyses were employed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
was used.
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Allocation concealment (selection bias) Low risk Central allocation was conducted by the
Epidemiology and Clinical Trials Unit of
the Institute
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Survival
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Outcome was not reported.
Selective reporting (reporting bias) Unclear risk Short-term and long-term adverse events
were not reported.
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Methods Study design: RCT (non-inferiority)
Country: Italy
Study period: 1999-2004
Inclusion criteria: patients with invasive breast cancer ≤ 3 cm and clinically negative
axilla
Exclusion criteria: non-palpable tumours, multiple tumours, ductal carcinoma in situ,
tumours > 3 cm, clinically positive axilla, distant metastases, previous neoadjuvant ther-
apy, pregnancy, > 80 years of age
Length of follow-up: median (IQR) = 55.6 (42.4-63.1) months
Participants No. in trial arms: ALND: N = 352; SLNB: N = 345
Age: ALND: mean (SD) = 58.2 (10.6) years; SLNB: mean (SD) = 57.6 (10.4) years
Stage distribution: not reported, but size of tumour was as follows: ALND: T1a, N =
7; T1b, N = 72; T1c, N = 208; T2 (≤ 3 cm), N = 63; T4, N = 0; not available, N =
2. SLNB: T1a N, 12; T1b N, 67; T1c N, 198, T2 (≤ 3 cm), N = 63; T4 N = 3, not
available, N = 2
Proportion node positive: ALND: N = 108/334 (with identified SLN); SLNB: N = 99/
328 (with identified SLN)
Pathological type of breast cancer: not reported
Interventions SLNB+ALND (at least nodes located at the I-II Berg levelswere removed) vs SLNBwith
frozen section and histological examination followed by ALND if SLNB was positive.
All participants had surgical treatment of the primary tumour before SLNB
Outcomes Disease-free survival, overall survival, physical morbidity, quality of life
Axillary node surgery Minimum no. nodes to be removed according to protocol: axillary clearance: see Inter-
ventions
Nodes removed ALND arm: not reported
Nodes removed SNLB + ALND: not reported
Method of node pathological analysis: For frozen section analysis, sentinel lymph nodes
of diameter 5 mm or less were bisected, larger nodes were sectioned every 2 to 3 mm.
For each sample, 2 frozen sections made at 40 µm were analysed. For the definitive
analysis, 2 consecutive 5 µm sections were cut from a paraffin block, 40 µm apart from
each other. These sections were hematoxylin-eosin stained and immunostained with a
monoclonal antibody to cytokeratin
Further treatment for node positive cases: yes (ALND and/or adjuvant therapy)
Radiotherapy All participants who underwent conservative breast surgery (ALND: N = 297; SLNB:
N = 293) received radiation to the ipsilateral breast with 50 Gy of high-energy photons
RT same in all trial arms? yes
Hormone and chemotherapy Participants with unfavourable prognostic features were given chemotherapy or hormone
therapy according to the practice of the treating centre
Notes ALND: N = 323/334 (with identified SLN) underwent ALDN (level I-II-III dissection:
N = 268; level I-II dissection: N = 55). In 11 cases, scheduled completion of ALDN was
not performed owing to protocol violation
SLNB: N = 94/99 (with positive SLN) received ALND (level I-II-III dissection: N = 78;
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level I-II dissection: N = 16). Five participants refused ALND completion
Designed as a non-inferiority study that aimed to recruit 1498 participants. Trial was
stopped early owing to participant and clinician preference for SLNB
Baseline differences? Groups appear to be comparable, but no statistical analyses are
reported to compare groups at baseline
Intention-to-treat analyses? All statistical analyses were based on the intent-to-treat prin-
ciple
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participant randomisation was carried out
by telephone through the Clinical Trials
and Biostatistics Unit of Padova, via com-
puter-generated random numbers to select
random permuted blocks stratified by par-
ticipating centre. Block lengths of 4 and 6
were randomly varied
Allocation concealment (selection bias) Low risk See cell above.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were provided.
Incomplete outcome data (attrition bias)
Survival
Unclear risk Study authors report that all participants
randomisedwere analysed for primary end-
point (5-year DFS; Zavagno, 2008), but
survival curves show incomplete follow-up
to 60 months
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all partici-
pants.
56Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
GIVOM Sentinella (Continued)
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk Study authors report that all participants
randomisedwere analysed for primary end-
point (5-year DFS; Zavagno, 2008), but
survival curves show incomplete follow-up
to 60 months
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk > 90% and 75% of participants, respec-
tively, completed morbidity assessments by
surgeons up until 18 months and at 24
months
Selective reporting (reporting bias) Unclear risk All major outcomes appear to have been
reported apart from short-term adverse
events
Guy’s
Methods Study design: 2 RCTs
Country: UK
Study period: 1961-1975 (RCT 1, 1961-1970; RCT 2, 1971-1975)
Inclusion criteria: women withManchester stage I or 2 (T1-2, N0-1 [RCT1], M0) breast
cancer judged suitable for radical mastectomy or extended tylectomy (wide excision).
RCT 1 included only women aged ≥ 50, whereas RCT 2 included women of any age
but restricted disease classifications to T1-2, N0-1a, M0
Exclusion criteria: none listed
Length of follow-up: median follow up = 24.7 years
Participants No. in trial arms: wide excision: N = 305; ALND: N = 324
Age: wide excision: mean (range) = 58 (27-80) years; ALND: mean (range) = 56 (25-
90) years (P = 0.03)
Stage distribution: not reported, but tumour size was ≤ 2 cm: N = 83 in wide excision
and N = 77 in ALND group; > 2 and ≤ 5 cm: N = 190 in wide excision and N = 209 in
ALND group; > 5 cm: N = 29 in wide excision and N = 28 in ALND group (P = 0.63)
Proportion node positive: 46% of participants treated via radical mastectomy had patho-
logically involved axillary nodes. Wide excision: clinically node positive 71/304 (from
Clarke 2005 meta-analysis web figures 10A/B); ALND: clinically node positive 85/326
(from Clarke 2005 meta-analysis web figures 10A/B)
Pathological type of breast cancer: histology: grade I: N = 63 in wide excision and N =
72 in ALND; grade II: N = 169 in wide excision and N = 176 in ALND; grade III: N =
60 in wide excision and N = 64 in ALND; lobular: N = 4 in wide excision and N = 2 in
ALND; other: N = 9 in wide excision and N = 10 in ALND; contralateral tumour: N =
28 in wide excision and N = 41 in ALND (P = 0.9)
Interventions Extended tylectomy, or wide excision, of the lump, together with surrounding breast
tissue within 3 cm of palpable or visible growth + thiotepa + radiotherapy vs radical
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mastectomy (standard Halsted operation, except that the clavicular head of the pectoralis
major muscle was conserved) + synoperative thiotepa + radiotherapy
Outcomes Overall survival, breast cancer survival, distant recurrence, local recurrence, arm function,
lymphoedema, activity, attitude
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed clearance arm: not reported
Nodes removed wide excision arm: not reported
Method of node pathological analysis: All nodes were sectioned in specimens removed
at radical mastectomy. No further details were reported
Further treatment for node positive cases: no
Radiotherapy Wide excision: same as ALND with the exception that overall treatment time to supr-
aclavicular triangle and axilla was 12 days (i.e. 25-27 Gy) and breast was treated with
parallel opposing fields on a 6 MeV linear accelerator via “Lincolnshire bolus” to bring
the peak dose to the surface. Tumour dose = 3500-3800 rads in 3 weeks (an additional
35-38 Gy)
ALND: RT to the axilla, supraclavicular triangle and internal mammary chain via a 300
kV machine with 10 × 8 cm field sizes for the axilla and supraclavicular triangle and 15
× 7.5 cm field sizes for the internal mammary chain. Supraclavicular and axillary fields
directed to cross at the apex of the axilla giving a tumour dose at this point of 2500-
2700 rads. Treatment was given 5 days a week for 18 days (25-27 Gy)
RT same in all trial arms? no
Hormone and chemotherapy Both arms: synoperative thiotepa at doses of 2 mg per 6.4 kg body weight with premed-
ication, 1.5 mg per 6.4 kg body weight on second postoperative day and 1 mg per 6.4
kg body weight on fourth postoperative day. However, no patient entering the trial after
1968 received thiotepa
Notes No. in trial arms differs slightly from that reported in the Clarke 2005 meta-analysis
(web figures 10A and B): ALND: N = 326, wide excision: N = 304
Baseline differences? With Bonferroni adjustment for multiple comparisons, the age
difference is no longer statistically significant
Intention-to-treat analyses? Survival, disease control in the axilla and breast cancer re-
currence: no details reported. Long-term adverse events: outcomes reported only for N
= 77-92 for wide excision arm, and for N = 90-104 for ALND arm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out by drawing
a ticket from a box
Allocation concealment (selection bias) Unclear risk It is unclear whether allocation could be
seen on the ticket
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Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were provided.
Incomplete outcome data (attrition bias)
Survival
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Axillary recurrence
Unclear risk No details were reported.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk No details were reported.
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
High risk Outcomes were reported only for RCT 1
and only for N = 77-92 from the wide ex-
cision arm, and for N = 90-104 from the
ALND arm
Selective reporting (reporting bias) Unclear risk Short-term adverse events were not re-
ported, and long-term adverse events were
reported for < 1/3 of participants
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Methods Study design: RCT
Country: UK
Study period: 1965-1970
Inclusion criteria: patients with clinical stage T1N0, T2N0, T1N1 and T2N1 primary
lesions and no evidence of distant metastatic disease; patients with T3 lesions for which
the T3 category was decided solely on the size of the tumour; and patients with clinically
involved axillary nodes were included, irrespective of the size and position of nodes, but
only if they remained mobile.
Exclusion criteria: patients with lesions that had excessive skin tethering or any attach-
ment to pectoral muscles, patients with fixed axillary nodes (N2) or involved supraclav-
icular nodes (N3)
Length of follow up: 4-9 years (median not reported. If recruitment was at a constant
rate, median follow-up would be 6.5 years by 1974)
Participants No. in trial arms: radical: N = 95; simple: N = 100
Age: not reported
Stage distribution: not reported
Proportion node positive: not reported by trial arm (overall 79/195 - 41% had clinically
involved nodes at time of trial entry)
Pathological type of breast cancer: not reported
Interventions Simple total mastectomy + postoperative radiotherapy vs radical mastectomy (Halsted)
+ postoperative radiotherapy
Outcomes Overall survival, short-term postoperative mortality, local recurrence, morbidity (stiff
shoulder, swollen arm)
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed clearance arm: not reported
Nodes removed SNLB: not reported
Method of node pathological analysis: not reported
Further treatment for node-positive cases: no
Radiotherapy Radical: postoperative radiotherapy to the apex of the axilla and to supraclavicular,
infraclavicular and internal mammary lymph nodes
Simple: postoperative radiotherapy to the chest wall, axilla and supraclavicular, infra-
clavicular and internal mammary lymph nodes
RT same in all trial arms? no
Hormone and chemotherapy All but 1 participant who were premenopausal or within 10 years of stopping menstrua-
tion also received ‘prophylactic’ oophorectomy, which usually was carried out at the time
of mastectomy
Notes 100% follow up (1974), although some follow-up was conducted by post. Need to locate
final trial report if it was ever published
Baseline differences? For allocation of participants, paired stratification was employed
with the following stratification factors: age, menopausal status, child-bearing history
and exact clinical stage (TNM). No further details were reported
Intention-to-treat analyses? Data were reported only for 76 matched participant pairs.
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22% of participants were excluded from analysis because they were unmatched. Were
these unmatched participants different in a systematic way?
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly allocated to 1
or another of the 2 treatment groups after
matching, via random number tables
Allocation concealment (selection bias) Unclear risk For allocation of participants, paired strat-
ification was employed with the following
stratification factors: age, menopausal sta-
tus, child-bearing history and exact clinical
stage (TNM). No further details were re-
ported
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were provided.
Incomplete outcome data (attrition bias)
Survival
Unclear risk Datawere reported only for the 76matched
participant pairs. 22% of participants were
excluded from analysis because they were
unmatched. Were these unmatched partic-
ipants different in a systematic way?
Incomplete outcome data (attrition bias)
Axillary recurrence
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk Datawere reported only for the 76matched
participant pairs. 22% of participants were
excluded from analysis because they were
unmatched. Were these unmatched partic-
ipants different in a systematic way?
61Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hammersmith (Continued)
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Low risk All 195 participants were measured for stiff
shoulder/swollen arm. Follow-up was re-
ported as 100%
Selective reporting (reporting bias) Unclear risk Short-term adverse events were not re-
ported.
IBCSG-10-93
Methods Study design: RCT (originally conceived as a non-inferiority trial - see notes
Country: international
Study period: 1993-2002
Inclusion criteria: postmenopausal patients aged≥ 60 years with clinically node-negative
operable breast cancer. All patients had a histologically proven unilateral breast cancer
of stage T1a-b, T2a-b, T3, N0 or M0 with ER-positive or ER-negative primary tumours
Exclusion criteria: treatment started before randomisation, prior or concurrent malig-
nancy
Length of follow up: median = 6.6 years
Participants No. in trial arms: surgery alone: N = 239; ALND: N = 234
Age: surgery alone: median (range) = 74 (60-91) years; ALND:median (range) = 74 (60-
91) years
Stage distribution: not reported, but tumour size was as follows: surgery alone: ≤ 20
mm, N = 137; > 20 mm, N = 100; unknown, N = 2. ALND: ≤ 20 mm, N = 126; > 20
mm, N = 100; unknown, N = 8
Proportion node positive: surgery alone: not examined (axilla not dissected in N = 232/
239); ALND: N = 64/230 (axilla not dissected in N = 4)
Pathological type of breast cancer: not reported, but ER status was as follows: surgery
alone: positive, N = 201; negative, N = 31; unknown, N = 7. ALND: positive, N = 179;
negative, N = 46; unknown, N = 9
Interventions Surgery alone (total mastectomy, N = 106; breast-conserving surgery with (N = 77) or
without (N = 56) radiotherapy) vs surgery (total mastectomy, N = 105; breast-conserving
surgery with (N = 78) or without (N = 51) radiotherapy) + axillary clearance
Outcomes Quality of life (including adverse events), disease-free survival, overall survival
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed clearance arm: not reported
Nodes removed no axillary surgery: not reported
Method of node pathological analysis: not reported
Further treatment for node-positive cases: no
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Radiotherapy Both arms: Radiotherapy using 2 tangential fields was recommended after breast-con-
serving surgery. No further details were reported
RT same in all trial arms? not reported
Hormone and chemotherapy HRT: surgery alone: no, N = 184; yes, N = 52; unknown, N = 3. ALND: no, N = 184;
yes, N = 50
Both arms: Participants were treated with adjuvant tamoxifen (20 mg) for 5 years. In
August 2002, IBCSG Scientific Commmittee made a recommendation to discontinue
tamoxifen for participants with endocrine non-responsive tumours
Notes N = 19 did not meet protocol eligibility criteria, but these patients were included in
intention-to-treat analyses. Originally designed as a non-inferiority trial with estimated
sample size of 1020 - poor accrual meant a change in design to assess whether avoiding
ALND improved quality of life
Baseline differences? Paper states that baseline characteristics were balanced according to
randomly assigned treatment arms
Intention-to-treat analyses? Survival, disease control in the axilla, breast cancer recur-
rence: Paper states that intention-to-treat analysis was employed. Short-term and long-
term adverse events: data not available for all participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted blocks randomisation sched-
ule was produced by use of pseudo-ran-
dom numbers generated by a congruence
method
Allocation concealment (selection bias) Low risk Random assignment was performed cen-
trally.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were provided.
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Incomplete outcome data (attrition bias)
Survival
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Short term adverse events
High risk Data were available only for subgroups of
surgery alone participants and ALND par-
ticipants
Incomplete outcome data (attrition bias)
Long term adverse events
High risk Data were available only for subgroups of
surgery alone participants and ALND par-
ticipants
Selective reporting (reporting bias) Unclear risk Some adverse events were not reported.
Institut Bergonie
Methods Study design: RCT (equivalence trial)
Country: France
Study period: 1995-2005
Inclusion criteria: postmenopausal female patients aged ≥ 50 years with early invasive
breast cancer (tumour size ≤ 10 cm)
Exclusion criteria: patients with inflammation, palpable axillary nodes (clinical N+),
metastasis, prior contralateral invasive cancer or other carcinoma or limited survival
prognosis (< 10 years)
Length of follow-up: 5 years
Participants No. in trial arms (these are reported per protocol): no ALND: N = 297 (ITT, N = 312)
; ALND: N = 310 (ITT, N = 313)
Age: no ALND: median (range) = 62.6 (50-81) years; ALND: mean (range) = 61.6 (50-
87) years
Stage distribution (histological tumour size): no ALND: mean = 7.1 mm; 1-5 mm, N =
86; 6-10 mm, N = 196; > 10 mm, N = 9; missing, N = 6. ALND: mean = 7.25 mm; 1-
5 mm, N = 82; 6-10 mm, N = 208; > 10 mm, N = 19; missing, N = 1
Proportion node positive: 42 ALND participants
Pathological type of breast cancer: no ALND: invasive ductal, N = 232; invasive lobular,
N = 23; other, N = 42. ALND: invasive ductal, N = 236; invasive lobular, N = 28; other:
N = 45
Interventions Standard surgery was performed according to the same technique for all eligible patients:
radical modified mastectomy or lumpectomy involving an excision ≥ 10 mm surround-
ing the tumour with section slices for histological analysis to ensure free margins. For
the ALND group, axillary lymph node clearance was standard and was limited to nodes
inferior to the axillary vein (Berg levels I and II): no ALND (standard surgery + adjuvant
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treatment if indicated) vs ALND (surgery + standard axillary lymph node clearance +
adjuvant treatment if indicated)
Outcomes 5-year overall survival, event-free survival, functional outcomes
Axillary node surgery Minimum no. nodes to be removed according to protocol: 10 or more
Nodes removed clearance arm: see “Interventions”
Nodes removed no ALND arm: none
Method of node pathological analysis: not reported
Further treatment for node-positive cases: yes (adjuvant chemotherapy if histologically
or biologically indicated)
Radiotherapy All lumpectomy participants and most mastectomy participants as indicated (i.e. with
involved nodes): 50 Gy over the whole breast or chest wall with no axillary irradiation
RT same in all trial arms? yes
Hormone and chemotherapy Both arms: Participants with oestrogen- or progesterone-positive receptors or unknown
status received 20 mg tamoxifen daily from surgery for 3 (participants randomised be-
fore 23/9/02) or 5 (participants randomised after 23/9/02) years. For negative receptor
participants, no endocrine therapy was prescribed, but adjuvant chemotherapy was pre-
scribed as indicated. If histologically or biologically indicated, adjuvant chemotherapy
was prescribed after surgery according to the practices of each centre
Notes At the first interim analysis, enrolment was stopped early (600 enrolled instead of the
1600 expected) owing to lack of equivalence in OS, better than predicted survival in
the no ALND arm and changes in clinical practice (e.g. sentinel lymph node dissection,
changes in adjuvant endocrine therapy)
Baseline differences? Groups appear to be comparable at baseline, except in terms of
receipt of adjuvant therapy with 270 and 6 of the 297 no ALND participants receiving
endocrine and chemotherapy, respectively, compared with 203 and 26 of 310 ALND
participants, respectively
Intention-to-treat analyses? Data available only on an intention-to-treat basis for overall
survival. Remaining outcomes are reported per protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomization was performed by block,
stratified by centre and by operation time:
either histological diagnosiswas knownand
randomisation was performed after histo-
logical analysis; or, randomisation was per-
formed intra-operatively and was based on
extemporaneously-assessed size.” No fur-
ther information was provided
Allocation concealment (selection bias) Unclear risk See cell above.
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Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were provided.
Incomplete outcome data (attrition bias)
Survival
Low risk All data appear to have been included as
intention-to-treat.
Incomplete outcome data (attrition bias)
Axillary recurrence
Unclear risk Data were reported only per protocol with
data missing from 15 no ALND and 3
ALND participants
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk Data were reported only per protocol with
data missing from 15 no ALND and 3
ALND participants
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Data were reported only per protocol for
543/625 participants
Selective reporting (reporting bias) Unclear risk All major outcomes appear to have been
reported apart from short-term adverse
events
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Methods Study design: RCT
Country: France
Study period: 1982-1987
Inclusion criteria: female patients aged < 70 years with no history of previous cancer, no
previous treatment, presenting with a unilateral invasive carcinoma < (Louis-Sylvestre
2004) or≤ (Cabanes 1992) 3 cm, no clinically involved axillary lymph node (N0, Louis-
Sylvestre 2004; or N0-N1a, Cabanes 1992) and non-metastatic (M0) disease
Exclusion criteria: patients age > 70 years with cancer at another site (apart from basal
cell carcinoma and intraepithelial carcinoma of the cervix), patients who could not be
regularly followed up at the Institut Curie
Length of follow up: median (range) = 180 (12-221) months
Participants No. in trial arms: RT: N = 332; ALND: N = 326
Age: RT: mean = 50.6 years; ALND: mean = 52 years
Stage distribution: RT: T1, N = 233; T2, N = 99; clinical N0, N = 256; clinical N1a, N
= 76. ALND: T1, N = 207; T2, N = 119; clinical N0, N = 270; clinical N1a, N = 56
Proportion node positive: 68/322 who received ALND (i.e. 2 RT participants and 320
ALND participants (see also notes))
Pathological type of breast cancer: RT: invasive intraductal, N = 286; other, N = 46.
ALND: invasive intraductal, N = 268; other, N = 58
Interventions Lumpectomy (wide local excision of the tumour with macroscopically healthy margins)
+ RT to the breast and axillary and internal mammary lymph nodes vs lumpectomy
(wide local excision (with macroscopically healthymargins) + axillary dissection (limited
to nodes inferior to the axillary vein; level I and lower level II nodes) + RT to supraclav-
icular and internal mammary lymph nodes in participants with histologically confirmed
metastatic lymph nodes. If medial or central tumour was diagnosed in this group, inter-
nal mammary lymph nodes were also irradiated
Outcomes Overall survival, local and lymph node recurrence, metastases, disease-free survival
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed clearance arm: see “Interventions”
Nodes removed RT arm: none
Method of node pathological analysis: not reported
Further treatment for node-positive cases: yes (hormone or chemotherapy)
Radiotherapy Both arms: 55 Gy fractionated over 6 weeks to the breast. 10-15 Gy boost to the tumour
bed
Axillary nodes: 50 Gy
Internal mammary nodes and supraclavicular nodes: 45 Gy
RT same in all trial arms? no
Hormone and chemotherapy Both arms: Adjuvantmedical treatmentwas available depending on the number of lymph
nodes invaded and menopausal status
Chemotherapy: RT: N = 9; ALND: N = 19
Hormone therapy: RT: N = 8; ALND: N = 14
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Notes The treatment protocol was not followed in 15 participants (RT: N = 2, N1 patients
underwent dissection; N = 4, underwent mastectomy; ALND: N = 6, did not have
dissection (and consequently received no treatment of the axilla); N = 3, underwent
mastectomy). In addition, 7 N1 participants (RT: N = 6; ALND: N = 1) were enrolled,
although they should not have been included in the protocol
N = 11 were lost to follow-up at 5 years, and N = 58 were lost to follow-up at 10 years,
but unclear to which group they belonged
Baseline differences? Groups appear to be comparable at baseline.
Intention-to-treat analyses? Cabanes (1992) and Louis-Sylvestre (2004; fromwhich data
were extracted): Both state that participants with protocol violations were maintained in
the group to which they had initially been assigned for purposes of statistical analysis,
which was conducted in an intention-to-treat fashion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Paper states that randomisation was done
by sealed envelopes (equilibrated every 6
participants) in the operating theatre after
verification that participants satisfied the
inclusion criteria. No further details were
provided
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were reported.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were reported.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Survival
Unclear risk N = 11 were lost to follow-up at 5 years; N
= 58 were lost to follow-up at 10 years, but
it is unclear to which group they belonged
Incomplete outcome data (attrition bias)
Axillary recurrence
Unclear risk See cell above.
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Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk See cell above.
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Outcome was not reported.
Selective reporting (reporting bias) Unclear risk Long-term and short-term adverse events
were not reported.
Malmo
Methods Study design: RCT
Country: Sweden
Study period: 1969-1974
Inclusion criteria: patients with microscopically verified breast cancer ≤ 5 cm and clini-
cally node negative
Exclusion criteria: none reported
Length of follow-up: range = 15-20 years
Participants No. in trial arms: ALND + RT: N = 97; mastectomy only: N = 98
Age: ALND + RT: mean (SD) = 54.6 (10.2) years; mastectomy only: mean (SD) = 57.
7 (10) years
Stage distribution: not reported, but Size of tumour was as follows: ALND + RT: mean
(SD) = 2 (1) cm; mastectomy only: mean (SD) = 1.9 (1) cm
Proportion node positive: ALND: 28/97; mastectomy only, N = 3 at surgery and N =
11 during first postoperative year
Pathological type of breast cancer: not reported
Interventions ALND + RT vs mastectomy alone
Outcomes Survival, chest wall recurrence
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed ALND + RT arm: not reported
Nodes removed mastectomy arm: not reported, but presumably none?
Method of node pathological analysis: not reported
Further treatment for node-positive cases: no
Radiotherapy ALDN + RT: Postoperative radiotherapy was delivered with conventional x-rays to the
axilla (140 kV, HVL 6.6 mmCu) and chest wall (100 kV, HVL 2.7 mmCu) with surface
doses to the chest wall of 31.5 Gy in 3.5 Gy fractions, and to the axilla of 28 Gy in 4
Gy fractions, 5 times a week. Supraclavicular and parasternal nodes were treated with
cobalt-60 or electrons, with peak absorbed doses of 48 Gy in fractions of 3 Gy, 4 times
per week.
Mastectomy only: If axillarymetastases were diagnosed later on during follow-up, axillary
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dissection with postoperative radiotherapy was performed
RT same in all trial arms? no
Hormone and chemotherapy Not reported
Notes N = 8 ALDN + RT and N = 6 mastectomy only participants were not strictly treated
according to protocol
Baseline differences? very few baseline characteristics reported
Intention-to-treat analyses? Survival: Per-protocol results are presented, but study authors
state in the text that results of intention-to-treat analyses were similar without presenting
data for these analyses. Disease control in the axilla and breast cancer recurrence: Some
participants were not treated according to protocol; it is unclear if they are included in
the analyses, and, if yes, it is unclear how they are included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables were used (page
557, Borgstrom 1994).
Allocation concealment (selection bias) Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Survival
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Data appear to be available for all partici-
pants.
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Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Outcome was not reported.
Selective reporting (reporting bias) Unclear risk Outcomes are incompletely reported, and
adverse events are not reported at all
Manchester
Methods Study design: RCT
Country: UK
Study period: 1970-1975
Inclusion criteria: new cases of clinical stage II (T1-2, N1, M0) breast carcinoma
Exclusion criteria: males, women aged > 70 years, history of cancer of the opposite breast,
intercurrent disease, unavailable for follow-up, pregnancy and lactation
Length of follow up: 5-10 years
Participants No. in trial arms: simple mastectomy + postoperative radiotherapy (PORT): N = 159;
ALND: N = 149
Age: simple mastectomy + PORT: mean (SD) = 55.2 (9.6) years; ALND: mean (SD) =
55.1 (9.9) years (latter value includes only N = 148)
Stage distribution: T2 = 83% in both groups
Proportion node positive: not reported
Pathological type of breast cancer: not reported
Interventions Simple mastectomy (removal of the whole breast including pectoral fascia but without
intentional removal of any axillary node; thin skin flaps were to be avoided and transverse
incisions preferred) + PORT vs radical mastectomy (removal of the whole breast with
dissection of axillary nodes; removal of pectoral muscles up to the individual surgeon)
Outcomes Local recurrence rate, breast cancer death, overall survival
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed clearance arm: not reported
Nodes removed sampling arm: NA
Nodes removed SNLB: NA
Method of node pathological analysis: not reported
Further treatment for node-positive cases: no
Radiotherapy Simple mastectomy arm: Participants were treated with adjuvant radiotherapy according
to 1 of the following 2 techniques.
1. Quadrate technique (3 fields (300 kV) at a tangent to the chest wall, irradiating the
chest wall, the parasternal region and the axilla; also a field to the supraclavicular fossa
and a posterior field to the apex of the of the axilla (est dose 3700 rads in 3 weeks); or
2. Peripheral and tangent pair technique as follows.
a. Single megavoltage (4 MV) field consisting of irradiation of the parasternal, supra-
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clavicular and axillary regions from the front (given dose 4000 rads in 3 weeks); or
b. Parallel pair of fields to the chest wall, 300 kV (mid-dose 3000 rads in 3 weeks; max
dose to the skin 3800-4500 rads)
RT same in all trial arms? no. RT given only in simple mastectomy arm
Hormone and chemotherapy Both arms: Participants who were premenopausal or < 3 years postmenopausal were
offered artificial menopause by x-ray or surgical castration.
Notes Treatment of N = 20 and 16, respectively, deviated from protocol in the simple mastec-
tomy + PORT and radical mastectomy arms. However, all participants were analysed
according to randomised treatment allocation (i.e. intention to treat-analyses were per-
formed)
Baseline differences? Paper states that the 2 groups of participants were similar with
respect to age, menopausal status and tumour site within the breast
Intention-to-treat analyses? Paper states that intention-to-treat analysis was employed.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly allocated, with
stratification by surgeon, to one or other of
the treatment groups under comparison.”
(Lythgoe 1978, page 744). No additional
details were provided
Allocation concealment (selection bias) Unclear risk “Patients were randomly allocated, with
stratification by surgeon, to one or other of
the treatment groups under comparison.”
(Lythgoe 1978, page 744). No additional
details were provided
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk Outcome was not reported.
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Incomplete outcome data (attrition bias)
Survival
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Outcome was not reported.
Selective reporting (reporting bias) Unclear risk Short-term and long-term adverse events
were not reported.
Milan
Methods Study design: randomised controlled trial
Country: Italy
Study period:1998 to 1999
Inclusion criteria: women aged 40-75 years with invasive primary breast cancer ≤ 2 cm,
treated with breast-conserving surgery
Exclusion criteria: history of other cancer (except non-melanoma skin cancer), multi-
centric breast cancer and previous excisional biopsy
Length of follow-up ( median and range): 102 months (1-120 months)
Participants No. in trial arm: ALND: N = 257; SLNB: N = 259
Age: ALND: median (range) = 56 (40-75) years; SLNB: median (range) = 55 (40-75)
years
Stage distribution: not reported
Proportion node positive: ALND: 83/259; SLNB: 92/259
Histological type of breast cancer: ALND: ductal infiltrating, N = 212; lobular infiltrat-
ing, N = 20; other, N = 25. SLNB: ductal infiltrating, N = 209; lobular infiltrating, N
= 18; other, N = 32
Interventions Sentinel lymph node biopsy (SLNB) plus axillary lymph node dissection (ALND) vs
SLNB followed by ALND only if metastases were found in the SLN. Both groups also
received breast-conserving surgery
Outcomes Overall survival, breast cancer-related events (axillary metastases, supraclavicular metas-
tases, intrabreast tumour reappearance, distant metastases), contralateral breast cancer,
axillary pain, numbness or paraesthesia on operated side, arm mobility, aesthetic ap-
pearance of axillary scar, arm swelling (difference between circumference of treated and
untreated arms)
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Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported, but at least 1
sentinel node should have been removed
Nodes removed ALND arm: 429 SLN from 257 participants (mean = 1.66 SLN/par-
ticipant; mean non-sentinel lymph nodes/participant = 24)
Nodes removed SLNB arm: 424 SLN from 259 participants (mean = 1.63 SLN/partic-
ipant; mean non-sentinel lymph nodes/participant = 24)
Method of node pathological analysis: Each sentinel node was bisected along major axis,
embedded in optimal-cutting-temperature compound, then frozen in isopentane cooled
with liquid nitrogen (SLNs < 5mmdiameter were embedded and frozenwhole). 15 pairs
of 4 µm thick sections were cut at 50 µm intervals, from each half node (60 sections/
node). Any remaining tissue was sectioned at 100 µm intervals. If more than 1 sentinel
node was found, all were analysed in this way. One section of each pair was hematoxylin
and eosin stained; if this was ambiguous, the other section of the pair was stained for
cytokeratins
Further treatment for node-positive cases: yes (ALND)
Radiotherapy RT ALND arm: 50 Gy to ipsilateral breast over 8 weeks, with 10 Gy boost to skin
surrounding the surgical scar
RT SLND arm: 50 Gy to ipsilateral breast over 8 weeks, with 10 Gy boost to skin
surrounding the surgical scar
RT same in all trial arms?yes
Hormone and chemotherapy ALND: hormonal therapy: N = 133; chemotherapy: N = 21; both hormonal and che-
motherapy: N = 99; neither: N = 4
ALND: Hormonal therapy: N = 126; chemotherapy: N = 16; both hormonal and che-
motherapy: N = 106; neither: N = 11
Significantly more women in ALND arm had chemotherapy than in SLNB arm, but
rates of hormone therapy - both hormone and chemotherapy and no hormone or che-
motherapy - did not differ between groups
Notes Baseline differences? Groups appear comparable.
Intention-to-treat analyses? Survival, disease control in axilla and breast cancer recur-
rence: per-protocol analysis employed, but few protocol violations (7/264 ALDN partic-
ipants and 9/268 SLNB participants were excluded from analyses). Long-term adverse
events: no intention-to-treat analyses undertaken. Only women with negative sentinel
nodes (who did not go on to have ALND) were included in the SLND group for long-
term adverse events analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated permuted blocks
Allocation concealment (selection bias) Low risk Randomised after resection of tumour.
Data centre telephoned surgeon with treat-
ment group information
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Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No information was provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No information was provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No information was provided.
Incomplete outcome data (attrition bias)
Survival
Low risk Participants are accounted for at 10-year
follow-up (Veronesi 2010)
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Participants are accounted for at 10-year
follow-up (Veronesi 2010)
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Participants are accounted for at 10-year
follow-up (Veronesi 2010)
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
High risk Only a sample of 100 women from each
group was included in this analysis. The
SLND group sample was biased - see below
Selective reporting (reporting bias) Unclear risk Short-term adverse events were not re-
ported.
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Methods Study design: randomised clinical trial
Country: Italy
Study period:1996 to 2000 (trial entry period)
Inclusion criteria:women with primary operable breast cancer≤ 2 cm inmammographic
diameter, clinically negative axillary nodes, aged 65 to 80 years
Exclusion criteria:synchronous bilateral breast cancer, distant metastases at diagnosis,
history of othermalignancy (except basal cell carcinoma or intraepithelial cervical cancer)
Length of follow-up: ALND: median (range) = 150 (125-175) months. No ALND:
median (range) = 149 (124-174) months
Participants No. in trial arm: ALND: N = 109; no ALDN: N = 110
Age: ALND: median (range) = 70 (65-80 ) years; no ALND: median (range) = 70 (65-
80 ) years
Stage distribution: ALDN: T1a, N = 2; T1b, N = 30; T1c, N = 69; T2, N = 8. No
ALDN: T1a, N = 6; T1b, N = 44; T1c, N = 52; T2, N = 8
Proportion node positive: ALDN: 25/109. No ALDN: not reported, but 2/110 (1.8%)
required delayed axillary dissection for overt axillary disease during follow-up
Pathological type of breast cancer: ALDN: Infiltrating ductal carcinoma, N = 60; infil-
trating lobular carcinoma, N = 20; other infiltrating carcinoma, N = 29. No ALDN:
infiltrating ductal carcinoma, N = 61; infiltrating lobular carcinoma, N = 19; other in-
filtrating carcinoma, N = 30
Interventions Quadrantectomy plus axillary dissection (all 3 Berg levels removed) vs quadrantectomy
alone
Outcomes Overall mortality, breast cancer mortality, breast events (ipsilateral tumour recurrence,
contralateral breast cancer, distant metastases)
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported
Nodes removed axillary dissection arm: not reported
Nodes removed no axillary dissection arm: not reported
Method of node pathological analysis: not reported
Further treatment for node-positive cases: no
Radiotherapy RT ALND arm: postoperative RT to residual breast within 4 weeks of surgery. Axillary,
supraclavicular and internal nodes were NOT irradiated, but RT fields used typically
included the lower part of level I of the axilla. 50 Gy over 5 weeks, with a supplemental
boost of 10 Gy to the tumour bed
RTnoALNDarm:postoperativeRT to residual breastwithin 4weeks of surgery. Axillary,
supraclavicular and internal nodes were NOT irradiated, but RT fields used typically
included the lower part of level I of the axilla. 50 Gy over 5 weeks, with a supplemental
boost of 10 Gy to the tumour bed
RT same in all trial arms?yes
Hormone and chemotherapy All women were prescribed 10 mg tamoxifen twice daily after surgery for 5 years. 15%
discontinued tamoxifen owing to side effects
Notes Baseline differences? possible excess of stage T1c in axillary dissection arm - Table 1 (page
3, Martelli et al 2005). No P values were reported
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Intention-to-treat analyses? yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list was reported (page 242,
Martelli et al 2005), but it was not reported
how this list was derived
Allocation concealment (selection bias) Low risk Allocation was performed by calling data
centre manager at study centre (page 2,
Martelli et al 2005)
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk This was not reported.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk This was not reported.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Survival
Unclear risk 14 participants were excluded from analysis
for protocol violation. It is unclear towhich
group they were randomised
Incomplete outcome data (attrition bias)
Axillary recurrence
Unclear risk 14 participants were excluded from analysis
for protocol violation. It is unclear towhich
group they were randomised
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk 14 participants were excluded from analysis
for protocol violation. It is unclear towhich
group they were randomised
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Outcome was not reported.
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Selective reporting (reporting bias) Unclear risk Short-term and long-term adverse events
were not reported.
Milan 3
Methods Study design: single-centre RCT (non-inferiority)
Country: Italy
Study period:1998 to 2003
Inclusion criteria: patients with mammographically detected T1 N0 breast cancer, aged
65 to 80 years
Exclusion criteria: bilateral or pluricentric breast cancer, distant metastases, history of
previous malignancy or histological evidence of non-infiltrating carcinoma only. Patients
with unexpected pathological findings of bifocal breast cancer (smaller lesion close to
the reference cancer); patients with T1 disease with tumour size > 2 cm at final histology
were not excluded
Length of follow-up: median (IQR) = 127.5 (112.5-141.1) months
Participants No. in trial arm: ALND: N = 272; no ALND: N = 245
Age: ALND: mean (SD) = 52.7 (7.5) years; no ALND: mean (SD) = 52.5 (7.9) years
Stage distribution: ALDN: T1A/B, N = 92; T1C, N = 174; T2, N = 6. No ALDN:
T1A/B, N = 88; T1C, N = 154; T2, N = 3
Proportion node positive (histopathologically confirmed): ALDN: 78/272 participants;
no ALDN: not reported
Pathological type of breast cancer: ALDN: invasive ductal carcinoma, N = 179; invasive
ductal carcinoma + invasive lobular carcinoma, N = 29; invasive lobular carcinoma, N
= 40; other, N = 24. No ALDN: invasive ductal carcinoma, N = 154; invasive ductal
carcinoma + invasive lobular carcinoma, N = 36; invasive lobular carcinoma, N = 32;
other, N = 23
Interventions Quadrantectomy + complete ALND (3 Berg levels) vs quadrantectomy without ALND
Outcomes Disease-free survival, overall survival, local recurrence, distant metastases, axillary relapse
Axillary node surgery Minimum no. nodes to be removed according to protocol: not reported, beyond 3 Berg
levels
Nodes removed axillary dissection arm: median (range) = 20 (11-43)
Nodes removed no axillary dissection arm: not reported
Method of node pathological analysis: Formalin-fixed paraffin-embedded surgical spec-
imens were sectioned and stained with hematoxylin and eosin. Tumours considered to
be positive for oestrogen receptor/progesterone receptors if > 10% of tumour cell nuclei
were immunostained
Further treatment for node-positive cases: yes, see the 2 cells below
Radiotherapy RT ALND arm: postoperative RT to the operated breast, with no attempt to include
the axilla or supraclavicular or internal mammary lymph nodes in the irradiation fields.
Participants (N = 132) with node-negative, oestrogen receptor-positive and grade I-II
received RT and no adjuvant treatment (outlined in cell below); patients (N = 140)
with node-positive and/or oestrogen receptor-negative and/or grade III received adjuvant
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treatment followed by radiotherapy
RT no ALND arm: postoperative RT to the operated breast, with no attempt to include
the axilla or supraclavicular or internal mammary lymph nodes in the irradiation fields.
Participants (N = 158) with oestrogen receptor-positive and up to 1 of the following
features: grade III, HER2-positive or laminin receptor-positive received RT and no
adjuvant treatment (outlined in cell below); patients (N = 87) with oestrogen receptor-
negative with or without more than 1 of the following features: grade III, HER2-positive
or laminin receptor-positive received adjuvant treatment followed by radiotherapy
RT same in all trial arms?yes, it seems so
Hormone and chemotherapy Anthracycline-based adjuvant chemotherapy consisted of epirubicin 120 mg/m2 every 3
weeks for 4 cycles followedby cyclophosphamide 600mg/m2 ondays 1 and8,methotrex-
ate 40 mg/m2 on days 1 and 8 and 5-fluorouracil 600 mg/m2 on days 1 and 8 every 4
weeks for 4 cycles. Hormonal treatment for all participants after chemotherapy consisted
of tamoxifen 20 mg/d for 5 years
140/ 272 (51%) participants in the ALND arm received chemotherapy, and 87/245
(36%) in the no ALND arm received chemotherapy (difference was significant at P < 0.
001)
Notes Baseline differences? possible difference in proportion of participants with a favourable
prognostic profile: ALND = 48.5%; no ALND = 64.5%
Intention-to-treat analyses? no, the only analyses presented were conducted on an as-
treated basis. Among randomised participants, 14 ALND participants and 34 no ALND
participants did not receive assigned treatment and were excluded from analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Email contact with the corresponding au-
thor confirmed that “The women for trial
INT09/98 were randomised by calling the
data manager at the study coordination
centre. After the inclusion and exclusion
criteria had been checked, eligible women
were assigned to axillary dissection vs no
axillary surgery using a randomisation list.
”
Allocation concealment (selection bias) Low risk See cell above.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No information was reported.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No information was reported.
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Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk No information was reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No information was reported.
Incomplete outcome data (attrition bias)
Survival
Low risk 14/286 ALND participants and 34/279
no ALND participants did not receive as-
signed treatment and were excluded from
analyses
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk 14/286 ALND participants and 34/279
no ALND participants did not receive as-
signed treatment and were excluded from
analyses
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk 14/286 ALND participants and 34/279
no ALND participants did not receive as-
signed treatment and were excluded from
analyses
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Outcome was not reported.
Selective reporting (reporting bias) High risk No morbidity outcomes were reported.
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Methods Study design: RCT
Country: USA and Canada
Study period: 1971-1974
Inclusion criteria: women with primary operable potentially curable breast cancer, with
tumours confined to breast or breast and axilla, with tumours moveable in relation to
underlying muscle and chest wall, with axillary nodes moveable in relation to chest wall
and neuromuscular bundle, with no arm oedema
Exclusion criteria: pregnancy, lactation previous treatment for current neoplasm, prior
or concomitant cancer other than an effectively managed basal or squamous cell skin
tumour, bilateral breast cancer, tumour other than a carcinoma, inflammatory tumour,
skin ulceration > 2 cm, peau d’orange involving more than one-third of the skin of the
breast, satellite or parasternal nodules, fixation of axillary lymph nodes (> 2 cm), lymph
nodes elsewhere suspected of containing tumour unproved by biopsy to be negative,
poor surgical risks precluding any treatment options, presence of non-malignant systemic
disease making prolonged follow-up unlikely
Length of follow-up: 25 years
Participants No. in trial arms: clinically node negative: ALND: N = 389; total mastectomy + RT: N =
386; total mastectomy alone: N = 384. Clinically node positive: ALND: N = 301; total
mastectomy + RT: N = 305
Age: clinically node negative: ALND: 56.5 years; total mastectomy + RT: 55.6 years;
total mastectomy alone: 56.4 years. Clinically node positive: ALND: 55.3 years; total
mastectomy + RT: 55.3 years
Stage distribution: not reported, but Pathologic size of tumour was (for 1599/1665
participants): clinically node negative: ALND: 3.2 (SD1.99) cm; total mastectomy +RT:
3.4 (SD 2.25) cm; total mastectomy alone: 3.1 (SD 1.73) cm. Clinically node positive:
ALND: 3.7 (SD 2.02) cm; total mastectomy + RT: 3.7 (SD 1.95) cm
Proportion node positive: See No. in trial arms entry above.
Pathological type of breast cancer (for 1578/1665 participants): clinically node negative:
ALND: infiltrating duct not otherwise stated (NOS) pure 46.3%, infiltrating duct NOS
combinations 35.1%,medullary 3.5%, lobular 5.6%,mucoid 2.9%, tubular 0.9%, other
5.6%. Total mastectomy + RT: infiltrating duct NOS pure 48.5%, infiltrating duct
NOS combinations 31%, medullary 3.3%, lobular 5.4%, mucoid 3.3%, tubular 1.5%,
other 6.9%. Total mastectomy alone: infiltrating duct NOS pure 41.2%, infiltrating
duct NOS combinations 37.2%, medullary 6%, lobular 7.1%, mucoid 2%, tubular 1.
1%, other 5.4%. Clinically node positive: ALND: infiltrating duct NOS pure 57.1%,
infiltrating duct NOS combinations 25.6%, medullary 8.4%, lobular 4.4%, mucoid 1.
5%, tubular 0.4%, other 2.6%. Total mastectomy + RT: infiltrating duct NOS pure
62.1%, infiltrating duct NOS combinations 23.4%, medullary 3.9%, lobular 4.3%,
mucoid 1.1%, tubular 0.7%, other 4.6%
Interventions Participants were clinically assessed to be axillary node positive or axillary node negative
before randomisation, then were randomly assigned to the following treatments:
If node negative: radical mastectomy (see below) vs total mastectomy (see below) + re-
gional radiation vs total mastectomy alone. Participants designated as having clinically
negative axillary nodes who had a total mastectomy and subsequently developed clinical
evidence of axillary node involvement in the absence of other manifestations of disease
were managed as follows. biopsy of involved nodes was performed to determine their
status. If such nodes were reported as tumour positive, an axillary dissection was per-
formed
81Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NSABP B-04 (Continued)
If node positive: radical mastectomy vs total mastectomy + regional radiation. Radical
mastectomy: removal of breast, pectoral muscles and axillary content en bloc. Total
(simple) mastectomy: total removal of breast tissue in that area bounded by the midline
of the sternum extending superiorly to the supraclavicular space, posteriorly along the
lateral edge of the latissimus dorsi and inferiorly to the costal margin. Removal of the
nipple was included. The pectoral fascia but not the pectoral muscles, together with an
adequate excision of skin affected by tumour, was removed. No operative intervention
was permissible in the axilla beyond the border of the pectoral muscle per protocol
Outcomes Disease-free survival, overall survival, arm oedema
Axillary node surgery Minimum no. nodes to be removed according to protocol: axillary clearance: see Inter-
ventions
Nodes removed ALND arm: median = 15.5 nodes, mean = 17.7 nodes (range, 3-63)
Nodes removed total mastectomy: two-thirds of participants having a total mastectomy
had no nodes in the specimen; in 90%, ≤ 5, in 97%, ≤ 10. Median = 0 nodes, mean =
2 nodes (range, 0-31)
Method of node pathological analysis: not reported
Further treatment for histological node-positive cases: no (but in the clinical node nega-
tive arm - ALNDwas done if nodes became clinically involved and histological evidence
showed node metastasis on biopsy)
Radiotherapy Participants in the total mastectomy + RT arm
Clinically negative axillary node: Both internal mammary and supraclavicular nodes
received a tumour dose of 45 Gy in 25 fractions. Both chest wall and mid-axilla received
a tumour dose of 50 Gy in 25 fractions
Clinically positive axillary node: as for clinically node-negative participants + an addi-
tional 10-20 Gy boost to the mid-axilla
RT same in all trial arms? no
Hormone and chemotherapy None received adjuvant systemic therapy.
Notes 68/365 node-negative women who received total mastectomy alone subsequently had
pathological confirmation of positive ipsilateral nodes. Positive nodes were identified
within 2 years of surgery in 51/68, > 2-5 years after surgery in 10/68, > 5-10 years
after surgery in 6/68 and > 10 years after surgery in 1/68. Median (range) time from
mastectomy to identification of positive axillary nodes = 14.8 (3-134.5) months
Baseline differences? Groups appear to be comparable at baseline.
Intention-to-treat analyses? not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details were reported.
Allocation concealment (selection bias) Unclear risk No details were reported.
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Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Survival
Unclear risk Data were reported for clinically node neg-
ative: ALND: N = 362/389; total mastec-
tomy +RT:N=352/386; total mastectomy
alone: N = 365/384. Clinically node pos-
itive: ALND: N = 292/301; total mastec-
tomy + RT: N = 294/305
Incomplete outcome data (attrition bias)
Axillary recurrence
Unclear risk Data were reported for clinically node neg-
ative: ALND: N = 362/389; total mastec-
tomy +RT:N=352/386; total mastectomy
alone: N = 365/384. Clinically node pos-
itive: ALND: N = 292/301; total mastec-
tomy + RT: N = 294/305
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk Data were reported for clinically node neg-
ative: ALND: N = 362/389; total mastec-
tomy +RT:N=352/386; total mastectomy
alone: N = 365/384. Clinically node pos-
itive: ALND: N = 292/301; total mastec-
tomy + RT: N = 294/305
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Outcome was not reported.
Selective reporting (reporting bias) Unclear risk Short-term and long-term adverse events
were not reported.
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Methods Study design: RCT (multi-centre)
Country: USA and Canada
Study period: 2001-2004
Inclusion criteria: patients with operable invasive primary breast cancer and clinically
node negative
Exclusion criteria: none listed
Length of follow up: median (for all participants) = 131.1 months; median (for SLN-
negative participants) = 9.4 years
Participants Total N = 5611, but data reported only in full publications for pathologically SLN-
negative participants:
No. in trial arms: ALND: N = 1975; SLN: N = 2011
Age: ALND: ≤ 49 years: N = 488; ≥ 50 years: N = 1490; SLN: ≤ 49 years: N = 491;
≥ 50 years: N = 1520
Stage distribution: not reported
Proportion node positive: Pathologically node-positive participants were not included
in the present analyses
Pathological type of breast cancer: not reported, but clinical tumour size was reported:
ALND: ≤ 2 cm: N = 1655; 2.1-4 cm: N = 291; ≥ 4.1 cm: N = 32; SLN: ≤ 2 cm: N =
1689; 2.1-4 cm: N = 294; ≥ 4.1 cm: N = 28
Interventions SLN resection + ALND vs SLN resection without ALND if SLN were negative, and
with ALND if SLN were positive or if no SLN were identified during SLN resection
Outcomes Survival, regional control, morbidity, quality of life
Axillary node surgery Minimum no. nodes to be removed according to protocol: ALND: not reported
Nodes removed ALND arm: not reported
Nodes removed SLN resection: not reported
Method of node pathological analysis: All SLNs were fixed and paraffin-embedded, and
serial sections were obtained in 2-3 mm slices. Staining with hematoxylin and eosin was
done, and immunohistochemistry was reserved for confirmation of suspected metastases
Radiotherapy Patients in the ALND arm: not reported
Patients in the SLN arm: not reported
RT same in all trial arms? unclear, but 1618/1975 ALND participants and 1650/2011
SLN participants received RT
Hormone and chemotherapy 1680/1975 ALND participants and 1694/2011 SLN participants received systemic ad-
juvant therapy (not further specified)
Notes A majority of data were reported only for pathologically SLN-negative participants: In
addition to these participants, N = 829 were pathologically SLN-positive/SLN-not as-
sessed in the ALND group, and N = 793 SLN-positive/SLN-not assessed in the SLN
group. A substudy was conducted within the whole study, which studied quality of
life: “By design, the sub study included all SN-negative patients randomly assigned at
participating institutions designated as members of the Community Clinical Oncology
Program, a National Cancer Institute program that encourages clinical trial participa-
tion by community-based physicians.” This substudy included data from 356 and 391
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ALND and SNL participants, respectively; these data are not included here, as it is un-
clear how participating institutions designated as members of the Community Clinical
Oncology Program differ from participating institutions not designated as members of
the Community Clinical Oncology Program. Email contact with study authors allowed
us to include results for all randomised participants (i.e. both node-positive and node-
negative participants for the following outcomes: overall survival, disease-free survival,
local/regional recurrence and axillary recurrence
Baseline differences? Groups appear to be comparable at baseline.
Intention-to-treat analyses? yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation was performed
with use of a biased coin minimisation
method
Allocation concealment (selection bias) Low risk Participants were randomly assigned in a 1:
1 ratio at the NSABP Biostatistical Centre
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No information was reported.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No information was reported.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk No information was reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No information was reported.
Incomplete outcome data (attrition bias)
Survival
Low risk All data from those participants were in-
cluded.
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk All data from those participants were in-
cluded.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk All data from those participant were in-
cluded.
Incomplete outcome data (attrition bias)
Short term adverse events
Low risk Most participants appear to have been in-
cluded.
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Incomplete outcome data (attrition bias)
Long term adverse events
High risk Data were reasonably complete at baseline,
but progressively larger proportions of data
were missing at week 1, weeks 2-3 and
months 6, 12, 18, 24, 30 and 36
Selective reporting (reporting bias) Unclear risk Data from SLN-positive participants were
not reported in detail, and poor report-
ing of short-term adverse events precluded
treatment group comparisons
Ostersund
Methods Study design: RCT
Country: Sweden
Study period: 1985-1987 and 1989-1991
Inclusion criteria: none listed directly, but it seems that included patients had to be
residents of the hospital’s catchment area with operable breast cancer
Exclusion criteria: none listed, but N = 62 patients who were residents of the catchment
areawho had breast cancer diagnosed during study periods were not included in the study
for the following reasons: N = 31 elderly or disabled patients treated with tamoxifen only,
N = 23 elderly patients who had simple mastectomy or lumpectomy without axillary
staging, N = 4 patients at stage IV on admission, N = 4 for other reasons
Length of follow-up: median (range) = 30 (5-76) months (for participants without
histologically confirmed lymph node involvement in the axilla)
Participants No. in trial arms: axillary clearance: N = 100 (N = 50 from each time period); axillary
sampling: N = 100 (N = 50 from each time period)
Age (1987-89 and 1989-91 samples): axillary clearance: median (range) = 60 (31-85)
years; axillary sampling: median (range) = 60 (37-84) years
Age (1987-89 sample only): axillary clearance: mean (SD) = 59 (12) years; axillary
sampling: mean (SD) = 61 (13) years
Stage distribution: not reported
Proportion node positive: axillary clearance: N = 43/100; axillary sampling: N = 46/100
Pathological type of breast cancer: not reported, but tumour diameter was reported
Tumour diameter (1987-89 and 1989-91 samples): axillary clearance: median (range) =
21 (7-70) mm; axillary sampling: median (range) = 21 (9-80) mm
Tumour diameter (1987-89 sample only): axillary clearance: mean (SD) = 24 (11) mm
(?); axillary sampling: mean (SD) = 23 (9) mm (?)
Primary surgery (1987-89 and 1989-91 samples): axillary clearance: total mastectomies
N = 67, partial mastectomies N = 33; axillary sampling: total mastectomies N = 63,
partial mastectomies N = 37
Primary surgery (1987-89 sample only): axillary clearance: total mastectomies N = 33,
partial mastectomies N = 17; axillary sampling: total mastectomies N = 33, partial
mastectomies N = 17
Interventions Axillary dissection (aimed to remove all fat tissue in axilla up to the axilla vein. No
muscles were divided. The vein and the nerves to the anterior serratus and latissimus
dorsi muscles were identified and carefully exposed. No attempt was made to save the
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intercostobrachial nerves; procedure corresponds to level II clearance) vs axillary node
sampling (aimed to excise axillary fat containing lymph nodes. If no nodes were palpable,
the lower half of the axillary fat was excised. Any suspected pathological nodes were also
removed. No special efforts were made to identify the vein or the nerves)
All: In general, women < 70 years or with T1 tumours (largest diameter onmammograms
< 2 cm) received partial mastectomy, and women with T2 tumours or > 70 years with
T1 tumours received mastectomy.
Outcomes Recurrence (1987-89 & 1989-91 samples), operating time (1987-89 sample only), post-
operative discharge (1987-89 sample only), duration of postoperative drainage (1987-
89 sample only), hospital stay (1987-89 sample only), seroma (1987-89 sample only)
, shoulder mobility (12 months; 1987-89 sample only), arm volume (3, 6, 12 months;
1987-89 sample only), sensibility (6 months; 1987-89 sample only)
Axillary node surgery Minimum no. nodes to be removed according to protocol: axillary clearance: not re-
ported beyond details in ‘Interventions’. Axillary sampling: not reported beyond details
in ‘Interventions’
Nodes removed clearance arm (1987-89 and 1989-91 samples): median (range) = 8.5
(0-16); median (range) positive nodes: 2 (1-14)
Nodes removed sampling arm (1987-89 and 1989-91 samples): median (range) = 6 (0-
14); median (range) positive nodes: 2 (1-9)
Nodes removed clearance arm (1987-89 sample only): mean (range) = 7.2 (3-16)
Nodes removed sampling arm (1987-89 sample only): mean (range) = 4.5 (0-10)
Nodes removed SNB + clearance: NA
Method of node pathological analysis: histopathological examination (axillary fat was
cut into slices 55 mm thick, and each slice was crushedmanually and searched for lymph
nodes, including microscopy)
Further treatment for node-positive cases: yes (radiotherapy)
Radiotherapy All: postoperative RT given to women < 70 years (1) after partial mastectomy, (2) with
T2 tumour irrespective of N status, (3) with lymph node metastases. RT included the
axilla (except in 3 participants with partial mastectomy; clearance N = 2, sampling N =
1, who received RT to the breast only). The type of axillary operation did not influence
indications for or extent of RT. RT generally began 1 month after surgery and was
given over 4-5 weeks. Radiation to the axilla was delivered with mega-voltage photons,
averaging 43 (38-46) Gy to the anterior port. Radiation after mastectomy was given with
electrons to the thoracic wall in doses averaging 38 Gy. After partial mastectomy, 58 Gy
was given to the breast with photons
RT same in all trial arms? yes
Hormone and chemotherapy Chemotherapywas not used, but tamoxifen was given toN = 24 postmenopausal women
with nodal metastases (clearance N = 11, sampling N = 13)
Notes For the 1987-89 sample, follow-up of 95 participants was complete follow-up. Of the
remaining 5 participants, 2 moved out of the area and 2 died of disseminated disease (1
of each from each treatment group and 1 dissection participant could not participate in
final follow-up).
Baseline differences? Only a few baseline characteristics were reported.
Intention-to-treat analyses? not reported
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information was reported beyond that
participants were randomised
Allocation concealment (selection bias) Unclear risk No information was reported.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk No details were provided.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were provided.
Incomplete outcome data (attrition bias)
Survival
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Data appear to be available for all partici-
pants.
Incomplete outcome data (attrition bias)
Short term adverse events
High risk Outcome was reported only for the 1987-
1989 sample, that is, for 50/100 partici-
pants
Incomplete outcome data (attrition bias)
Long term adverse events
High risk Outcome was reported only for the 1987-
1989 sample, that is, for 50/100 partici-
pants
Selective reporting (reporting bias) Unclear risk Survival was not reported (but this may
be reasonable given the low rates of recur-
rence). However, adverse events were re-
ported only for the 1987-89 sample
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Methods Study design: RCT
Country: Scotland
Study period: 1964-1971
Inclusion criteria: operable breast cancer (stage I, II and some III), age 35 to 60 years
Exclusion criteria: skin involvement wider than the tumour, ulceration > 3 cm, peau
d’orange wide of the tumour, tumour fixed to the chest wall, homolateral axillary nodes
fixed to each other or to adjacent structures, homolateral supraclavicular or infraclavicular
nodes moveable or fixed, oedema of the arm, distant metastases detected by clinical
examination or X-rays of chest and pelvis
Length of follow-up (median and range): 5-12 years
Participants No. in trial arms: axillary clearance: N = 256 (N = 288 in Clarke 2005 meta-analysis);
simple mastectomy: N = 242 (N = 273 in Clarke 2005 meta-analysis)
Age: axillary clearance: mean (SD) = 54.7 (9.2) years; simple mastectomy: mean (SD) =
55.4 (8.8) years
Stage distribution: axillary clearance: stage I: N = 144, stage II: N = 60, stage III: N =
52. Simple mastectomy: stage I: N = 131, stage II: N = 64, stage 3: N = 47
Proportion node positive: axillary clearance: N = 89/288; simple mastectomy: N = 93/
273
Pathological type of breast cancer: not reported
Interventions Radical mastectomy (breast, pectoral muscles and axillary contents were removed en
bloc) vs simple mastectomy (breast removed) plus (postoperative) radiotherapy
Outcomes Overall survival, breast cancer recurrence, long-term and short-term complications
Axillary node surgery Minimum no. nodes to be removed according to protocol
Nodes removed axillary dissection arm: not reported, but see “Interventions”
Nodes removed no axillary dissection arm: none
Method of node pathological analysis: not reported
Further treatment for node-positive cases: no
Radiotherapy RT ALND arm: none
RT simple mastectomy: 45 Gy to the breast/chest wall/internal mammary nodes in 10
fractions over 4 weeks. 42.5 Gy to the axilla and supraclavicular regions in 10 fractions
over 4 weeks
RT same in all trial arms? no
Hormone and chemotherapy All participants aged 35-60 years were given prophylactic bilateral oophorectomy. Par-
ticipants who refused oophorectomy were given ovarian irradiation (aged 41-59 years)
or were withdrawn from the trial (aged 35-40 years and aged 41-59 years who refused
ovarian irradiation)
Notes 1099 participants were randomised, and 512/1099 were withdrawn owing to benign
breast tumour; an additional 89 participants were excluded from study publications ow-
ing to protocol violations, leaving 498 treated within the trial protocol (Hamilton 1977)
; however, data do not match Clarke 2005 numbers. All participants in the per-protocol
analysis had bilateral surgical oophorectomy or ovarian ablation by radiotherapy, some
included in the Clarke 2005 analysis may not have received this. We have assumed that
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the reason participant numbers are higher in the Clarke 2005 analysis is that investigators
included some of the 89 patients excluded owing to protocol violations
Baseline differences? Groups appear to be comparable at baseline.
Intention-to-treat analyses? No. N = 89 were excluded owing to protocol violations.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation was not re-
ported.
Allocation concealment (selection bias) Low risk Random allocation was conducted by cen-
tral office.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk No details were reported.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk No details were reported.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk No details were reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk No details were reported.
Incomplete outcome data (attrition bias)
Survival
Low risk The Clarke 2005 analysis includes 561 of
the eligible 587 participants (i.e. included
participants + those excluded for protocol
violations)
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Although no participants have been lost to
follow-up, data are reported only for per-
protocol treated participants. These num-
bers seem to be balanced between groups
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk The Clarke 2005 analysis contains 561 of
the 587 eligible patients (i.e. included par-
ticipants + those excluded for protocol vi-
olations)
Incomplete outcome data (attrition bias)
Short term adverse events
High risk Data were reported only for the first 100
participants included in each group
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Incomplete outcome data (attrition bias)
Long term adverse events
High risk Data were reported only for the first 100
participants included in each group
Selective reporting (reporting bias) Unclear risk Thsi trial was conducted in 1964-1971;
still, no updated results have been pub-
lished for short-term and long-term adverse
events
SNAC
Methods Study design: RCT
Country: Australia
Study period: 2001-2005
Inclusion criteria: patients with primary unifocal breast cancer, ≤ (Gill 2009) or < (Gill
2004; Smith 2009; Ung 2004) 3 cm in diameter, node negative on clinical evaluation,
WHO PS 0-1 and able to maintain regular follow-up
Exclusion criteria: surgery for prior ipsilateral breast cancer or prior ipsilateral axillary
surgery, < 18 years old, pregnant, allergic to blue dye or radioisotope, multi-centric
cancer, ductal carcinoma in situ, evidence of metastatic disease
Length of follow-up: 12 months
Participants No. in trial arms: SLNB: N = 544; ALND: N = 544
Age: SLNB: ≤ 30 years, N = 2; 30-49 years, N = 118; 50-69 years, N = 354; ≥ 70 years,
N = 71. ALND: age ≤ 30 years, N = 2; 30-49 years, N = 117; 50-69 years, N = 358; ≥
70 years, N = 66
Stage distribution: not reported, but Primary tumour size was as follows: SLND: ≤ 1
cm, N = 149; > 1-2 cm, N =243; > 2-3 cm, N = 101; ≥ 3 cm, N = 48. ALND: ≤ 1 cm,
N = 146; > 1-2 cm, N =244; > 2-3 cm, N = 103; ≥ 3 cm N = 42
Proportion node positive: SLNB: 159/544 (sentinel node); ALND: 137/544 (sentinel
node positive)
Pathological type of breast cancer: not reported
Interventions Sentinel lymph node biopsy (SLNB; performedwith blue dye together with preoperative
radioisotope lymphoscintigraphy (N = 954) or blue dye alone (N = 119) + axillary
clearance if any node from the SLNDwas positive (regardless of its location. If a sentinel
node was not identified, axillary clearance was performed during the initial procedure) vs
standard level I and II axillary lymph node dissection (ALND; removal of all anatomical
level I and II nodes). All participants also had wide local excision or mastectomy
Outcomes Arm morbidity, surgery-related morbidity
Axillary node surgery Minimum no. nodes to be removed according to protocol: SLND (all nodes judged to
be hot, blue or both) followed by level I and level II axillary node dissection
Nodes removed clearance arm: mean = 16 (lower and upper quartiles = 12 and 20,
respectively) nodes per participant
Nodes removed SNLB: mean = 16 (lower and upper quartiles = 10 and 20, respectively)
nodes per participant
Across both groups, the mean number of sentinel nodes removed was 1.8 (SD = 1)
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SNAC (Continued)
Method of node pathological analysis: SLNs sliced grossly into 2 mm slices embedded in
paraffin blocks, sectioned in 4 steps at 200-micron intervals and H&E stained. Sections
were also prepared on coated slides with anti-keratin antibody CAM 5.2 to facilitate
visualisation of smaller metastases. 33 women in the SLND arm had intraoperative
pathology. Nodes from axillary clearance were examined with 1 H&E section
Further treatment for node-positive cases: yes (ALND)
Radiotherapy Both arms: Postoperative adjuvant therapies were prescribed at the discretion of local
clinicians according to national guidelines based on standard criteria
RT same in all trial arms? not reported
Hormone and chemotherapy Both arms: No participants had received neoadjuvant chemotherapy. See also cell above
Notes Data for several outcomes were missing.
Baseline differences? The 2 groups of participants appear to be balanced with respect to
participant characteristics
Intention-to-treat analyses? Paper states that all analyses were performed on an intention-
to-treat basis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central random assignmentwas performed
by staff at theNational Health andMedical
Research Council Clinical Trials Centre on
the basis of a computerised minimisation
algorithm for balancing randomisation for
each institution and the following charac-
teristics: age < 50 years, palpable primary
tumour, planned lymphatic mapping with
blue dye alone
Allocation concealment (selection bias) Low risk See cell above.
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk No details were reported.
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Blinding of outcome assessment (detection
bias)
Long term adverse events
High risk Arm volume, shoulder movement and sen-
sation were measured by a clinician who
was not blinded to participants’ treatment
groups. Participants assessed arm mor-
bidity subjectively by using study-specific
scales; they were not blinded
Incomplete outcome data (attrition bias)
Survival
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Axillary recurrence
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Short term adverse events
Low risk Data appear to be available for 539/544
ALNDparticipants and for 544/544SLNB
participants
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Data appear to be available for 456-519/
544 SLND participants and for 457-509/
544 ALND participants
Selective reporting (reporting bias) Unclear risk Survival, disease-free survival and recur-
rence were not reported. Arm swelling and
symptoms were assessed but were not re-
ported at 1 month
WSSA Glasgow
Methods Study design: 3-arm RCT
Country: Scotland
Study period:1972-1977
Inclusion criteria: aged ≤ 76 years, operable breast cancer, no deep fixation or skin
involvement, no fixation of axillary lymph nodes
Exclusion criteria: none reported
Length of follow-up: 5 years in EBCTCG 1990
Participants Simple mastectomy with radiotherapy to the chest wall but not to nodal areas (Arm A)
vs simple mastectomy with radiotherapy to both chest wall and nodal areas (Arm B) vs
simple mastectomy with axillary clearance and radiotherapy to the chest wall but not to
nodal areas (Arm C)
No. in trial arm: Arm A: N = 123; Arm B: N = 94; Arm C: N = 118
Age median and range: not reported
Stage distribution: not reported
Proportion node positive: Arm A: N = 16/123; Arm B: N = 9/94; Arm C: N = 17/118
Pathological type of breast cancer: not reported
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WSSA Glasgow (Continued)
Interventions Simple mastectomy with radiotherapy to the chest wall but not to nodal areas (Arm A)
vs simple mastectomy with radiotherapy to both chest wall and nodal areas (Arm B) vs
simple mastectomy with axillary clearance and radiotherapy to the chest wall but not to
nodal areas (Arm C)
Outcomes Overall survival, local recurrence
Axillary node surgery Minimum no. nodes to be removed according to protocol: see the next 3 lines
Arm A: Protocol specifies no disturbance of nodes.
Arm B: Protocol specifies no disturbance of nodes.
Arm C: Axillary contents were removed.
Method of node pathological analysis: not reported
Further treatment for node-positive cases: no
Radiotherapy Arm A:Radiotherapy to chest wall (42 Gy in 2.1 Gy fractions)
ArmB: Radiotherapy to chest wall (42 Gy in 2.1 Gy fractions) and nodal areas, including
axilla and supraclavicular fossa (42 Gy in 2.1 Gy fractions)
Arm C: Radiotherapy to chest wall (42 Gy in 2.1 Gy fractions)
RT same in all trial arms?no
Hormone and chemotherapy Not reported
Notes Study included 3 arms:
1. Simple mastectomy with RT to chest wall but not to nodal areas;
2: Simple mastectomy with RT to both chest wall and nodal areas, including axilla and
supraclavicular fossa; and
3: Simple mastectomy with axillary clearance plus RT to chest wall but not to nodal
areas: results derived from arms 1 and 3 only. Data from meta-analysis forest plot only
Central randomisation
Sealed cards
Baseline differences? not reported
Intention-to-treat analyses? not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Numbered envelopes: It is unclear how se-
quence was generated
Allocation concealment (selection bias) Unclear risk Sealed envelopes: It is unclear whether en-
velopes were opaque
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk This was not reported.
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Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk This was not reported.
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Outcome was not reported.
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Survival
Low risk Data appear to be available for all included
participants.
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk Data appear to be available for all included
participants.
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk Data appear to be available for all included
participants.
Incomplete outcome data (attrition bias)
Short term adverse events
Unclear risk Outcome was not reported.
Incomplete outcome data (attrition bias)
Long term adverse events
Unclear risk Outcome was not reported.
Selective reporting (reporting bias) Unclear risk Short-term and long-term adverse events
were not reported.
Xu 2003
Methods Study design: RCT
Country: China
Study period: 1992-2003
Inclusion criteria: “Females with invasive breast cancer of stage or , who were hospi-
talised from Jun 1992 to October 1995, agreed and signed the informed consent form”
Exclusion criteria: none reported
Length of follow-up (median and range): 99.5 months (12-136 months)
Participants No. in trial arm: Axillary dissection level 1 ± ovariectomy: N = 96; ALND± ovariectomy:
N = 96
Age median and range: Axillary dissection level 1 ± ovariectomy: 50.4 (31-69) years;
ALND ± ovariectomy: 48.3 (29-69) years
Stage distribution: Axillary dissection level 1 ± ovariectomy: clinical stage I/II: N = 17/79;
TMN stage T1/T2/T3: N = 20/74/2; TMN stage N0/1/4/10: N = 62/23/8/3; ALND ±
ovariectomy: clinical stage I/II: N = 12/84; TNM stage T1/T2/T3: N = 15/78/3; TNM
stage N0/1/4/10: N = 56/26/11/3
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Xu 2003 (Continued)
Proportion node positive: unclear, but possibly as reported in the lines above
Pathological type of breast cancer: not reported, but ER status was as follows: Axillary
dissection level 1 ± ovariectomy: ER +/-: N = 64/32; ALND ± ovariectomy: ER+/-: N =
64/32
Interventions Mastectomy and axillary dissection (level I axillary lymph nodes were cleared) ± ovariec-
tomy (16 participants received ovariectomy) vs radical mastectomy ± ovariectomy (20
participants received ovariectomy; 35 underwent Halsted radical mastectomy; and 61
had a modified radical mastectomy operation (retaining pectoralis major muscle and
medialis and lateralis branches of the thoracic nerve, cutting off the pectoralis minor
muscle. The clearing scope of the axillary lymph node is the same as that for a Halsted
radical mastectomy))
Outcomes 10-Year overall survival, 10-year disease-free survival, local recurrence, upper limb
oedema, distant metastasis, involved upper limb disorder, cardiovascular events, cere-
brovascular accident
Axillary node surgery Minimum no. nodes to be removed according to protocol: see the next 3 lines
Axillary dissection level 1 ±ovariectomy: Level lymph node clearance (only the lower
axillary lymph nodes were cleared)
ALND ±ovariectomy: Halsted radical mastectomy (all upper, middle and lower axillary
lymph nodes were cleared) was performed for 35 participants, and 61 were treated with
modified radical mastectomy (type )
Method of node pathological analysis:“Confirmed by pathological examination”
Further treatment for node-positive cases: yes
Radiotherapy “Postoperative radiotherapy was delivered to the internal mammary and clavicle area, to
the metastasis in patients with axillary lymph node number ≥ 4, or to patients whose
primary tumour were located inside to the nipple.”
Radiotherapy was given to 30 participants in the axillary dissection level 1 ± ovariectomy
arm and to 42 in the ALND ± ovariectomy arm.
RT same in all trial arms? yes
Hormone and chemotherapy Postoperative adjuvant CMF chemotherapy was administered to participants with breast
cancer stage - , tumour size > 1 cm. The chemotherapy regimen was composed of
CTX 500 mg/m2, 5-FU 500 mg/m2, MTX 30 mg/m2.
Axillary dissection level 1 ±ovariectomy: 34 participants completed 6 cycles of chemo-
therapy.
ALND ±ovariectomy: 35 participants completed 6 cycles of chemotherapy
Oral tamoxifen was given to participants after chemotherapy, to participants intolerant
to chemotherapy and to ER-positive participants (10 mg daily, 2 times a day)
Notes The study was published in Chinese and was kindly translated and data extracted by
Lixin Ma (School of Public Health, Hebei University, China). Risk of bias was discussed
by 2 review authors. One review author entered this information into Review Manager
Baseline differences? Groups appear to be comparable at baseline.
Intention-to-treat analyses? no. Analyses were per-protocol.
Risk of bias
96Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Xu 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “192 cases invasive breast cancer patients
diagnosed as phase - during the period
from Jun 1992 to October 1995 signed in-
formed consent, and participated in this
study. They were randomly divided into
two groups. 96 cases were in MAD ±
ovariectomized group and 96 cases in RM±
ovariectomized group.” No further infor-
mation was reported
Allocation concealment (selection bias) Unclear risk “The selected patients were then acknowl-
edged and allocated to two groups through
sealed envelope.” No further information
was reported
Blinding of outcome assessment (detection
bias)
Disease control in the axilla
Unclear risk Information was collected from clinical
records and clinical examination. No fur-
ther information was reported
Blinding of outcome assessment (detection
bias)
Breast cancer recurrence
Unclear risk Information was collected from clinical
records and clinical examination. No fur-
ther information was reported
Blinding of outcome assessment (detection
bias)
Short term adverse events
Unclear risk Information was collected from clinical
records and clinical examination. No fur-
ther information was reported
Blinding of outcome assessment (detection
bias)
Long term adverse events
Unclear risk Information was collected from clinical
records and clinical examination. No fur-
ther information was reported
Incomplete outcome data (attrition bias)
Survival
Low risk 10-Year follow-up: loss to follow-up: 3 par-
ticipants in the level I clearance group; 8
in the ALND group. Participant flow chart
was unavailable
Incomplete outcome data (attrition bias)
Axillary recurrence
Low risk 10-Year follow-up: Loss to follow-up: 3
participants in the level I clearance group; 8
in the ALND group. Participant flow chart
was unavailable
Incomplete outcome data (attrition bias)
Breast cancer recurrence
Low risk 10-Year follow-up: Loss to follow-up: 3
participants in the level I clearance group; 8
in the ALND group. Participant flow chart
was unavailable
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Incomplete outcome data (attrition bias)
Short term adverse events
Low risk 10-Year follow-up: Loss to follow-up: 3
participants in the level I clearance group; 8
in the ALND group. Participant flow chart
was unavailable
Incomplete outcome data (attrition bias)
Long term adverse events
Low risk 10-Year follow-up: Loss to follow-up: 3
participants in the level I clearance group; 8
in the ALND group. Participant flow chart
was unavailable
Selective reporting (reporting bias) Unclear risk Not enough information is available, and
reporting of morbidity outcomes is limited
5-FU: 5-fluorouracil.
ALND: axillary lymph node dissection.
BIS: bispectral index scale.
CMF: cyclophosphamide, methotrexate, 5-fluorouracil.
CTX: cyclophosphamide.
DFS: disease-free survival.
ER: oestrogen receptor.
H&E: hematoxylin and eosin.
IQR: interquartile ratio.
ITT: intention-to-treat.
NA: not applicable.
MAC: minimal alveolar concentration.
MTX: methotrexate.
QOL: quality of life.
RCT: randomised controlled trial.
RT: radiotherapy.
SD: standard deviation.
SLN: sentinel lymph node.
SLNB: sentinel lymph node biopsy.
WHO PS: World Health Organization Perfomance Scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
AATRM-048-13-2000 Inclusion criteria included positive sentinel lymph node: Participants were randomised before sentinel
lymph node biopsy but were included only if the biopsy indicated micrometastasis
ACOSOG Z0011 Participants were eligible only if they had positive sentinel lymph node biopsy: Randomisation took place
after sentinel lymph node biopsy results were known
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Buenos Aires Participants were not randomised: Participants born on evenmonths received axillary lymph node dissection
(ALND), and those born on odd months were given wide tumour excision
Copenhagen Participants were not randomised: On arrival, participants were given consecutive numbering of their
records. Participants with even numbers were allocated to the axillary lymph node dissection (ALND)
group, and those with odd numbers were allocated to the simple mastectomy + radiotherapy (RT) group
Edinburgh SES Study compared radiotherapy vs no radiotherapy after simplemastectomy in clinically node-negativewomen
IBCSG-23-01 Participants were eligible only if they had positive sentinel lymph node biopsy: Randomisation took place
after sentinel lymph node biopsy results were known
IPO-P Participants were eligible only if they had negative sentinel lymph node biopsy: Randomisation took place
after sentinel lymph node biopsy results were known
OTOASOR Study compared completion axillary lymph node dissection vs axillary nodal irradiation in participants with
sentinel lymph node-positive primary invasive breast cancer
Characteristics of studies awaiting assessment [ordered by study ID]
ISRCTN88463711
Methods Study design: randomised controlled trial (RCT)
Country: United Kingdom
Participants Inclusion criteria: histologically proven breast cancer, tumour size no greater than 4 cm, no skin involvement, aged
< 70 years, no medical contraindications to treatment protocols
Exclusion criteria: none listed
Interventions Surgery (wide local excision) and axillary node sampling, followed by radiotherapy to the breast and, if the sample is
positive, radiotherapy to the axillary lymph nodes vs surgery (wide local excision) and axillary lymph node dissection
(ALND) + radiotherapy to the breast
Outcomes Not reported
Notes
Semiglazov 2003
Methods Study design: described as randomised; no further information reported
Participants 212 patients with T1-2N0M0 breast cancer (superficial tumours no larger than 2.5 cm in diameter)
Interventions Modified mastectomy by Patey-Dyson (1985-90, 207 participants) vs organ-sparing treatment (segmental resection
of a breast + axillary dissection + radiotherapy - 1985-97, 211 participants): sectorial or segmental resection performed
1 cm away from the tumour margin with axillary resection at the I-II level. Radiotherapy done on gamma-therapeutic
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apparatus “Rocus” with the use of classic fractionation (2 Gy daily 5 times a week) at a summative local dosage (SLD)
applied to the breast of 50-60 Gy. To the bed of the tumour, 10 Gy was applied additionally in 5 fractions. Zones of
lymphatic collectors (axillary-subclavian and parasternal) in cases when metastases were found were radiotreated with
the analogous regimen (SLD = 40 Gr). All participants with receptor-positive tumours received hormonal therapy
with tamoxifen 20 mg daily for 5 years. Those with receptor-negative tumours received adjuvant chemotherapy CMF
(cyclophosphamide + methotrexate + 5-fluorouracil) or FAC (5-flurouracil + doxorubicin + cyclophosphamide) up
to 6 courses
Outcomes Survival, local recurrence, distant metastasis
Notes Paper was published in Russian and, after initial translation of sections related to treatment group allocation and
axillary treatment by Dr Liliya-Eugenevna Ziganshina (Department of Basic and Clinical Pharmacology, Kazan
Federal University, Russian Federation), which showed that these sections did not provide sufficient detail, we emailed
study author on 16/6/15 to ask for additional study details, specifically answers to the following two questions:
1. How were participants allocated to receive EITHERmodifiedmastectomyORorgan-sparing treatment (segmental
resection of a breast + axillary dissection + radiotherapy)? Were they randomised to either of these treatment groups,
and, if yes, how were they randomised? We would appreciate it if you would give us as much detail as possible about
the recruitment and treatment allocation process
2. Exactly what interventions did the 2 treatment groups receive to the axilla? Again, we are interested in learning as
much detail as possible, including the level of node clearance (level I, I, or III)
On 9/7/15, we received the following response:
”Thank you for your attention to our studies performed in 1985 and 1990, “Sparing and organ-saving operations in
breast cancer,” and “The modern organ- and function-sparing surgical treatment in oncology
“The first trial included patients with clinically early breast cancer (c)T1-2N0M0. The second one included only
patientswith (c)T1N0M0. Patientswere randomly assigned in a 1:1 ratio to receive Patey-Dysonmodifiedmastectomy
versus segmental resection of the breast + axillary lymph node dissection up to level I or level II (in case of detection of
axillary metastases in level I nodes as a result of intraoperative biopsy - in 20% of conservative surgery arm and 23%
in modified mastectomy group). Randomization was done centrally at the department of Epidemiology and Statistics
at the N.N. Petrov Research Institute of Oncology operation office with a computer program and a minimization
technique, taking into account age, histologic type and grade (G) and hormone-receptor status. The same principles
were used in the second trial in which patients with (c)T1N0M0 were undergoing breast conservative surgery ±
radiotherapy. Sentinel lymph node biopsy with the use of radio-tracer has been routinely performed in (c)N0 patients
in our institute for ten years by now. In 2014 we initiated a study to evaluate the role of the sentinel node biopsy in
patients who had undergone neoadjuvant systemic therapy.”
Study author emailed again on 13/7/15, as no clear response had been received to the second question in our
original email, i.e. exactly which interventions did patients receive to the axilla (e.g. what is a Patey-Dyson modified
mastectomy). Our second email was re-sent on 17/8/15, as no response had been received. To date, we have received
no response
Characteristics of ongoing studies [ordered by study ID]
100Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
AMAROS
Trial name or title AMAROS
Methods Study design: RCT (multi-centre, non-inferiority)
Country: Europe
Participants Inclusion criteria: patientswith operable unifocal invasive breast cancer (5-30mm) and clinically node negative
Exclusion criteria: metastatic disease, previous treatment of the axilla by surgery or radiotherapy, previous
treatment of cancer (except basal cell carcinoma of the skin and in situ carcinoma of the cervix), pregnancy
Interventions Women were randomised before surgery and SLNB to the treatment they would receive if their SLNB proved
positive. Women with negative SLNB received no additional treatment. Those with a positive lymph node
received axillary lymph node dissection (level I and II) or axillary radiation therapy. Patients could also receive
adjuvant systemic chemo/endocrine therapy according to local guidelines
Outcomes Regional control, survival, long-term morbidity
Starting date 2001
Contact information Emiel Rutgers, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands.
Email: e.rutgers@nki.nl
Notes Target number of participants is 4766; up until December 2008, more than 4000 participants had been
enrolled
GF-GS 01
Trial name or title GF-GS 01/NCT00144898
Methods Study design: RCT
Country: France
Participants Inclusion criteria: women aged 18-90 years with clinically node-negative operable unifocal N0 breast cancer
(clinical tumour size < 30 mm)
Exclusion criteria: none listed
Interventions ALND vs SLN resection
Outcomes Recurrence-free survival
Starting date 2003
Contact information Alain LEIZOROVICZ, Université Claude Bernard Lyon I (responsible party), Gilles Houvenaeghel, Institut
Paoli Calmette (principal investigator)
Notes
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Trial name or title KiSS (Klinisch-Interdisziplinäre-SentinelNode-Studie)
Methods Study design: RCT
Country: Germany
Participants Inclusion criteria: histologically provenunifocal breast cancer <25mmdiameter, clinically and sonographically
unsuspicious ipsilateral axillary lymph nodes
Exclusion criteria: none listed
Interventions SLNB + ALND vs SLNB + ALND only if the SLN was positive. Women received adjuvant therapy according
to St. Gallen and AGO eV guidelines
Outcomes Axillary recurrence, shoulder and arm morbidity
Starting date Unclear, but the trial was definitely running from November 20000 until September 2002
Contact information Contacted study author on Helms (2009): R Kreienberg, +49 731 500 58501, rolf.kreienberg@uniklinik-
ulm.de
Notes Although some trial data are published in the Schem (2011) abstract, this trial is not published in full in any of
the identified publications (Helms 2009 published only data from a subgroup of about 10% of participants)
, and we cannot extract relevant data for full inclusion of this study
NCT01717131
Trial name or title NCT01717131/Institut Paoli-Calmettes
Methods Study design: RCT
Country: France
Participants Inclusion criteria: patients aged≥ 18 years with (histologically or cytologically (by fine-needle biopsy)) proven,
invasive (unifocal tumour, TI-T2 (up to 5 cm, clinical or imagery)) breast cancer, clinically N0 and M0, who
have received no previous therapy (neoadjuvant or hormone therapy), for whom conservative surgery with
SLN technique is feasible from the start in terms of carcinoembryology, and who are affiliated with a social
security system of benefiting from such a system. The clinicaltrials.gov record further states, “All patients
with lymph node involvement (GS+), whatever the size of the metastasis (macro-metastasis, cellular cluster
or isolated tumour cells)”
Exclusion criteria: tumour > 5 cm, indication of neoadjuvant therapy by chemotherapy or hormone therapy,
history of breast cancer (ipsilateral, i.e. recurrence, or contralateral breast, history of any invasive cancer other
than a past cutaneous cancer correctly treated, initial metastatic disease known, presence of clinical axillary
adenopathy, contraindication to surgical excision, contraindication to the SLN technique, pregnant women,
women of child-bearing potential, lactating women, patients deprived of liberty or under supervision of a
guardian, impossibility to undergo medical examination of the study for geographical, social or psychological
reasons
Interventions ALND vs no ALND
Outcomes Disease-free survival, axillary recurrence rate, overall survival
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Starting date 2012
Contact information Dominique Genre and Sandra Cournier, +33 0491223778, bec@ipc.unicancer.fr
Notes
NCT02167490
Trial name or title Sentinel Node Vs Observation After Axillary Ultra-souND
Methods Study design: RCT
Country: Italy
Participants Inclusion criteria: breast cancer < 2 cm, clinically negative axilla, any age, candidates to receive breast-
conserving surgery + radiotherapy, negative preoperative assessment of the axilla (ultrasound with or without
FNAC in case 1, doubtful node is found), written informed consent must be signed and dated by both
participant and investigator before inclusion, participants must be accessible for follow-up
Exclusion criteria: synchronous distant metastases, previous malignancy, bilateral breast cancer, multi-centric
or multi-focal breast cancer, previous primary systemic therapy, pregnancy or breastfeeding, preoperative
diagnosis (cytology or histology) of axillary lymph node metastases, preoperative radiological evidence of
multiple involved or suspicious nodes, psychiatric, addictive or any disorder that may compromise ability to
give informed consent for participation in this study
Interventions SLNB ± axillary dissection vs no axillary surgical staging (no axillary dissection will be performed in case of
negative SLN or in the presence of isolated tumour cells or micrometastases. SLNB will be completed by
axillary dissection in the presence of macrometastases diagnosed in the SLN)
Outcomes Distant disease-free survival, distant recurrence, disease-free survival, overall survival, axillary recurrence
Starting date 2014
Contact information Nicole Rotmensz, MS; Tel: +39 02 57489810; email: nicole.rotmensz@ieo.it
Claudia Sangalli, MS; Tel: +39 02 57489840; email: claudia.sangalli@ieo.it
Notes Other study ID number: IEO S637/311
NCT02271828
Trial name or title Omitting sentinel node procedure in breast cancer patients undergoing breast conserving therapy
Methods Study design: RCT
Country: The Netherlands
Participants Inclusion criteria: female, aged 18 years or older, pathologically confirmed invasive breast carcinoma, clinical
T1-2 tumour, will be treated with lumpectomy and whole breast radiotherapy, clinically node-negative status:
no signs of axillary lymph node metastases at physical examination and preoperative axillary ultrasound (or
negative cyto/histopathology), written informed consent
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Exclusion criteria: clinically node-positive preoperative, bilateral breast cancer, evidence of metastatic disease,
history of invasive breast cancer, previous treatment of the axilla with surgery or radiotherapy (except surgery
for hidradenitis suppurativa or for other superficially located skin lesions, such as nevi), pregnant or nursing,
other prior malignancies within the past 5 years (except successfully treated basal cell and squamous cell
skin cancer, carcinoma in situ of the cervix or carcinoma in situ of the ipsilateral or contralateral breast) or
unsuccessfully treated malignancies > 5 years before randomisation, unable or unwilling to give informed
consent
Interventions SLNB vs no SLNB (or other SLN procedure)
Outcomes Regional recurrence rate
Starting date 2015
Contact information Marjolein L Smidt, MD, PhD, Maastricht University Medical Centre, Maastricht, the Netherlands
Hans JW de Wilt, MD, PhD, Radboud University Medical Centre, Nijmegen, the Netherlands
Notes Other study ID numbers: BOOG 2013-08, BOOG 2013-08, KWF UM 2014-6679
SNAC2
Trial name or title SNAC2/ACTRN12605000409673
Methods Study design: RCT (multi-centre)
Country: New Zealand, Australia (?)
Participants Inclusion criteria: histologically or cytologically confirmed invasive breast cancer, single or multiple ipsilateral
primary breast cancer, primary breast cancer may be less than or greater than 3 cm
Exclusion criteria: in situ carcinoma only, clinically involved nodes for which the investigator deems axillary
clearance is essential, evidence of metastatic disease, previous breast cancer or in situ carcinoma in the same
breast
Interventions SLNB (+ ALND if SLNB positive) vs SLNB + ALND
Outcomes Locoregional recurrence, overall survival, distant disease-free survival
Starting date 2006
Contact information Dr Ian Campbell (Study Chair), Department of Surgery, Waikato Hospital, Private Bag 3200, Hamilton,
New Zealand, Tel: +64 7 8398899 (Ext. 8279), email: CAMPBELI@waikatodhb.govt.nz
Xanthi Coskinas (Trial Co-ordinator), National Health and Medical Research Council (NHMRC) Clinical
Trials Centre, Locked Bag 77, Camperdown NSW 1450, Australia. Tel: +61 2 95625049, email: xanthi.
coskinas@ctc.usyd.edu.au. Trial web site: http://www.ctc.usyd.edu.au/trials/cancer/breast.htm
Notes
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SOUND
Trial name or title SOUND (Sentinel node vs Observation After Axillary UltraSouND)
Methods Study design: RCT
Country: Italy
Participants Inclusion criteria: breast cancer ≤ 2 cm and clinically negative axilla, any age, candidates to receive breast-
conserving surgery + radiotherapy, negative preoperative assessment of the axilla (ultrasound with or without
FNAC in case 1 doubtful node is found), written informed consentmust be signed and dated by the participant
and the investigator before inclusion, patients must be accessible for follow-up
Exclusion criteria: synchronous distant metastases, previous malignancy, bilateral breast cancer, multi-centric
or multi-focal breast cancer, previous primary systemic therapy, pregnancy or breastfeeding, preoperative
diagnosis (cytology or histology) of axillary lymph node metastases, preoperative radiological evidence of
multiple involved or suspicious nodes, patients with psychiatric/addictive/any disorder that compromises the
ability to give informed consent for participation in the study
Interventions SLND with axillary dissection in the presence of macrometastases diagnosed in the sentinel lymph node and
SLND without axillary dissection in the case of negative sentinel lymph node or in the presence of isolated
tumour cells or micrometastases vs no axillary surgical staging
Outcomes Distant disease-free survival, cumulative incidence of distant recurrences, cumulative incidence of axillary
recurrences, disease-free survival, overall survival, quality of life, evaluation of type of adjuvant treatment
administered
Starting date 2012
Contact information Oreste Gentilini, oreste.gentilini@ieo.it
Notes
ALND: axillary lymph node dissection.
FNAC: fine-needle aspiration cytology.
RCT: randomised controlled trial.
SLN: sentinel lymph node.
SLNB: sentinel lymph node biopsy.
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D A T A A N D A N A L Y S E S
Comparison 1. No axillary surgery versus full axillary surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality (radiotherapy
subgroups)
10 3849 Hazard Ratio (95% CI) 1.06 [0.96, 1.17]
1.1 no radiotherapy 1 773 Hazard Ratio (95% CI) 0.96 [0.80, 1.15]
1.2 radiotherapy 9 3076 Hazard Ratio (95% CI) 1.11 [0.98, 1.25]
2 All-cause mortality (extra
treatment for positive node
subgroups)
10 3849 Hazard Ratio (95% CI) 1.06 [0.96, 1.17]
2.1 additional treatment for
node-positive patients
3 1174 Hazard Ratio (95% CI) 1.51 [1.09, 2.09]
2.2 no specific additional
treatment for node-positive
patients
7 2675 Hazard Ratio (95% CI) 1.02 [0.92, 1.13]
3 Locoregional recurrence
(radiotherapy subgroups)
4 20863 Hazard Ratio (95% CI) 2.35 [1.91, 2.89]
3.1 no radiotherapy 1 7284 Hazard Ratio (95% CI) 2.94 [2.05, 4.23]
3.2 radiotherapy 3 13579 Hazard Ratio (95% CI) 2.11 [1.64, 2.72]
4 Locoregional recurrence (extra
treatment for positive-node
subgroups)
4 20863 Hazard Ratio (95% CI) 2.35 [1.91, 2.89]
4.1 additional treatment for
node-positive patients
1 4171 Hazard Ratio (95% CI) 1.10 [0.69, 1.75]
4.2 no specific additional
treatment for node-positive
patients
3 16692 Hazard Ratio (95% CI) 2.83 [2.25, 3.57]
5 Distant metastasis 2 946 Hazard Ratio (95% CI) 1.06 [0.87, 1.30]
5.1 no radiotherapy 1 727 Hazard Ratio (95% CI) 1.10 [0.89, 1.35]
5.2 radiotherapy 1 219 Hazard Ratio (95% CI) 0.64 [0.28, 1.42]
6 Lymphoedema (≥ 12 months
postop) - fixed-effect model
4 1714 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.23, 0.43]
6.1 additional treatment for
node-positive patients
1 532 Odds Ratio (M-H, Fixed, 95% CI) 0.07 [0.02, 0.22]
6.2 no additional treatment
for node-positive patients
3 1182 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.28, 0.54]
7 Lymphoedema (≥ 12 months
postop) - random-effects model
4 1714 Odds Ratio (M-H, Random, 95% CI) 0.22 [0.08, 0.57]
7.1 additional treatment for
node-positive patients
1 532 Odds Ratio (M-H, Random, 95% CI) 0.07 [0.02, 0.22]
7.2 no additional treatment
for node-positive patients
3 1182 Odds Ratio (M-H, Random, 95% CI) 0.40 [0.28, 0.55]
8 Arm or shoulder movement
impairment (≥ 12 months
postop)
5 1495 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.49, 1.05]
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8.1 radiotherapy 5 1495 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.49, 1.05]
9 Pain (≥ 12 months postop) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 radiotherapy 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Paraesthesia (≥ 12 months
postop)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
10.1 radiotherapy 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Delayed healing 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
11.1 radiotherapy 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Skin graft 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
12.1 radiotherapy 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 All-cause mortality (allocation
concealment subgroups)
10 3849 Hazard Ratio (95% CI) 1.06 [0.96, 1.17]
13.1 adequate allocation
concealment
4 1442 Hazard Ratio (95% CI) 0.98 [0.81, 1.18]
13.2 unclear or inadequate
allocation concealment
6 2407 Hazard Ratio (95% CI) 1.09 [0.97, 1.23]
Comparison 2. Axillary sampling versus full axillary surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 3 967 Hazard Ratio (95% CI) 0.94 [0.73, 1.21]
1.1 radiotherapy 2 872 Hazard Ratio (95% CI) 0.84 [0.64, 1.11]
1.2 no radiotherapy 1 95 Hazard Ratio (95% CI) 1.47 [0.84, 2.56]
2 Local recurrence 3 1404 Hazard Ratio (95% CI) 1.41 [0.94, 2.12]
2.1 radiotherapy 2 659 Hazard Ratio (95% CI) 1.40 [0.89, 2.19]
2.2 no radiotherapy 1 745 Hazard Ratio (95% CI) 1.48 [0.58, 3.82]
3 Axillary recurrence 1 Hazard Ratio (95% CI) Totals not selected
4 Locoregional recurrence 1 Hazard Ratio (95% CI) Totals not selected
4.1 radiotherapy 1 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
4.2 no radiotherapy 0 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
5 Distant metastasis 1 Hazard Ratio (95% CI) Totals not selected
5.1 radiotherapy 1 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
5.2 no radiotherapy 0 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
6 Lymphoedema. Increase in arm
circumference (≥ 12 months
postop)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 radiotherapy 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Shoulder lateral rotation (12
months postop)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 radiotherapy 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Seroma 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 radiotherapy 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 3. Sentinel node biopsy versus full axillary surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 3 6352 Hazard Ratio (95% CI) 1.05 [0.89, 1.25]
1.1 radiotherapy 2 6127 Hazard Ratio (95% CI) 1.05 [0.88, 1.25]
1.2 no radiotherapy 1 225 Hazard Ratio (95% CI) 1.30 [0.35, 4.84]
2 Local recurrence 1 Hazard Ratio (95% CI) Totals not selected
2.1 radiotherapy 1 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
2.2 no radiotherapy 0 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
3 Axillary recurrence 1 Hazard Ratio (95% CI) Totals not selected
3.1 radiotherapy 1 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
4 Locoregional recurrence 1 Hazard Ratio (95% CI) Totals not selected
4.1 radiotherapy 1 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
4.2 no radiotherapy 0 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
5 Distant metastasis 1 Hazard Ratio (95% CI) Totals not selected
5.1 radiotherapy 1 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
5.2 no radiotherapy 0 Hazard Ratio (95% CI) 0.0 [0.0, 0.0]
6 Lymphoedema. Increase in arm
circumference (≥ 12 months
postop)
3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 radiotherapy 3 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Lymphoedema. Patient reported
(at 12 or more months postop)
3 Odds Ratio (Fixed, 95% CI) 0.33 [0.23, 0.47]
7.1 adequate allocation
concealment
2 Odds Ratio (Fixed, 95% CI) 0.33 [0.22, 0.48]
7.2 unclear allocation
concealment
1 Odds Ratio (Fixed, 95% CI) 0.36 [0.15, 0.86]
8 Shoulder flexion (12 months
postop)
3 2257 Mean Difference (IV, Fixed, 95% CI) 1.55 [-0.19, 3.29]
8.1 radiotherapy 3 2257 Mean Difference (IV, Fixed, 95% CI) 1.55 [-0.19, 3.29]
9 Shoulder abduction (12 months
postop)
3 2252 Mean Difference (IV, Fixed, 95% CI) -1.02 [-2.79, 0.75]
9.1 radiotherapy 3 2252 Mean Difference (IV, Fixed, 95% CI) -1.02 [-2.79, 0.75]
10 Shoulder internal rotation (12
months postop)
2 1227 Mean Difference (IV, Fixed, 95% CI) 0.50 [-1.10, 2.09]
10.1 radiotherapy 2 1227 Mean Difference (IV, Fixed, 95% CI) 0.50 [-1.10, 2.09]
11 Shoulder external rotation (12
months postop)
2 1227 Mean Difference (IV, Fixed, 95% CI) -0.56 [-2.21, 1.09]
11.1 radiotherapy 2 1227 Mean Difference (IV, Fixed, 95% CI) -0.56 [-2.21, 1.09]
12 Subjective arm movement
impairment (≥ 12 months
postop)
2 877 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.22, 0.67]
12.1 radiotherapy 2 877 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.22, 0.67]
13 Pain (≥ 12 months postop) 2 877 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.30, 0.67]
13.1 radiotherapy 2 877 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.30, 0.67]
14 Paraesthesia (≥ 12 months
postop)
2 495 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.09, 0.23]
14.1 radiotherapy 2 495 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.09, 0.23]
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15 Numbness (≥ 12 months
postop)
3 1799 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.34, 0.54]
15.1 radiotherapy 3 1799 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.34, 0.54]
16 Seroma 2 1381 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.31, 0.51]
16.1 radiotherapy 2 1381 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.31, 0.51]
17 Wound infection 2 2074 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.50, 0.85]
17.1 radiotherapy 2 2074 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.50, 0.85]
18 Brachial plexus injury at 6
months postop
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
18.1 radiotherapy 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Radiotherapy versus full axillary surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 4 2469 Hazard Ratio (95% CI) 1.10 [1.00, 1.21]
2 Local recurrence 4 22256 Hazard Ratio (95% CI) 0.80 [0.64, 0.99]
3 Distant metastasis 1 1313 Hazard Ratio (95% CI) 1.07 [0.93, 1.25]
4 Lymphoedema. Increase in arm
circumference (≥ 12 months
postop)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Delayed healing 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Wound infection 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Skin graft 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Haematoma 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 5. Less surgery versus ALND
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 19 12089 Hazard Ratio (95% CI) 1.08 [1.01, 1.17]
1.1 no axillary surgery vs
ALND
9 3076 Hazard Ratio (95% CI) 1.11 [0.98, 1.25]
1.2 axillary sampling vs
ALND
3 967 Hazard Ratio (95% CI) 0.94 [0.73, 1.21]
1.3 SLNB vs ALND 3 6352 Hazard Ratio (95% CI) 1.05 [0.89, 1.25]
1.4 radiotherapy vs ALND 4 1694 Hazard Ratio (95% CI) 1.11 [0.99, 1.25]
2 All-cause mortality (radiotherapy
subgroups)
19 13637 Hazard Ratio (95% CI) 1.07 [1.00, 1.14]
2.1 radiotherapy (same in
both groups)
13 10075 Hazard Ratio (95% CI) 1.06 [0.96, 1.16]
2.2 radiotherapy (in less
surgery group only)
4 2469 Hazard Ratio (95% CI) 1.10 [1.00, 1.21]
2.3 no radiotherapy 3 1093 Hazard Ratio (95% CI) 1.00 [0.85, 1.19]
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3 All-cause mortality (additional
treatment for histologically
positive nodes)
5 1708 Hazard Ratio (95% CI) 0.90 [0.72, 1.14]
3.1 additional treatment for
histologically positive nodes
4 1613 Hazard Ratio (95% CI) 0.82 [0.64, 1.05]
3.2 no additional treatment
for histologically positive nodes
1 95 Hazard Ratio (95% CI) 1.47 [0.84, 2.56]
4 Local recurrence 8 24176 Hazard Ratio (95% CI) 0.90 [0.75, 1.09]
4.1 axillary sampling vs
ALND
3 1404 Hazard Ratio (95% CI) 1.41 [0.94, 2.12]
4.2 SLNB vs ALND 1 516 Hazard Ratio (95% CI) 0.94 [0.24, 3.77]
4.3 radiotherapy vs ALND 4 22256 Hazard Ratio (95% CI) 0.80 [0.64, 0.99]
5 Locoregional recurrence 6 26880 Hazard Ratio (95% CI) 1.53 [1.31, 1.78]
5.1 no axillary surgery vs
ALND
4 20863 Hazard Ratio (95% CI) 2.35 [1.91, 2.89]
5.2 axillary sampling vs
ALND
1 406 Hazard Ratio (95% CI) 0.74 [0.46, 1.20]
5.3 SLNB vs ALND 1 5611 Hazard Ratio (95% CI) 0.96 [0.74, 1.24]
6 Distant metastasis 3 2665 Hazard Ratio (95% CI) 1.07 [0.95, 1.20]
6.1 no axillary surgery vs
ALND
2 946 Hazard Ratio (95% CI) 1.06 [0.87, 1.30]
6.2 axillary sampling vs
ALND
1 406 Hazard Ratio (95% CI) 1.05 [0.74, 1.49]
6.3 radiotherapy vs ALND 1 1313 Hazard Ratio (95% CI) 1.07 [0.93, 1.25]
7 Lymphoedema. Increase in arm
volume at 12 months postop
9 3964 Odds Ratio (M-H, Fixed, 95% CI) 0.37 [0.29, 0.46]
7.1 no axillary surgery vs
ALND
4 1714 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.23, 0.43]
7.2 axillary sampling vs
ALND
1 85 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.13, 0.81]
7.3 SLNB vs ALND 3 1965 Odds Ratio (M-H, Fixed, 95% CI) 0.48 [0.33, 0.69]
7.4 radiotherapy vs ALND 1 200 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.16, 1.44]
8 Paraesthesia (≥ 12 months
postop)
3 1027 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.10, 0.21]
8.1 no axillary surgery vs
ALND
1 532 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.06, 0.32]
8.2 SLNB vs ALND 2 495 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.09, 0.23]
9 Pain (≥ 12 months postop) 3 1256 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.32, 0.68]
9.1 no axillary surgery vs
ALND
1 379 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.24, 1.47]
9.2 SLNB vs ALND 2 877 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.30, 0.67]
10 Delayed healing 2 404 Odds Ratio (M-H, Fixed, 95% CI) 0.25 [0.13, 0.46]
10.1 no axillary surgery vs
ALND
1 204 Odds Ratio (M-H, Fixed, 95% CI) 0.27 [0.11, 0.67]
10.2 radiotherapy vs ALND 1 200 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.10, 0.55]
11 Seroma 3 1481 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.32, 0.52]
11.1 SLNB vs ALND 2 1381 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.31, 0.51]
11.2 axillary sampling vs
ALND
1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.20, 1.20]
12 Wound infection 3 2274 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.50, 0.84]
12.1 SLNB vs ALND 2 2074 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.50, 0.85]
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12.2 radiotherapy vs ALND 1 200 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.22, 1.89]
13 Skin graft 2 404 Odds Ratio (M-H, Fixed, 95% CI) 0.15 [0.04, 0.57]
13.1 no axillary surgery vs
ALND
1 204 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.07, 2.19]
13.2 radiotherapy vs ALND 1 200 Odds Ratio (M-H, Fixed, 95% CI) 0.04 [0.00, 0.74]
14 Haematoma 2 1283 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.53, 1.20]
14.1 SLNB vs ALND 1 1083 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.78, 2.09]
14.2 radiotherapy vs ALND 1 200 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.08, 0.52]
Analysis 1.1. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 1 All-cause mortality
(radiotherapy subgroups).
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 1 All-cause mortality (radiotherapy subgroups)
Study or subgroup No axillary surgery ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 no radiotherapy
NSABP B-04 256/384 259/389 31.1 % 0.96 [ 0.80, 1.15 ]
Subtotal (95% CI) 384 389 31.1 % 0.96 [ 0.80, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
2 radiotherapy
Addenbrookes 108/121 107/112 12.3 % 0.94 [ 0.70, 1.25 ]
Guy’s (1) 64/71 82/85 8.2 % 1.15 [ 0.81, 1.64 ]
Guy’s (2) 185/233 178/241 15.6 % 1.26 [ 0.98, 1.63 ]
Hammersmith 40/76 35/76 3.1 % 1.13 [ 0.64, 2.00 ]
IBCSG-10-93 71/239 72/234 9.6 % 1.05 [ 0.76, 1.46 ]
Institut Bergonie 0/0 0/0 1.9 % 2.49 [ 1.19, 5.21 ]
Institut Curie 43/331 29/326 4.6 % 1.50 [ 0.94, 2.40 ]
Malmo 0/98 0/97 6.0 % 0.83 [ 0.55, 1.25 ]
Milan 2 35/110 31/109 4.4 % 0.85 [ 0.52, 1.37 ]
Milan 3 0/272 0/245 3.3 % 1.15 [ 0.66, 2.02 ]
Subtotal (95% CI) 1551 1525 68.9 % 1.11 [ 0.98, 1.25 ]
Heterogeneity: Chi2 = 11.77, df = 9 (P = 0.23); I2 =24%
Test for overall effect: Z = 1.64 (P = 0.10)
0.2 0.5 1 2 5
Favours no axill. surgery Favours ALND
(Continued . . . )
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(. . . Continued)
Study or subgroup No axillary surgery ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Total (95% CI) 100.0 % 1.06 [ 0.96, 1.17 ]
Heterogeneity: Chi2 = 13.46, df = 10 (P = 0.20); I2 =26%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 1.69, df = 1 (P = 0.19), I2 =41%
0.2 0.5 1 2 5
Favours no axill. surgery Favours ALND
(1) Clinically node positive
(2) Clinically node negative
Analysis 1.2. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 2 All-cause mortality
(extra treatment for positive node subgroups).
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 2 All-cause mortality (extra treatment for positive node subgroups)
Study or subgroup No axillary surgery ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 additional treatment for node-positive patients
Institut Bergonie 0/0 0/0 1.9 % 2.49 [ 1.19, 5.21 ]
Institut Curie 43/331 29/326 4.6 % 1.50 [ 0.94, 2.40 ]
Milan 3 0/272 0/245 3.3 % 1.15 [ 0.66, 2.02 ]
Subtotal (95% CI) 603 571 9.7 % 1.51 [ 1.09, 2.09 ]
Heterogeneity: Chi2 = 2.65, df = 2 (P = 0.27); I2 =25%
Test for overall effect: Z = 2.51 (P = 0.012)
2 no specific additional treatment for node-positive patients
Addenbrookes 108/121 107/112 12.3 % 0.94 [ 0.70, 1.25 ]
Guy’s (1) 64/71 82/85 8.2 % 1.15 [ 0.81, 1.64 ]
Guy’s (2) 185/233 178/241 15.6 % 1.26 [ 0.98, 1.63 ]
Hammersmith 40/76 35/76 3.1 % 1.10 [ 0.62, 1.95 ]
0.1 0.2 0.5 1 2 5 10
Favours no axill. surgery Favours ALND
(Continued . . . )
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(. . . Continued)
Study or subgroup No axillary surgery ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
IBCSG-10-93 71/239 72/234 9.6 % 1.05 [ 0.76, 1.46 ]
Malmo 0/98 0/97 6.0 % 0.83 [ 0.55, 1.25 ]
Milan 2 35/110 31/109 4.4 % 0.85 [ 0.52, 1.37 ]
NSABP B-04 256/384 259/389 31.1 % 0.96 [ 0.80, 1.15 ]
Subtotal (95% CI) 1332 1343 90.3 % 1.02 [ 0.92, 1.13 ]
Heterogeneity: Chi2 = 5.57, df = 7 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 100.0 % 1.06 [ 0.96, 1.17 ]
Heterogeneity: Chi2 = 13.43, df = 10 (P = 0.20); I2 =26%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 5.20, df = 1 (P = 0.02), I2 =81%
0.1 0.2 0.5 1 2 5 10
Favours no axill. surgery Favours ALND
(1) Clinically node positive
(2) Clinically node negative
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Analysis 1.3. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 3 Locoregional
recurrence (radiotherapy subgroups).
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 3 Locoregional recurrence (radiotherapy subgroups)
Study or subgroup No axillary surgery ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 no radiotherapy
NSABP B-04 94/3335 35/3949 32.7 % 2.94 [ 2.05, 4.23 ]
Subtotal (95% CI) 3335 3949 32.7 % 2.94 [ 2.05, 4.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.83 (P < 0.00001)
2 radiotherapy
Guy’s (1) 81/2383 35/3267 29.6 % 3.06 [ 2.09, 4.48 ]
Institut Curie 39/2045 34/2126 19.6 % 1.10 [ 0.69, 1.75 ]
Addenbrookes 15/1218 7/1148 6.0 % 1.84 [ 0.79, 4.28 ]
Guy’s (2) 31/519 17/873 12.1 % 2.64 [ 1.46, 4.80 ]
Subtotal (95% CI) 6165 7414 67.3 % 2.11 [ 1.64, 2.72 ]
Heterogeneity: Chi2 = 11.79, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 5.79 (P < 0.00001)
Total (95% CI) 100.0 % 2.35 [ 1.91, 2.89 ]
Heterogeneity: Chi2 = 13.95, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 8.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.16, df = 1 (P = 0.14), I2 =54%
0.2 0.5 1 2 5
Favours no axill. surgery Favours ALND
(1) Node negative
(2) node positive
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Analysis 1.4. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 4 Locoregional
recurrence (extra treatment for positive-node subgroups).
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 4 Locoregional recurrence (extra treatment for positive-node subgroups)
Study or subgroup No axillary surgery ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 additional treatment for node-positive patients
Institut Curie 39/2045 34/2126 19.6 % 1.10 [ 0.69, 1.75 ]
Subtotal (95% CI) 2045 2126 19.6 % 1.10 [ 0.69, 1.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
2 no specific additional treatment for node-positive patients
Addenbrookes 15/1218 7/1148 6.0 % 1.84 [ 0.79, 4.28 ]
Guy’s (1) 81/2383 35/3267 29.6 % 3.06 [ 2.09, 4.48 ]
Guy’s (2) 31/519 17/873 12.1 % 2.64 [ 1.46, 4.80 ]
NSABP B-04 94/3335 35/3949 32.7 % 2.94 [ 2.05, 4.23 ]
Subtotal (95% CI) 7455 9237 80.4 % 2.83 [ 2.25, 3.57 ]
Heterogeneity: Chi2 = 1.24, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 8.83 (P < 0.00001)
Total (95% CI) 100.0 % 2.35 [ 1.91, 2.89 ]
Heterogeneity: Chi2 = 13.95, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 8.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 12.71, df = 1 (P = 0.00), I2 =92%
0.1 0.2 0.5 1 2 5 10
Favours no axill. surgery Favours ALND
(1) clinically node negative
(2) clinically node positive
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Analysis 1.5. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 5 Distant metastasis.
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 5 Distant metastasis
Study or subgroup No axillary surgery ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 no radiotherapy
NSABP B-04 107/365 101/362 93.7 % 1.10 [ 0.89, 1.35 ]
Subtotal (95% CI) 365 362 93.7 % 1.10 [ 0.89, 1.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
2 radiotherapy
Milan 2 9/110 9/109 6.3 % 0.64 [ 0.28, 1.42 ]
Subtotal (95% CI) 110 109 6.3 % 0.64 [ 0.28, 1.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 100.0 % 1.06 [ 0.87, 1.30 ]
Heterogeneity: Chi2 = 1.66, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Chi2 = 1.66, df = 1 (P = 0.20), I2 =40%
0.2 0.5 1 2 5
Favours no axill. surgery Favours ALND
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Analysis 1.6. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 6 Lymphoedema (≥ 12
months postop) - fixed-effect model.
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 6 Lymphoedema (≥ 12 months postop) - fixed-effect model
Study or subgroup No axillary surgery ALND Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 additional treatment for node-positive patients
Institut Bergonie (1) 3/258 41/274 24.3 % 0.07 [ 0.02, 0.22 ]
Subtotal (95% CI) 258 274 24.3 % 0.07 [ 0.02, 0.22 ]
Total events: 3 (No axillary surgery), 41 (ALND)
Heterogeneity: not applicable
Test for overall effect: Z = 4.47 (P < 0.00001)
2 no additional treatment for node-positive patients
Addenbrookes (2) 6/53 12/45 7.1 % 0.35 [ 0.12, 1.03 ]
Guy’s (3) 0/91 6/104 3.7 % 0.08 [ 0.00, 1.49 ]
NSABP B-04 (4) 48/312 177/577 64.9 % 0.41 [ 0.29, 0.59 ]
Subtotal (95% CI) 456 726 75.7 % 0.39 [ 0.28, 0.54 ]
Total events: 54 (No axillary surgery), 195 (ALND)
Heterogeneity: Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 5.55 (P < 0.00001)
Total (95% CI) 714 1000 100.0 % 0.31 [ 0.23, 0.43 ]
Total events: 57 (No axillary surgery), 236 (ALND)
Heterogeneity: Chi2 = 9.68, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 7.29 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.86, df = 1 (P = 0.01), I2 =87%
0.005 0.1 1 10 200
Favours no axill. surgery Favours ALND
(1) Study does not report the threshold used.
(2) Increase≥ 2.54 cm in circumference
(3) Increase > 2.5 cm in circumference
(4) Increase in arm circumference ≥ 2cm, at final measurement
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Analysis 1.7. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 7 Lymphoedema (≥ 12
months postop) - random-effects model.
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 7 Lymphoedema (≥ 12 months postop) - random-effects model
Study or subgroup No axillary surgery ALND Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 additional treatment for node-positive patients
Institut Bergonie (1) 3/258 41/274 25.3 % 0.07 [ 0.02, 0.22 ]
Subtotal (95% CI) 258 274 25.3 % 0.07 [ 0.02, 0.22 ]
Total events: 3 (No axillary surgery), 41 (ALND)
Heterogeneity: not applicable
Test for overall effect: Z = 4.47 (P < 0.00001)
2 no additional treatment for node-positive patients
Addenbrookes (2) 6/53 12/45 27.1 % 0.35 [ 0.12, 1.03 ]
Guy’s (3) 0/91 6/104 8.7 % 0.08 [ 0.00, 1.49 ]
NSABP B-04 (4) 48/312 177/577 38.9 % 0.41 [ 0.29, 0.59 ]
Subtotal (95% CI) 456 726 74.7 % 0.40 [ 0.28, 0.55 ]
Total events: 54 (No axillary surgery), 195 (ALND)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 5.42 (P < 0.00001)
Total (95% CI) 714 1000 100.0 % 0.22 [ 0.08, 0.57 ]
Total events: 57 (No axillary surgery), 236 (ALND)
Heterogeneity: Tau2 = 0.59; Chi2 = 9.68, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Chi2 = 8.01, df = 1 (P = 0.00), I2 =88%
0.005 0.1 1 10 200
Favours no axill. surgery Favours ALND
(1) Study does not report the threshold used.
(2) Increase≥ 2.54 cm in circumference
(3) Increase > 2.5 cm in circumference
(4) Increase in arm circumference ≥ 2cm, at final measurement
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Analysis 1.8. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 8 Arm or shoulder
movement impairment (≥ 12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 8 Arm or shoulder movement impairment (≥ 12 months postop)
Study or subgroup No axillary surgery ALND Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
Addenbrookes 6/91 8/113 10.6 % 0.93 [ 0.31, 2.77 ]
Guy’s 14/92 16/101 20.5 % 0.95 [ 0.44, 2.08 ]
Hammersmith 18/100 6/95 8.0 % 3.26 [ 1.23, 8.60 ]
IBCSG-10-93 (1) 6/187 19/188 29.1 % 0.29 [ 0.12, 0.76 ]
Institut Bergonie 5/257 21/271 31.8 % 0.24 [ 0.09, 0.64 ]
Total (95% CI) 727 768 100.0 % 0.72 [ 0.49, 1.05 ]
Total events: 49 (No axillary surgery), 70 (ALND)
Heterogeneity: Chi2 = 18.29, df = 4 (P = 0.001); I2 =78%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours no axill. surgery Favours ALND
(1) Physician reported
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Analysis 1.9. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 9 Pain (≥ 12 months
postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 9 Pain (≥ 12 months postop)
Study or subgroup No axillary surgery ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
IBCSG-10-93 8/190 13/189 0.60 [ 0.24, 1.47 ]
0.02 0.1 1 10 50
Favours no axill. surgery Favours ALND
Analysis 1.10. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 10 Paraesthesia (≥ 12
months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 10 Paraesthesia (≥ 12 months postop)
Study or subgroup No axillary surgery ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
Institut Bergonie 6/258 41/274 0.14 [ 0.06, 0.32 ]
0.002 0.1 1 10 500
Favours no axill. surgery Favours ALND
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Analysis 1.11. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 11 Delayed healing.
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 11 Delayed healing
Study or subgroup No axillary surgery ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
Addenbrookes 7/113 18/91 0.27 [ 0.11, 0.67 ]
0.01 0.1 1 10 100
Favours no axill. surgery Favours ALND
Analysis 1.12. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 12 Skin graft.
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 12 Skin graft
Study or subgroup No axillary surgery ALND Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 radiotherapy
Addenbrookes 2/113 4/91 0.39 [ 0.07, 2.19 ]
0.001 0.01 0.1 1 10 100 1000
Favours experimental Favours control
121Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.13. Comparison 1 No axillary surgery versus full axillary surgery, Outcome 13 All-cause
mortality (allocation concealment subgroups).
Review: Axillary treatment for operable primary breast cancer
Comparison: 1 No axillary surgery versus full axillary surgery
Outcome: 13 All-cause mortality (allocation concealment subgroups)
Study or subgroup No axillary surgery ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 adequate allocation concealment
Addenbrookes 108/121 107/112 12.3 % 0.94 [ 0.70, 1.25 ]
IBCSG-10-93 71/239 72/234 9.6 % 1.05 [ 0.76, 1.46 ]
Milan 2 35/110 31/109 4.4 % 0.85 [ 0.52, 1.37 ]
Milan 3 0/272 0/245 3.3 % 1.15 [ 0.66, 2.02 ]
Subtotal (95% CI) 742 700 29.5 % 0.98 [ 0.81, 1.18 ]
Heterogeneity: Chi2 = 0.95, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
2 unclear or inadequate allocation concealment
Guy’s (1) 64/71 82/85 8.2 % 1.15 [ 0.81, 1.64 ]
Guy’s (2) 185/233 178/241 15.6 % 1.26 [ 0.98, 1.63 ]
Hammersmith 40/76 35/76 3.1 % 1.10 [ 0.62, 1.95 ]
Institut Bergonie 0/0 0/0 1.9 % 2.49 [ 1.19, 5.21 ]
Institut Curie 43/331 29/326 4.6 % 1.50 [ 0.94, 2.40 ]
Malmo 0/98 0/97 6.0 % 0.83 [ 0.55, 1.25 ]
NSABP B-04 256/384 259/389 31.1 % 0.96 [ 0.80, 1.15 ]
Subtotal (95% CI) 1193 1214 70.5 % 1.09 [ 0.97, 1.23 ]
Heterogeneity: Chi2 = 11.55, df = 6 (P = 0.07); I2 =48%
Test for overall effect: Z = 1.44 (P = 0.15)
Total (95% CI) 100.0 % 1.06 [ 0.96, 1.17 ]
Heterogeneity: Chi2 = 13.43, df = 10 (P = 0.20); I2 =26%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 0.93, df = 1 (P = 0.33), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours no axill. surgery Favours ALND
(1) Clinically node positive
(2) Clinically node negative
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Analysis 2.1. Comparison 2 Axillary sampling versus full axillary surgery, Outcome 1 All-cause mortality.
Review: Axillary treatment for operable primary breast cancer
Comparison: 2 Axillary sampling versus full axillary surgery
Outcome: 1 All-cause mortality
Study or subgroup Axillary sampling ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 radiotherapy
E’dburgh Sample/Clear 71/203 76/203 58.8 % 0.90 [ 0.65, 1.25 ]
Edinburgh 1 (1) 0/234 0/232 21.3 % 0.70 [ 0.41, 1.21 ]
Subtotal (95% CI) 437 435 80.1 % 0.84 [ 0.64, 1.11 ]
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
2 no radiotherapy
Cape Town 30/52 21/43 19.9 % 1.47 [ 0.84, 2.56 ]
Subtotal (95% CI) 52 43 19.9 % 1.47 [ 0.84, 2.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Total (95% CI) 100.0 % 0.94 [ 0.73, 1.21 ]
Heterogeneity: Chi2 = 3.63, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 3.04, df = 1 (P = 0.08), I2 =67%
0.1 0.2 0.5 1 2 5 10
Favours sampling Favours ALND
(1) Total events 53 - but not reported by treatment group
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Analysis 2.2. Comparison 2 Axillary sampling versus full axillary surgery, Outcome 2 Local recurrence.
Review: Axillary treatment for operable primary breast cancer
Comparison: 2 Axillary sampling versus full axillary surgery
Outcome: 2 Local recurrence
Study or subgroup Axillary sampling ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 radiotherapy
Cardiff 31/99 19/94 50.5 % 1.73 [ 0.98, 3.06 ]
Edinburgh 1 15/234 14/232 31.0 % 0.99 [ 0.48, 2.04 ]
Subtotal (95% CI) 333 326 81.6 % 1.40 [ 0.89, 2.19 ]
Heterogeneity: Chi2 = 1.42, df = 1 (P = 0.23); I2 =29%
Test for overall effect: Z = 1.46 (P = 0.14)
2 no radiotherapy
Cape Town (1) 9/173 5/134 8.6 % 1.00 [ 0.25, 4.00 ]
Cape Town (2) 8/232 3/206 9.9 % 2.09 [ 0.58, 7.63 ]
Subtotal (95% CI) 405 340 18.4 % 1.48 [ 0.58, 3.82 ]
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 100.0 % 1.41 [ 0.94, 2.12 ]
Heterogeneity: Chi2 = 2.01, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.095)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours sampling Favours ALND
(1) Clinically node positive
(2) Clinically node negative
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Analysis 2.3. Comparison 2 Axillary sampling versus full axillary surgery, Outcome 3 Axillary recurrence.
Review: Axillary treatment for operable primary breast cancer
Comparison: 2 Axillary sampling versus full axillary surgery
Outcome: 3 Axillary recurrence
Study or subgroup Axillary sampling ALND Hazard Ratio Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Edinburgh 1 8/234 8/232 0.99 [ 0.58, 1.69 ]
0.1 0.2 0.5 1 2 5 10
Favours sampling Favours ALND
Analysis 2.4. Comparison 2 Axillary sampling versus full axillary surgery, Outcome 4 Locoregional
recurrence.
Review: Axillary treatment for operable primary breast cancer
Comparison: 2 Axillary sampling versus full axillary surgery
Outcome: 4 Locoregional recurrence
Study or subgroup Axillary sampling ALND Hazard Ratio Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 radiotherapy
E’dburgh Sample/Clear 29/203 38/203 0.74 [ 0.46, 1.20 ]
2 no radiotherapy
0.1 0.2 0.5 1 2 5 10
Favours sampling Favours ALND
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Analysis 2.5. Comparison 2 Axillary sampling versus full axillary surgery, Outcome 5 Distant metastasis.
Review: Axillary treatment for operable primary breast cancer
Comparison: 2 Axillary sampling versus full axillary surgery
Outcome: 5 Distant metastasis
Study or subgroup Axillary sampling ALND Hazard Ratio Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 radiotherapy
E’dburgh Sample/Clear 53/203 51/203 1.05 [ 0.74, 1.49 ]
2 no radiotherapy
0.1 0.2 0.5 1 2 5 10
Favours sampling Favours ALND
Analysis 2.6. Comparison 2 Axillary sampling versus full axillary surgery, Outcome 6 Lymphoedema.
Increase in arm circumference (≥ 12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 2 Axillary sampling versus full axillary surgery
Outcome: 6 Lymphoedema. Increase in arm circumference (≥ 12 months postop)
Study or subgroup Axillary sampling ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
Cardiff (1) 11/45 20/40 0.32 [ 0.13, 0.81 ]
0.002 0.1 1 10 500
Favours sampling Favours ALND
(1) Increase≥ 2cm in circumference
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Analysis 2.7. Comparison 2 Axillary sampling versus full axillary surgery, Outcome 7 Shoulder lateral
rotation (12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 2 Axillary sampling versus full axillary surgery
Outcome: 7 Shoulder lateral rotation (12 months postop)
Study or subgroup Axillary sampling ALND
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 radiotherapy
Edinburgh 1 59 0.72 (4.7623) 132 0.77 (4.5957) -0.05 [ -1.50, 1.40 ]
-10 -5 0 5 10
Favours sampling Favours ALND
Analysis 2.8. Comparison 2 Axillary sampling versus full axillary surgery, Outcome 8 Seroma.
Review: Axillary treatment for operable primary breast cancer
Comparison: 2 Axillary sampling versus full axillary surgery
Outcome: 8 Seroma
Study or subgroup Axillary sampling ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
Ostersund 10/50 17/50 0.49 [ 0.20, 1.20 ]
0.01 0.1 1 10 100
Favours sampling Favours ALND
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Analysis 3.1. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 1 All-cause mortality.
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 1 All-cause mortality
Study or subgroup SLNB ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 radiotherapy
Milan 15/259 23/257 6.9 % 0.62 [ 0.32, 1.19 ]
NSABP B-32 252/2804 228/2807 91.4 % 1.09 [ 0.91, 1.30 ]
Subtotal (95% CI) 3063 3064 98.3 % 1.05 [ 0.88, 1.25 ]
Heterogeneity: Chi2 = 2.69, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.53 (P = 0.60)
2 no radiotherapy
Genoa 5/110 4/115 1.7 % 1.30 [ 0.35, 4.84 ]
Subtotal (95% CI) 110 115 1.7 % 1.30 [ 0.35, 4.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 100.0 % 1.05 [ 0.89, 1.25 ]
Heterogeneity: Chi2 = 2.79, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours SLNB Favours ALND
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Analysis 3.2. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 2 Local recurrence.
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 2 Local recurrence
Study or subgroup SLNB ALND Hazard Ratio Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 radiotherapy
Milan (1) 4/259 4/257 0.94 [ 0.24, 3.77 ]
2 no radiotherapy
0.01 0.1 1 10 100
Favours SLNB Favours ALND
(1) Breast recurrence only
Analysis 3.3. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 3 Axillary recurrence.
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 3 Axillary recurrence
Study or subgroup SLNB ALND Hazard Ratio Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 radiotherapy
Milan 2/259 0/257 6.96 [ 0.44, 111.25 ]
0.01 0.1 1 10 100
Favours SLNB Favours ALND
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Analysis 3.4. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 4 Locoregional
recurrence.
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 4 Locoregional recurrence
Study or subgroup SLNB ALND Hazard Ratio Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 radiotherapy
NSABP B-32 112/2804 121/2807 0.96 [ 0.74, 1.24 ]
2 no radiotherapy
0.5 0.7 1 1.5 2
Favours SLNB Favours ALND
Analysis 3.5. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 5 Distant metastasis.
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 5 Distant metastasis
Study or subgroup SLNB ALND Hazard Ratio Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 radiotherapy
Milan 17/259 20/257 0.80 [ 0.42, 1.53 ]
2 no radiotherapy
0.01 0.1 1 10 100
Favours SNLB Favours ALND
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Analysis 3.6. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 6 Lymphoedema.
Increase in arm circumference (≥ 12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 6 Lymphoedema. Increase in arm circumference (≥ 12 months postop)
Study or subgroup SLNB ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
GIVOM Sentinella (1) 15/336 30/341 0.48 [ 0.26, 0.92 ]
Milan (2) 0/100 12/100 0.04 [ 0.00, 0.60 ]
SNAC (3) 29/544 47/544 0.60 [ 0.37, 0.96 ]
0.002 0.1 1 10 500
Favours SLNB Favours ALND
(1) Threshold not reported
(2) Increase > 2cm in circumference
(3) Increase in arm volume≥ 15%
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Analysis 3.7. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 7 Lymphoedema.
Patient reported (at 12 or more months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 7 Lymphoedema. Patient reported (at 12 or more months postop)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 adequate allocation concealment
ALMANAC -1.0788 (0.2725) 44.0 % 0.34 [ 0.20, 0.58 ]
SNAC (1) -1.1653 (0.287) 39.7 % 0.31 [ 0.18, 0.55 ]
Subtotal (95% CI) 83.6 % 0.33 [ 0.22, 0.48 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 5.67 (P < 0.00001)
2 unclear allocation concealment
Addenbrookes 2 -1.0217 (0.4467) 16.4 % 0.36 [ 0.15, 0.86 ]
Subtotal (95% CI) 16.4 % 0.36 [ 0.15, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
Total (95% CI) 100.0 % 0.33 [ 0.23, 0.47 ]
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 6.11 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours SLND Favours ALND
(1) At 3 years post op
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Analysis 3.8. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 8 Shoulder flexion
(12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 8 Shoulder flexion (12 months postop)
Study or subgroup SLNB ALND
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 radiotherapy
Addenbrookes 2 134 6.7 (15.6) 141 13 (32.9) 8.3 % -6.30 [ -12.34, -0.26 ]
ALMANAC 478 2.7 (16.6899) 476 0.1 (15.5445) 72.1 % 2.60 [ 0.55, 4.65 ]
SNAC 519 7 (32.2131) 509 6 (31.9013) 19.7 % 1.00 [ -2.92, 4.92 ]
Total (95% CI) 1131 1126 100.0 % 1.55 [ -0.19, 3.29 ]
Heterogeneity: Chi2 = 7.58, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
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Analysis 3.9. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 9 Shoulder
abduction (12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 9 Shoulder abduction (12 months postop)
Study or subgroup SLNB ALND
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 radiotherapy
Addenbrookes 2 132 3.1 (15.7) 138 6.3 (11.5) 28.8 % -3.20 [ -6.49, 0.09 ]
ALMANAC 478 2.5 (21.1405) 476 1.9 (17.7651) 50.9 % 0.60 [ -1.88, 3.08 ]
SNAC 519 6 (32.2131) 509 8 (31.9013) 20.3 % -2.00 [ -5.92, 1.92 ]
Total (95% CI) 1129 1123 100.0 % -1.02 [ -2.79, 0.75 ]
Heterogeneity: Chi2 = 3.56, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours SLNB Favours ALND
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Analysis 3.10. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 10 Shoulder
internal rotation (12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 10 Shoulder internal rotation (12 months postop)
Study or subgroup SLNB ALND
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 radiotherapy
Addenbrookes 2 134 0.3 (12) 139 1.7 (12.7) 29.7 % -1.40 [ -4.33, 1.53 ]
ALMANAC 478 1.7 (14.4646) 476 0.4 (15.5445) 70.3 % 1.30 [ -0.61, 3.21 ]
Total (95% CI) 612 615 100.0 % 0.50 [ -1.10, 2.09 ]
Heterogeneity: Chi2 = 2.29, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours SLNB Favours ALND
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Analysis 3.11. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 11 Shoulder
external rotation (12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 11 Shoulder external rotation (12 months postop)
Study or subgroup SLNB ALND
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 radiotherapy
Addenbrookes 2 134 1.5 (11) 139 2.9 (12.3) 35.4 % -1.40 [ -4.17, 1.37 ]
ALMANAC 478 0.6 (15.5772) 476 0.7 (16.6548) 64.6 % -0.10 [ -2.15, 1.95 ]
Total (95% CI) 612 615 100.0 % -0.56 [ -2.21, 1.09 ]
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 3.12. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 12 Subjective arm
movement impairment (≥ 12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 12 Subjective arm movement impairment (≥ 12 months postop)
Study or subgroup SLNB ALND Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
GIVOM Sentinella 17/336 23/341 50.3 % 0.74 [ 0.39, 1.41 ]
Milan 0/100 21/100 49.7 % 0.02 [ 0.00, 0.31 ]
Total (95% CI) 436 441 100.0 % 0.38 [ 0.22, 0.67 ]
Total events: 17 (SLNB), 44 (ALND)
Heterogeneity: Chi2 = 8.47, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 3.38 (P = 0.00073)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
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Analysis 3.13. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 13 Pain (≥ 12
months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 13 Pain (≥ 12 months postop)
Study or subgroup SLNB ALND Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
GIVOM Sentinella 30/336 39/341 49.6 % 0.76 [ 0.46, 1.25 ]
Milan 8/100 39/100 50.4 % 0.14 [ 0.06, 0.31 ]
Total (95% CI) 436 441 100.0 % 0.44 [ 0.30, 0.67 ]
Total events: 38 (SLNB), 78 (ALND)
Heterogeneity: Chi2 = 12.25, df = 1 (P = 0.00046); I2 =92%
Test for overall effect: Z = 3.88 (P = 0.00011)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours SLNB Favours ALND
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Analysis 3.14. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 14 Paraesthesia (≥
12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 14 Paraesthesia (≥ 12 months postop)
Study or subgroup SLNB ALND Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
Addenbrookes 2 92/140 130/155 38.6 % 0.37 [ 0.21, 0.64 ]
Milan 1/100 68/100 61.4 % 0.00 [ 0.00, 0.04 ]
Total (95% CI) 240 255 100.0 % 0.15 [ 0.09, 0.23 ]
Total events: 93 (SLNB), 198 (ALND)
Heterogeneity: Chi2 = 22.01, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 8.39 (P < 0.00001)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours SLNB Favours ALND
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Analysis 3.15. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 15 Numbness (≥ 12
months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 15 Numbness (≥ 12 months postop)
Study or subgroup SLNB ALND Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
Addenbrookes 2 68/143 115/155 25.6 % 0.32 [ 0.19, 0.51 ]
ALMANAC 69/423 124/401 47.1 % 0.44 [ 0.31, 0.61 ]
GIVOM Sentinella 41/336 71/341 27.3 % 0.53 [ 0.35, 0.80 ]
Total (95% CI) 902 897 100.0 % 0.43 [ 0.34, 0.54 ]
Total events: 178 (SLNB), 310 (ALND)
Heterogeneity: Chi2 = 2.50, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 7.20 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours SLNB Favours ALND
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Analysis 3.16. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 16 Seroma.
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 16 Seroma
Study or subgroup SLNB ALND Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
SNAC 93/544 195/539 85.6 % 0.36 [ 0.27, 0.48 ]
Addenbrookes 2 20/143 33/155 14.4 % 0.60 [ 0.33, 1.11 ]
Total (95% CI) 687 694 100.0 % 0.40 [ 0.31, 0.51 ]
Total events: 113 (SLNB), 228 (ALND)
Heterogeneity: Chi2 = 2.14, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 7.03 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SLNB Favours ALND
Analysis 3.17. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 17Wound infection.
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 17 Wound infection
Study or subgroup SLNB ALND Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
ALMANAC 54/495 74/496 48.9 % 0.70 [ 0.48, 1.02 ]
SNAC 48/544 75/539 51.1 % 0.60 [ 0.41, 0.88 ]
Total (95% CI) 1039 1035 100.0 % 0.65 [ 0.50, 0.85 ]
Total events: 102 (SLNB), 149 (ALND)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SLNB Favours ALND
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Analysis 3.18. Comparison 3 Sentinel node biopsy versus full axillary surgery, Outcome 18 Brachial plexus
injury at 6 months postop.
Review: Axillary treatment for operable primary breast cancer
Comparison: 3 Sentinel node biopsy versus full axillary surgery
Outcome: 18 Brachial plexus injury at 6 months postop
Study or subgroup SLNB ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 radiotherapy
ALMANAC 4/410 10/394 0.38 [ 0.12, 1.22 ]
0.01 0.1 1 10 100
Favours SLNB Favours ALND
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Analysis 4.1. Comparison 4 Radiotherapy versus full axillary surgery, Outcome 1 All-cause mortality.
Review: Axillary treatment for operable primary breast cancer
Comparison: 4 Radiotherapy versus full axillary surgery
Outcome: 1 All-cause mortality
Study or subgroup Radiotherapy ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Manchester 140/159 126/149 14.1 % 1.10 [ 0.85, 1.42 ]
NSABP B-04 (1) 271/386 259/389 29.5 % 1.07 [ 0.90, 1.28 ]
NSABP B-04 (2) 244/305 244/301 26.4 % 1.08 [ 0.89, 1.30 ]
SE Scotland (3) 143/180 143/199 15.8 % 1.31 [ 1.02, 1.66 ]
SE Scotland (4) 77/93 72/89 8.2 % 1.20 [ 0.86, 1.68 ]
WSSA Glasgow (5) 12/16 13/17 0.8 % 0.86 [ 0.29, 2.53 ]
WSSA Glasgow (6) 42/85 56/101 5.2 % 0.77 [ 0.51, 1.18 ]
Total (95% CI) 100.0 % 1.10 [ 1.00, 1.21 ]
Heterogeneity: Chi2 = 5.17, df = 6 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours radiotherapy Favours ALND
(1) Node negative
(2) Node positive
(3) clinically node negative
(4) clinically node positive
(5) Node positive. RT to Chest wall and axilla.
(6) Node negative. RT to chest wall and axilla
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Analysis 4.2. Comparison 4 Radiotherapy versus full axillary surgery, Outcome 2 Local recurrence.
Review: Axillary treatment for operable primary breast cancer
Comparison: 4 Radiotherapy versus full axillary surgery
Outcome: 2 Local recurrence
Study or subgroup Radiotherapy ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
NSABP B-04 (1) 18/3896 35/3949 15.8 % 0.51 [ 0.30, 0.88 ]
WSSA Glasgow 1/41 3/69 1.1 % 0.57 [ 0.07, 4.53 ]
Manchester 41/1113 48/997 24.2 % 0.75 [ 0.48, 1.17 ]
SE Scotland (2) 17/878 24/943 11.9 % 0.74 [ 0.40, 1.39 ]
SE Scotland (3) 21/2204 26/2880 13.7 % 0.96 [ 0.53, 1.71 ]
WSSA Glasgow (4) 13/483 15/510 8.1 % 1.00 [ 0.47, 2.13 ]
NSABP B-04 (5) 42/2025 45/2268 25.2 % 0.98 [ 0.64, 1.50 ]
Total (95% CI) 100.0 % 0.80 [ 0.64, 0.99 ]
Heterogeneity: Chi2 = 4.34, df = 6 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours radiotherapy Favours ALND
(1) Node negative
(2) Clinically node positive
(3) clinically node negative
(4) Node negative. RT to chest
(5) Node positive
144Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.3. Comparison 4 Radiotherapy versus full axillary surgery, Outcome 3 Distant metastasis.
Review: Axillary treatment for operable primary breast cancer
Comparison: 4 Radiotherapy versus full axillary surgery
Outcome: 3 Distant metastasis
Study or subgroup Radiotherapy ALND Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
NSABP B-04 (1) 111/365 101/362 49.6 % 1.08 [ 0.88, 1.33 ]
NSABP B-04 (2) 127/294 120/292 50.4 % 1.07 [ 0.87, 1.32 ]
Total (95% CI) 100.0 % 1.07 [ 0.93, 1.25 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours radiotherapy Favours ALND
(1) Clinically lymph node negative
(2) Clinically lymph node positive
Analysis 4.4. Comparison 4 Radiotherapy versus full axillary surgery, Outcome 4 Lymphoedema. Increase
in arm circumference (≥ 12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 4 Radiotherapy versus full axillary surgery
Outcome: 4 Lymphoedema. Increase in arm circumference (≥ 12 months postop)
Study or subgroup Radiotherapy ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SE Scotland 5/100 10/100 0.47 [ 0.16, 1.44 ]
0.002 0.1 1 10 500
Favours radiotherapy Favours ALND
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Analysis 4.5. Comparison 4 Radiotherapy versus full axillary surgery, Outcome 5 Delayed healing.
Review: Axillary treatment for operable primary breast cancer
Comparison: 4 Radiotherapy versus full axillary surgery
Outcome: 5 Delayed healing
Study or subgroup Radiotherapy ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SE Scotland 8/100 27/100 0.24 [ 0.10, 0.55 ]
0.01 0.1 1 10 100
Favours radiotherapy Favours ALND
Analysis 4.6. Comparison 4 Radiotherapy versus full axillary surgery, Outcome 6 Wound infection.
Review: Axillary treatment for operable primary breast cancer
Comparison: 4 Radiotherapy versus full axillary surgery
Outcome: 6 Wound infection
Study or subgroup Radiotherapy ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SE Scotland 6/100 9/100 0.65 [ 0.22, 1.89 ]
0.01 0.1 1 10 100
Favours radiotherapy Favours ALND
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Analysis 4.7. Comparison 4 Radiotherapy versus full axillary surgery, Outcome 7 Skin graft.
Review: Axillary treatment for operable primary breast cancer
Comparison: 4 Radiotherapy versus full axillary surgery
Outcome: 7 Skin graft
Study or subgroup Radiotherapy ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SE Scotland 0/100 10/100 0.04 [ 0.00, 0.74 ]
0.01 0.1 1 10 100
Favours radiotherapy Favours ALND
Analysis 4.8. Comparison 4 Radiotherapy versus full axillary surgery, Outcome 8 Haematoma.
Review: Axillary treatment for operable primary breast cancer
Comparison: 4 Radiotherapy versus full axillary surgery
Outcome: 8 Haematoma
Study or subgroup Radiotherapy ALND Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SE Scotland 6/100 24/100 0.20 [ 0.08, 0.52 ]
0.01 0.1 1 10 100
Favours radiotherapy Favours ALND
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Analysis 5.1. Comparison 5 Less surgery versus ALND, Outcome 1 All-cause mortality.
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 1 All-cause mortality
Study or subgroup Less surgery More surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 no axillary surgery vs ALND
Addenbrookes 108/121 107/112 6.2 % 0.94 [ 0.70, 1.25 ]
Guy’s (1) 64/71 82/85 4.1 % 1.15 [ 0.81, 1.64 ]
Guy’s (2) 185/233 178/241 7.9 % 1.26 [ 0.98, 1.63 ]
Hammersmith 40/76 35/76 1.6 % 1.10 [ 0.62, 1.95 ]
IBCSG-10-93 71/239 72/234 4.8 % 1.05 [ 0.76, 1.46 ]
Institut Bergonie 0/0 0/0 0.9 % 2.49 [ 1.19, 5.21 ]
Institut Curie 43/331 29/326 2.3 % 1.50 [ 0.94, 2.40 ]
Malmo 0/98 0/97 3.1 % 0.83 [ 0.55, 1.25 ]
Milan 2 35/110 31/109 2.2 % 0.85 [ 0.52, 1.37 ]
Milan 3 0/272 0/245 1.7 % 1.15 [ 0.66, 2.02 ]
Subtotal (95% CI) 1551 1525 34.9 % 1.11 [ 0.98, 1.25 ]
Heterogeneity: Chi2 = 11.76, df = 9 (P = 0.23); I2 =24%
Test for overall effect: Z = 1.62 (P = 0.10)
2 axillary sampling vs ALND
Cape Town 30/52 21/43 1.7 % 1.47 [ 0.84, 2.56 ]
E’dburgh Sample/Clear 71/203 76/203 4.9 % 0.90 [ 0.65, 1.25 ]
Edinburgh 1 (3) 0/234 0/232 1.8 % 0.70 [ 0.41, 1.21 ]
Subtotal (95% CI) 489 478 8.3 % 0.94 [ 0.73, 1.21 ]
Heterogeneity: Chi2 = 3.63, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 0.47 (P = 0.64)
3 SLNB vs ALND
Genoa 5/110 4/115 0.3 % 1.30 [ 0.35, 4.84 ]
Milan 15/259 23/257 1.2 % 0.62 [ 0.32, 1.19 ]
NSABP B-32 252/2804 228/2807 16.1 % 1.09 [ 0.91, 1.30 ]
Subtotal (95% CI) 3173 3179 17.6 % 1.05 [ 0.89, 1.25 ]
Heterogeneity: Chi2 = 2.79, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 0.57 (P = 0.57)
0.2 0.5 1 2 5
Favours less surgery Favours more surgery
(Continued . . . )
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(. . . Continued)
Study or subgroup Less surgery More surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
4 radiotherapy vs ALND
Manchester 140/159 126/149 7.9 % 1.10 [ 0.85, 1.42 ]
NSABP B-04 (4) 244/305 244/301 14.7 % 1.08 [ 0.89, 1.30 ]
SE Scotland (5) 77/93 72/89 4.6 % 1.20 [ 0.86, 1.68 ]
SE Scotland (6) 143/180 143/199 8.8 % 1.31 [ 1.02, 1.66 ]
WSSA Glasgow (7) 12/16 13/17 0.4 % 0.86 [ 0.29, 2.53 ]
WSSA Glasgow (8) 42/85 56/101 2.9 % 0.77 [ 0.51, 1.18 ]
Subtotal (95% CI) 838 856 39.2 % 1.11 [ 0.99, 1.25 ]
Heterogeneity: Chi2 = 5.05, df = 5 (P = 0.41); I2 =1%
Test for overall effect: Z = 1.84 (P = 0.066)
Total (95% CI) 100.0 % 1.08 [ 1.01, 1.17 ]
Heterogeneity: Chi2 = 24.90, df = 21 (P = 0.25); I2 =16%
Test for overall effect: Z = 2.22 (P = 0.027)
Test for subgroup differences: Chi2 = 1.67, df = 3 (P = 0.64), I2 =0.0%
0.2 0.5 1 2 5
Favours less surgery Favours more surgery
(1) Clinically node positive
(2) Clinically node negative
(3) Total events 53 - but not reported by treatment group
(4) Node positive
(5) clinically node positive
(6) clinically node negative
(7) Node positive. RT to Chest wall and axilla.
(8) Node negative. RT to chest wall and axilla
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Analysis 5.2. Comparison 5 Less surgery versus ALND, Outcome 2 All-cause mortality (radiotherapy
subgroups).
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 2 All-cause mortality (radiotherapy subgroups)
Study or subgroup Less surgery More surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 radiotherapy (same in both groups)
Addenbrookes 108/121 107/112 4.7 % 0.94 [ 0.70, 1.25 ]
E’dburgh Sample/Clear 71/203 76/203 3.7 % 0.90 [ 0.65, 1.25 ]
Edinburgh 1 (1) 0/234 0/232 1.3 % 0.70 [ 0.41, 1.21 ]
Guy’s (2) 185/233 178/241 6.0 % 1.26 [ 0.98, 1.63 ]
Guy’s (3) 64/71 82/85 3.1 % 1.15 [ 0.81, 1.64 ]
Hammersmith 40/76 35/76 1.2 % 1.10 [ 0.62, 1.95 ]
IBCSG-10-93 71/239 72/234 3.7 % 1.05 [ 0.76, 1.46 ]
Institut Bergonie 0/0 0/0 0.7 % 2.49 [ 1.19, 5.21 ]
Institut Curie 43/331 29/326 1.8 % 1.50 [ 0.94, 2.40 ]
Malmo 0/98 0/97 2.3 % 0.83 [ 0.55, 1.25 ]
Milan 15/259 23/257 0.9 % 0.62 [ 0.32, 1.19 ]
Milan 2 35/110 31/109 1.7 % 0.85 [ 0.52, 1.37 ]
Milan 3 0/272 0/245 1.3 % 1.15 [ 0.66, 2.02 ]
NSABP B-32 252/2804 228/2807 12.2 % 1.09 [ 0.91, 1.30 ]
Subtotal (95% CI) 5051 5024 44.5 % 1.06 [ 0.96, 1.16 ]
Heterogeneity: Chi2 = 18.12, df = 13 (P = 0.15); I2 =28%
Test for overall effect: Z = 1.13 (P = 0.26)
2 radiotherapy (in less surgery group only)
Manchester 140/159 126/149 5.9 % 1.10 [ 0.85, 1.42 ]
NSABP B-04 (4) 271/386 259/389 12.4 % 1.07 [ 0.90, 1.28 ]
NSABP B-04 (5) 244/305 244/301 11.1 % 1.08 [ 0.89, 1.30 ]
SE Scotland (6) 143/180 143/199 6.7 % 1.31 [ 1.02, 1.66 ]
SE Scotland (7) 77/93 72/89 3.5 % 1.20 [ 0.86, 1.68 ]
WSSA Glasgow (8) 42/85 56/101 2.2 % 0.77 [ 0.51, 1.18 ]
WSSA Glasgow (9) 12/16 13/17 0.3 % 0.86 [ 0.29, 2.53 ]
0.2 0.5 1 2 5
Favours less surgery Favours more surgery
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(. . . Continued)
Study or subgroup Less surgery More surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Subtotal (95% CI) 1224 1245 42.1 % 1.10 [ 1.00, 1.21 ]
Heterogeneity: Chi2 = 5.17, df = 6 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
3 no radiotherapy
Cape Town 30/52 21/43 1.3 % 1.47 [ 0.84, 2.56 ]
Genoa 5/110 4/115 0.2 % 1.30 [ 0.35, 4.84 ]
NSABP B-04 256/384 259/389 11.9 % 0.96 [ 0.80, 1.15 ]
Subtotal (95% CI) 546 547 13.4 % 1.00 [ 0.85, 1.19 ]
Heterogeneity: Chi2 = 2.18, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI) 100.0 % 1.07 [ 1.00, 1.14 ]
Heterogeneity: Chi2 = 26.46, df = 23 (P = 0.28); I2 =13%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Chi2 = 0.99, df = 2 (P = 0.61), I2 =0.0%
0.2 0.5 1 2 5
Favours less surgery Favours more surgery
(1) Total events 53 - but not reported by treatment group
(2) Clinically node negative
(3) Clinically node positive
(4) Node negative
(5) Node positive
(6) clinically node negative
(7) clinically node positive
(8) Node negative. RT to chest wall and axilla
(9) Node positive. RT to Chest wall and axilla.
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Analysis 5.3. Comparison 5 Less surgery versus ALND, Outcome 3 All-cause mortality (additional
treatment for histologically positive nodes).
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 3 All-cause mortality (additional treatment for histologically positive nodes)
Study or subgroup Less surgery More surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 additional treatment for histologically positive nodes
E’dburgh Sample/Clear 71/203 76/203 49.8 % 0.90 [ 0.65, 1.25 ]
Edinburgh 1 (1) 0/234 0/232 18.0 % 0.70 [ 0.41, 1.21 ]
Genoa 5/110 4/115 3.0 % 1.30 [ 0.35, 4.84 ]
Milan 15/259 23/257 12.4 % 0.62 [ 0.32, 1.19 ]
Subtotal (95% CI) 806 807 83.2 % 0.82 [ 0.64, 1.05 ]
Heterogeneity: Chi2 = 1.81, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
2 no additional treatment for histologically positive nodes
Cape Town 30/52 21/43 16.8 % 1.47 [ 0.84, 2.56 ]
Subtotal (95% CI) 52 43 16.8 % 1.47 [ 0.84, 2.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Total (95% CI) 100.0 % 0.90 [ 0.72, 1.14 ]
Heterogeneity: Chi2 = 5.32, df = 4 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Chi2 = 3.50, df = 1 (P = 0.06), I2 =71%
0.2 0.5 1 2 5
Favours less surgery Favours more surgery
(1) Total events 53 - but not reported by treatment group
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Analysis 5.4. Comparison 5 Less surgery versus ALND, Outcome 4 Local recurrence.
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 4 Local recurrence
Study or subgroup Less surgery More surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 axillary sampling vs ALND
Cape Town (1) 8/232 3/206 2.1 % 2.09 [ 0.58, 7.63 ]
Cape Town (2) 9/173 5/134 1.9 % 1.00 [ 0.25, 4.00 ]
Cardiff 31/99 19/94 10.9 % 1.73 [ 0.98, 3.06 ]
Edinburgh 1 15/234 14/232 6.7 % 0.99 [ 0.48, 2.04 ]
Subtotal (95% CI) 738 666 21.6 % 1.41 [ 0.94, 2.12 ]
Heterogeneity: Chi2 = 2.01, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.095)
2 SLNB vs ALND
Milan (3) 4/259 4/257 1.9 % 0.94 [ 0.24, 3.77 ]
Subtotal (95% CI) 259 257 1.9 % 0.94 [ 0.24, 3.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
3 radiotherapy vs ALND
Manchester 41/1113 48/997 18.5 % 0.75 [ 0.48, 1.17 ]
NSABP B-04 (4) 42/2025 45/2268 19.3 % 0.98 [ 0.64, 1.50 ]
NSABP B-04 (5) 18/3896 35/3949 12.1 % 0.51 [ 0.30, 0.88 ]
SE Scotland (6) 21/2204 26/2880 10.5 % 0.96 [ 0.53, 1.71 ]
SE Scotland (7) 17/878 24/943 9.1 % 0.74 [ 0.40, 1.39 ]
WSSA Glasgow (8) 13/483 15/510 6.2 % 1.00 [ 0.47, 2.13 ]
WSSA Glasgow 1/41 3/69 0.8 % 0.57 [ 0.07, 4.53 ]
Subtotal (95% CI) 10640 11616 76.5 % 0.80 [ 0.64, 0.99 ]
Heterogeneity: Chi2 = 4.34, df = 6 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
Total (95% CI) 100.0 % 0.90 [ 0.75, 1.09 ]
Heterogeneity: Chi2 = 12.34, df = 11 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Chi2 = 5.99, df = 2 (P = 0.05), I2 =67%
0.01 0.1 1 10 100
Favours less surgery Favours more surgery
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(1) Clinically node negative
(2) Clinically node positive
(3) Breast recurrence only
(4) Node positive
(5) Node negative
(6) clinically node negative
(7) Clinically node positive
(8) Node negative. RT to chest
Analysis 5.5. Comparison 5 Less surgery versus ALND, Outcome 5 Locoregional recurrence.
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 5 Locoregional recurrence
Study or subgroup Less surgery More surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 no axillary surgery vs ALND
Addenbrookes 15/1218 7/1148 3.3 % 1.84 [ 0.79, 4.28 ]
Guy’s (1) 81/2383 35/3267 16.1 % 3.06 [ 2.09, 4.48 ]
Guy’s (2) 31/519 17/873 6.6 % 2.64 [ 1.46, 4.80 ]
Institut Curie 39/2045 34/2126 10.7 % 1.10 [ 0.69, 1.75 ]
NSABP B-04 94/3335 35/3949 17.8 % 2.94 [ 2.05, 4.23 ]
Subtotal (95% CI) 9500 11363 54.5 % 2.35 [ 1.91, 2.89 ]
Heterogeneity: Chi2 = 13.95, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 8.08 (P < 0.00001)
2 axillary sampling vs ALND
E’dburgh Sample/Clear 29/203 38/203 10.0 % 0.74 [ 0.46, 1.20 ]
Subtotal (95% CI) 203 203 10.0 % 0.74 [ 0.46, 1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
3 SLNB vs ALND
0.01 0.1 1 10 100
Favours less surgery Favours more surgery
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(. . . Continued)
Study or subgroup Less surgery More surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
NSABP B-32 112/2804 121/2807 35.5 % 0.96 [ 0.74, 1.24 ]
Subtotal (95% CI) 2804 2807 35.5 % 0.96 [ 0.74, 1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 100.0 % 1.53 [ 1.31, 1.78 ]
Heterogeneity: Chi2 = 51.71, df = 6 (P<0.00001); I2 =88%
Test for overall effect: Z = 5.40 (P < 0.00001)
Test for subgroup differences: Chi2 = 37.75, df = 2 (P = 0.00), I2 =95%
0.01 0.1 1 10 100
Favours less surgery Favours more surgery
(1) Node negative
(2) node positive
Analysis 5.6. Comparison 5 Less surgery versus ALND, Outcome 6 Distant metastasis.
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 6 Distant metastasis
Study or subgroup Less surgery More surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 no axillary surgery vs ALND
Milan 2 9/110 9/109 2.0 % 0.64 [ 0.28, 1.42 ]
NSABP B-04 107/365 101/362 29.5 % 1.10 [ 0.89, 1.35 ]
Subtotal (95% CI) 475 471 31.4 % 1.06 [ 0.87, 1.30 ]
Heterogeneity: Chi2 = 1.66, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 0.59 (P = 0.55)
2 axillary sampling vs ALND
E’dburgh Sample/Clear 53/203 51/203 10.2 % 1.05 [ 0.74, 1.49 ]
Subtotal (95% CI) 203 203 10.2 % 1.05 [ 0.74, 1.49 ]
Heterogeneity: not applicable
0.1 0.2 0.5 1 2 5 10
Favours less surgery Favours more surgery
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(. . . Continued)
Study or subgroup Less surgery More surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Test for overall effect: Z = 0.27 (P = 0.79)
3 radiotherapy vs ALND
NSABP B-04 (1) 127/294 120/292 29.4 % 1.07 [ 0.87, 1.32 ]
NSABP B-04 (2) 111/365 101/362 28.9 % 1.08 [ 0.88, 1.33 ]
Subtotal (95% CI) 659 654 58.3 % 1.07 [ 0.93, 1.25 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 100.0 % 1.07 [ 0.95, 1.20 ]
Heterogeneity: Chi2 = 1.69, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 0.02, df = 2 (P = 0.99), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours less surgery Favours more surgery
(1) Clinically lymph node positive
(2) Clinically lymph node negative
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Analysis 5.7. Comparison 5 Less surgery versus ALND, Outcome 7 Lymphoedema. Increase in arm volume
at 12 months postop.
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 7 Lymphoedema. Increase in arm volume at 12 months postop
Study or subgroup Less surgery More surgery Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 no axillary surgery vs ALND
Addenbrookes (1) 6/53 12/45 4.2 % 0.35 [ 0.12, 1.03 ]
Guy’s (2) 0/91 6/104 2.2 % 0.08 [ 0.00, 1.49 ]
Institut Bergonie (3) 3/258 41/274 14.4 % 0.07 [ 0.02, 0.22 ]
NSABP B-04 (4) 48/312 177/577 38.5 % 0.41 [ 0.29, 0.59 ]
Subtotal (95% CI) 714 1000 59.4 % 0.31 [ 0.23, 0.43 ]
Total events: 57 (Less surgery), 236 (More surgery)
Heterogeneity: Chi2 = 9.68, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 7.29 (P < 0.00001)
2 axillary sampling vs ALND
Cardiff (5) 11/45 20/40 5.9 % 0.32 [ 0.13, 0.81 ]
Subtotal (95% CI) 45 40 5.9 % 0.32 [ 0.13, 0.81 ]
Total events: 11 (Less surgery), 20 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
3 SLNB vs ALND
GIVOM Sentinella (6) 15/336 30/341 10.4 % 0.48 [ 0.26, 0.92 ]
Milan (7) 0/100 12/100 4.6 % 0.04 [ 0.00, 0.60 ]
SNAC (8) 29/544 47/544 16.3 % 0.60 [ 0.37, 0.96 ]
Subtotal (95% CI) 980 985 31.3 % 0.48 [ 0.33, 0.69 ]
Total events: 44 (Less surgery), 89 (More surgery)
Heterogeneity: Chi2 = 4.06, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 3.92 (P = 0.000090)
4 radiotherapy vs ALND
SE Scotland 5/100 10/100 3.5 % 0.47 [ 0.16, 1.44 ]
Subtotal (95% CI) 100 100 3.5 % 0.47 [ 0.16, 1.44 ]
Total events: 5 (Less surgery), 10 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 1839 2125 100.0 % 0.37 [ 0.29, 0.46 ]
Total events: 117 (Less surgery), 355 (More surgery)
Heterogeneity: Chi2 = 16.78, df = 8 (P = 0.03); I2 =52%
Test for overall effect: Z = 8.64 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.25, df = 3 (P = 0.36), I2 =8%
0.001 0.01 0.1 1 10 100 1000
Favours less surgery Favours more surgery
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(1) Increase≥ 2.54 cm in circumference
(2) Increase > 2.5 cm in circumference
(3) Study does not report the threshold used.
(4) Increase in arm circumference ≥ 2cm, at final measurement
(5) Increase≥ 2cm in circumference
(6) Threshold not reported
(7) Increase > 2cm in circumference
(8) Increase in arm volume≥ 15%
Analysis 5.8. Comparison 5 Less surgery versus ALND, Outcome 8 Paraesthesia (≥ 12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 8 Paraesthesia (≥ 12 months postop)
Study or subgroup Less surgery More surgery Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 no axillary surgery vs ALND
Institut Bergonie 6/258 41/274 26.2 % 0.14 [ 0.06, 0.32 ]
Subtotal (95% CI) 258 274 26.2 % 0.14 [ 0.06, 0.32 ]
Total events: 6 (Less surgery), 41 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 4.48 (P < 0.00001)
2 SLNB vs ALND
Addenbrookes 2 92/140 130/155 28.5 % 0.37 [ 0.21, 0.64 ]
Milan 1/100 68/100 45.3 % 0.00 [ 0.00, 0.04 ]
Subtotal (95% CI) 240 255 73.8 % 0.15 [ 0.09, 0.23 ]
Total events: 93 (Less surgery), 198 (More surgery)
Heterogeneity: Chi2 = 22.01, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 8.39 (P < 0.00001)
Total (95% CI) 498 529 100.0 % 0.14 [ 0.10, 0.21 ]
Total events: 99 (Less surgery), 239 (More surgery)
Heterogeneity: Chi2 = 22.33, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 9.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
0.002 0.1 1 10 500
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Analysis 5.9. Comparison 5 Less surgery versus ALND, Outcome 9 Pain (≥ 12 months postop).
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 9 Pain (≥ 12 months postop)
Study or subgroup Less surgery More surgery Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 no axillary surgery vs ALND
IBCSG-10-93 8/190 13/189 14.9 % 0.60 [ 0.24, 1.47 ]
Subtotal (95% CI) 190 189 14.9 % 0.60 [ 0.24, 1.47 ]
Total events: 8 (Less surgery), 13 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
2 SLNB vs ALND
GIVOM Sentinella 30/336 39/341 42.2 % 0.76 [ 0.46, 1.25 ]
Milan 8/100 39/100 42.9 % 0.14 [ 0.06, 0.31 ]
Subtotal (95% CI) 436 441 85.1 % 0.44 [ 0.30, 0.67 ]
Total events: 38 (Less surgery), 78 (More surgery)
Heterogeneity: Chi2 = 12.25, df = 1 (P = 0.00046); I2 =92%
Test for overall effect: Z = 3.88 (P = 0.00011)
Total (95% CI) 626 630 100.0 % 0.47 [ 0.32, 0.68 ]
Total events: 46 (Less surgery), 91 (More surgery)
Heterogeneity: Chi2 = 12.43, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 4.00 (P = 0.000063)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
0.02 0.1 1 10 50
Favours less surgery Favours more surgery
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Analysis 5.10. Comparison 5 Less surgery versus ALND, Outcome 10 Delayed healing.
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 10 Delayed healing
Study or subgroup Less surgery More surgery Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 no axillary surgery vs ALND
Addenbrookes 7/113 18/91 43.0 % 0.27 [ 0.11, 0.67 ]
Subtotal (95% CI) 113 91 43.0 % 0.27 [ 0.11, 0.67 ]
Total events: 7 (Less surgery), 18 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0051)
2 radiotherapy vs ALND
SE Scotland 8/100 27/100 57.0 % 0.24 [ 0.10, 0.55 ]
Subtotal (95% CI) 100 100 57.0 % 0.24 [ 0.10, 0.55 ]
Total events: 8 (Less surgery), 27 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.00080)
Total (95% CI) 213 191 100.0 % 0.25 [ 0.13, 0.46 ]
Total events: 15 (Less surgery), 45 (More surgery)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 4.37 (P = 0.000013)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 5.11. Comparison 5 Less surgery versus ALND, Outcome 11 Seroma.
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 11 Seroma
Study or subgroup Less surgery More surgery Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 SLNB vs ALND
Addenbrookes 2 20/143 33/155 13.4 % 0.60 [ 0.33, 1.11 ]
SNAC 93/544 195/539 79.9 % 0.36 [ 0.27, 0.48 ]
Subtotal (95% CI) 687 694 93.3 % 0.40 [ 0.31, 0.51 ]
Total events: 113 (Less surgery), 228 (More surgery)
Heterogeneity: Chi2 = 2.14, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 7.03 (P < 0.00001)
2 axillary sampling vs ALND
Ostersund 10/50 17/50 6.7 % 0.49 [ 0.20, 1.20 ]
Subtotal (95% CI) 50 50 6.7 % 0.49 [ 0.20, 1.20 ]
Total events: 10 (Less surgery), 17 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Total (95% CI) 737 744 100.0 % 0.40 [ 0.32, 0.52 ]
Total events: 123 (Less surgery), 245 (More surgery)
Heterogeneity: Chi2 = 2.32, df = 2 (P = 0.31); I2 =14%
Test for overall effect: Z = 7.19 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
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Analysis 5.12. Comparison 5 Less surgery versus ALND, Outcome 12 Wound infection.
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 12 Wound infection
Study or subgroup Less surgery More surgery Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 SLNB vs ALND
ALMANAC 54/495 74/496 46.1 % 0.70 [ 0.48, 1.02 ]
SNAC 48/544 75/539 48.0 % 0.60 [ 0.41, 0.88 ]
Subtotal (95% CI) 1039 1035 94.1 % 0.65 [ 0.50, 0.85 ]
Total events: 102 (Less surgery), 149 (More surgery)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
2 radiotherapy vs ALND
SE Scotland 6/100 9/100 5.9 % 0.65 [ 0.22, 1.89 ]
Subtotal (95% CI) 100 100 5.9 % 0.65 [ 0.22, 1.89 ]
Total events: 6 (Less surgery), 9 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 1139 1135 100.0 % 0.65 [ 0.50, 0.84 ]
Total events: 108 (Less surgery), 158 (More surgery)
Heterogeneity: Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0011)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 5.13. Comparison 5 Less surgery versus ALND, Outcome 13 Skin graft.
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 13 Skin graft
Study or subgroup Less surgery More surgery Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 no axillary surgery vs ALND
Addenbrookes 2/113 4/91 29.4 % 0.39 [ 0.07, 2.19 ]
Subtotal (95% CI) 113 91 29.4 % 0.39 [ 0.07, 2.19 ]
Total events: 2 (Less surgery), 4 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
2 radiotherapy vs ALND
SE Scotland 0/100 10/100 70.6 % 0.04 [ 0.00, 0.74 ]
Subtotal (95% CI) 100 100 70.6 % 0.04 [ 0.00, 0.74 ]
Total events: 0 (Less surgery), 10 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.030)
Total (95% CI) 213 191 100.0 % 0.15 [ 0.04, 0.57 ]
Total events: 2 (Less surgery), 14 (More surgery)
Heterogeneity: Chi2 = 1.98, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 2.76 (P = 0.0057)
Test for subgroup differences: Chi2 = 1.70, df = 1 (P = 0.19), I2 =41%
0.001 0.01 0.1 1 10 100 1000
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Analysis 5.14. Comparison 5 Less surgery versus ALND, Outcome 14 Haematoma.
Review: Axillary treatment for operable primary breast cancer
Comparison: 5 Less surgery versus ALND
Outcome: 14 Haematoma
Study or subgroup Less surgery More surgery Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 SLNB vs ALND
SNAC 38/544 30/539 55.4 % 1.27 [ 0.78, 2.09 ]
Subtotal (95% CI) 544 539 55.4 % 1.27 [ 0.78, 2.09 ]
Total events: 38 (Less surgery), 30 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
2 radiotherapy vs ALND
SE Scotland 6/100 24/100 44.6 % 0.20 [ 0.08, 0.52 ]
Subtotal (95% CI) 100 100 44.6 % 0.20 [ 0.08, 0.52 ]
Total events: 6 (Less surgery), 24 (More surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 3.32 (P = 0.00090)
Total (95% CI) 644 639 100.0 % 0.80 [ 0.53, 1.20 ]
Total events: 44 (Less surgery), 54 (More surgery)
Heterogeneity: Chi2 = 11.57, df = 1 (P = 0.00067); I2 =91%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Chi2 = 11.46, df = 1 (P = 0.00), I2 =91%
0.01 0.1 1 10 100
Favours less surgery Favours more surgery
A D D I T I O N A L T A B L E S
Table 1. Summary time-to-event statistics
Study Outcome
reported
Observed Expected Variance HR 95% CIs P value Follow-up Notes
Adden-
brookes
Overall
mortality
ALND:
107/112
No
ALND:
108/121
o-e = -3.1 46.5 0.94 (0.70 to 1.
25)
NA 15 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 9b),
then
inverted to
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Table 1. Summary time-to-event statistics (Continued)
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
The
number of
patients re-
ported
by Clarke
2005
differs from
that
reported
by Brinkley
(1971).
Adden-
brookes
Breast can-
cer mortal-
ity
ALND:
74/112
No
ALND:
78/121
o-e = -2.2 32.8 - - NA 15 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 9b),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition. Not
included in
meta-
analysis
Adden-
brookes
Isolated lo-
cal recur-
rence
ALND: 7
events/
1148
women-
years
No
ALND: 15
events/
o-e = 3.3 5.4 1.8 (0.79 to 4.
28)
NA 5 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 9b),
then
inverted to
165Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Summary time-to-event statistics (Continued)
1218
women-
years
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
AL-
MANAC
Overall
mortality
ALDN: 7/
476
SLNB: 7/
478
NA NA NA NA NA 1 year Cannot cal-
culate o-e.
Not
included in
meta-
analysis
AL-
MANAC
Axillary re-
currence
ALDN: 4/
476
SLNB: 1/
478
NA NA NA NA NA 1 year Cannot cal-
culate o-e.
Not
included in
meta-
analysis
Cape
Town
Overall
mortality
ALND:
21/43
Simple:
30/52
o-e = 4.74 12.35 1.47 (0.84 to 2.
56)
0.1775 10 years Tierney
et al (2007)
method
7 used log-
rank test re-
sults from
figure 1.
Cape Town
Cape
Town
Over-
all mortal-
ity (node-
negative)
ALND:
14/21
Simple:
26/30
o-e = 1.8 7.6 - - NA Taken from
Clarke
2005 (Ap-
pendix web
figure
9a; Groote-
Schuur)
, then O-E
sign
changed to
reflect that
more
surgery is
our
166Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Summary time-to-event statistics (Continued)
control and
less surgery
is our re-
search con-
dition. Not
included in
meta-
analysis
Cape
Town
Over-
all mortal-
ity (node-
positive)
ALND:
19/22
Simple:
22/25
o-e = -1.9 7.7 - - NA Taken from
Clarke
2005 (Ap-
pendix web
figure
9b; Groote-
Schuur)
, then O-E
sign
changed to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition. Not
included in
meta-
analysis
Cape
Town
Isolated lo-
cal recur-
rence
(node-
negative)
ALND: 3/
206
women-
years
Simple: 8/
232
women-
years
o-e = 1.7 2.3 2.09 (0.58 to 7.
63)
NA Taken from
Clarke
2005 (Ap-
pendix web
figure
9a; Groote-
Schuur),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
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Table 1. Summary time-to-event statistics (Continued)
is our re-
search con-
dition
Cape
Town
Isolated lo-
cal recur-
rence
(node-
positive)
ALND: 5/
134
women-
years
Simple: 9/
173
women-
years
o-e = 0.0 2.0 1.00 (0.25 to 4.
00)
NA Taken from
Clarke
2005 (Ap-
pendix web
figure
9b; Groote-
Schuur),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
Cape
Town
Axillary re-
currence
ALND: 2/
43
Simple: 8/
52
NA NA NA NA NA 10 years Cannot cal-
culate o-e.
Not
included in
meta-
analysis
Cape
Town
Any lo-
coregional
recurrence
ALND:
11/43
Simple:
19/52
NA NA NA NA NA 10 years Cannot cal-
culate o-e.
Not
included in
meta-
analysis
Cape
Town
Distant
metastases
ALND:
11/43
Simple:
13/52
NA NA NA NA NA 10 years Cannot cal-
culate o-e.
Not
included in
meta-
analysis
Cardiff Overall
survival
ALND: N
= 97
Sampling:
N =103
To-
o-e: 7.4 38 1.21 (0.29 to 0.
99)
0.23 20 years HR calcu-
lated using
log-rank P
value from
Stewart et al
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Table 1. Summary time-to-event statistics (Continued)
tal events
= 152
Fig 2 data:
ALND:
23/97
Sampling:
13/103
(1994, page
42)
by Tierney
2007
method
8, 9. Owing
to non-pro-
portion-
ality of haz-
ard rates,
HR cannot
be included
in meta-
analysis
Cardiff Disease-
free
survival
ALND: 97
Sampling:
103
5.87 7.75 2.13 (1.05 to 4.
31)
0.035 20 years Log-rank P
value
Tierney
2007
method 8,
9
(page 43 &
Fig 5 Stew-
art et al,
1994)
Cardiff Locore-
gional re-
currence
(chest wall,
ax-
illa, supra-
clavicular/
internal
mammary
nodes)
ALND:
19/94
Sampling:
31/99
Fig
4: ALND:
11/97
Sampling:
22/103
o-e: 6.46 11.78 1.73 (0.87 to 3.
42)
NA 20 years Tierney
et al (2007)
method
4 used and
data
from Figure
4&page 42
Stewart et al
(1994)
Cardiff Distant re-
lapse
ALND:
43/94
Sampling:
59/99
o-e: 8.4 24.87 1.4 (0.99 to 1.
71)
0.092 20 years Data from
Table 2,
Stewart et al
(1994): ex-
cludes pa-
tients
with radio-
therapy vi-
olations.
Per-pro-
tocol anal-
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Table 1. Summary time-to-event statistics (Continued)
ysis - not
included in
meta-
analysis
Cardiff Breast can-
cer recur-
rence (to-
tal)
(locore-
gional and
distant re-
lapse)
ALND:
62/94
Sampling:
90/99
o-e: 12.77 36.71 1.42 (1.18 to 1.
61)
0.035 20 years Calcu-
lated from
Stewart et al
(1994) (ex-
cludes RT
violations)
per-proto-
col analysis
Risk
of overesti-
mation not
certain
as these are
first events
or total
events.- not
included in
meta-
analysis
Edinburgh
1
Overall
survival
ALND: ?/
232
Sampling:
?/234
To-
tal events
= 53
ALND:
207/232
Sampling:
190/234
o-e: -4.66 13.25 0.7 (0.41 to 1.
21)
0.20 5 years HR calcu-
lated using
log rank P
- figure 2,
Chetty
(2000)
Edinburgh
1
Axillary re-
currence
ALND: /
232
Sampling:
/234
o-e: -0.15 13.25 0.99 (0.58 to 1.
69)
0.94 Up to 8
years
Log-rank P
value
Tierney
2007
method 7,
8, 9 used
Fig 3
Chetty
(2000)
Edinburgh
1
Local re-
currence in
ALND:
14/232
o-e: -0.10 7.24 0.99 (0.48 to 2.
04)
0.97 Up to 8
years
Tierney
2007
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Table 1. Summary time-to-event statistics (Continued)
the breast Sampling:
15/234
method 7,
8, 9 used
Table 2 &
page
87 Chetty
(2000)
Edinburgh
1
Distant re-
currence
ALND:
29/232
Sampling:
29/234
Not avail-
able
Not avail-
able
Not avail-
able
Not avail-
able
NA Up to 8
years
Table 2,
Chetty
(2000)
. Unable to
estimate
HR - not
included in
analysis
E’dburgh
Sample/
Clear
Overall
survival
ALND:
76/203
Sampling:
71/203
o-e: -3.81 36.55 0.90 (0.62 to 1.
25)
NA 13 years Tierney
2007
method 3
used (using
1995 data
- Clarke
2005 paper
re-
ports more
deaths)
Fig
1 and page
82 HR (CI)
in Forrest et
al (1995) -
inverted the
HR
E’dburgh
Sample/
Clear
Distant
metastases
ALND:
51/203
Sampling:
53/203
o-e: 1.5 30.78 0.92 (0.67 to 1.
35)
NA 13 years Tierney
2007
method 3
used (using
1995 data)
, Fig 2 and
HR (CI)
page 82 in
Forrest et al
(1995), in-
verted the
HR
E’dburgh
Sample/
Clear
Locore-
gional re-
lapse
ALND:
38/203
Sampling:
o-e: -4.9 16.32 0.74 (0.46 to 1.
20)
NA 13 years Tierney
2007
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Table 1. Summary time-to-event statistics (Continued)
(chest wall,
ax-
illa, supra-
clavicular)
29/203 method 3
used (using
1995 data)
Method 3
Fig 3 from
HR (CI)
, page 82 in
Forrest et al
(1995), in-
verted the
HR
Genoa Overall
survival
ALND: 4/
115
SLNB: 5/
110
o-e: 0.58 2.22 1.32 (0.35 to 4.
92)
0.679 5 years Log-rank P
value
(Canavese
2009 - fig
3) Tierney
2007
method 7
used
Fig 3 KM
curve gives
P = 0.679.
I assumed
that was
correct as it
appears on
the graph.
The text
value (page
20) may be
a typo
0.697. HR
are similar;
CI differ
Genoa Axillary re-
currence
ALND: 1/
115
SLNB: 0/
110
NA NA NA NA NA 5 years Not
included in
meta-
analysis
Genoa Breast can-
cer recur-
rence
(local and
contralat-
eral recur-
rence, ax-
illary and
dis-
ALND:
10/115
SLNB: 8/
110
NA NA NA NA NA 5 years Not
included in
meta-
analysis
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Table 1. Summary time-to-event statistics (Continued)
tant metas-
tases)
Genoa 5-Year
event-free
survival
ALND:
12/115
SLNB: 10/
110
o-e: -0.85 5.45 0.86 (0.37 to 1.
98)
0.715 5 years Log-rank P
value from
Fig
2, Canavese
(2009)
method 7
Tierney
2007 used
GIVOM
Sentinella
Overall
survival
ALND:
14/352
SLNB: 21/
345
NA NA NA NA NA 5 years Not
included in
meta-
analysis
GIVOM
Sentinella
Disease-
free
survival
ALND:
28/352
SLNB: 39/
345
o-e = 1.18 16.3 1.08 0.769 5 years Method 7
Tierney
2007 used
GIVOM
Sentinella
Axillary re-
currence
ALND: 0/
352
SLNB: 1/
345
NA NA NA NA NA 5 years Cannot cal-
culate o-e.
Not
included in
meta-
analysis
GIVOM
Sentinella
Locore-
gional re-
currence
ALND: 3/
352
SLNB: 16/
345
NA NA NA NA NA 5 years Cannot cal-
culate o-e.
Not
included in
meta-
analysis
GIVOM
Sentinella
Distant re-
currence
ALND:
16/352
SLNB: 11/
345
NA NA NA NA NA 5 years Cannot cal-
culate o-e.
Not
included in
meta-
analysis
Guy’s Over-
all mortal-
ity (clini-
cally node
negative)
ALND:
178/241
No ALND
(wide ex-
cision):
185/233
o-e = 13.8 80.7 1.26 (0.98 to 1.
63)
0.1 15 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10a),
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Table 1. Summary time-to-event statistics (Continued)
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our
research in-
tervention
Guy’s Over-
all mortal-
ity (clini-
cally node
positive)
ALND:
82/85
No ALND
(wide ex-
cision):
64/71
o-e = 4.3 30.9 1.15 (0.81 to 1.
64)
0.4 15 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10b),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our
research in-
tervention
Guy’s Breast can-
cer mortal-
ity (clini-
cally node
negative)
ALND:
122/241
No ALND
(wide ex-
cision):
142/233
o-e = 13.8 58.8 - - 0.07 15 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10a),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our
research in-
tervention
Not
included in
meta-
analysis
174Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Summary time-to-event statistics (Continued)
Guy’s Breast can-
cer mortal-
ity (clini-
cally node
positive)
ALND:
53/85
No ALND
(wide ex-
cision):
54/71
o-e = 6.2 23.6 - - 0.2 15 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10b),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our
research in-
tervention.
Not
included in
meta-
analysis
Guy’s Isolated lo-
cal recur-
rence (clin-
ically node
negative)
ALND: 35
events/
3267
women-
years
No
ALND: 81
events/
2383
women-
years
o-e = 29.5 26.4 3.06 (2.09 to 4.
48)
< .00001 5 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10a),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our
research in-
tervention
Guy’s Isolated lo-
cal recur-
rence (clin-
ically node
positive)
ALND: 17
events/
873
women-
years
No
ALND: 31
events/
519
women-
years
o-e = 10.5 10.8 2.64 (1.46 to 4.
80)
0.001 5 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10b),
then
inverted to
reflect that
more
surgery is
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Table 1. Summary time-to-event statistics (Continued)
our
control and
less surgery
is our
research in-
tervention
Hammer-
smith
Overall
survival
Radical:
35/76
Simple:
40/76
o-e = 1.44 11.78 1.13 (0.64 to 2.
00)
NA 8 years Extracted
from
Fig 3, Burn
et al (1968)
Tierney
2007
method 10
on
Simple is
input as “re-
search” and
rad-
ical as “con-
trol”. Min
and
max follow-
up input as
3-96
months
Hammer-
smith
Local
recurrence
Radical:
10/76
Simple:
11/76
NA NA NA NA NA 4-9 years Not
included in
meta-
analysis
Hammer-
smith
Mean time
to
recurrence
Rad-
ical: 15.7
months
Sim-
ple: 25.9
months
NA NA NA NA NA 4-9 years Not
included in
meta-
analysis
IBCSG-
10-93
Overall
survival
ALND:
72/234
Surgery
only: 71/
239
o-e = 1.76
(survival
curves
cross)
36.05 1.05 (0.76 to 1.
46)
0.77 6-7 years HR
reported on
page 340 of
IBCSG
(2006),
used
Tierney
2007
method 3
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Table 1. Summary time-to-event statistics (Continued)
IBCSG-
10-93
Disease-
free
survival
ALND:
92/234
Surgery
only: 89/
239
o-e = 2.6 44.69 1.06 (0.79 to 1.
42)
0.69 6-7 years HR
reported on
page 340 of
IBCSG
(2006),
used
Tierney
2007
method 3
IBCSG-
10-93
Ax-
illa recur-
rence (as
first event)
ALND: 2/
234
Surgery
only: 6/
239
NA NA NA NA NA 6-7 years Not
included in
meta-
analysis
Institut
Bergonie
Over-
all survival
(whole fol-
low-up pe-
riod) ITT
no ALND:
NR
ALND:
NR
o-e = 6.42 7.04 2.49 90% CI
(1.34 to 4.
63)
NA Whole fol-
low-up
period (un-
clear how
long that is)
HR
reported on
page 566 of
Avril
(2011),
used
Tierney
2007
method 3
Institut
Bergonie
Event-free
survival
(whole fol-
low-up pe-
riod) ITT
no ALND:
44/297
ALND:
31/297
o-e = 8.75 18.37 1.61 90%
CI (1.1 to
2.37)
NA Whole fol-
low-up
period (un-
clear how
long that is)
HR
reported on
page 566 of
Avril
(2011),
used
Tierney
2007
method 3
Institut
Bergonie
Axillary
event
Within 5
years:
no ALND:
4/297
ALND: 0/
310
After 5
years:
no ALND:
2/297
ALND: 0/
310
NA NA NA NA NA Not
included in
meta-
analysis
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Table 1. Summary time-to-event statistics (Continued)
Institut
Bergonie
Lymph
node (excl
axillary)
event
Within 5
years:
no ALND:
1/297
ALND:
NA
After 5
years:
no ALND:
0/297
ALND:
NA
NA NA NA NA NA Not
included in
meta-
analysis
Institut
Bergonie
Breast/
chest wall
event
Within 5
years:
no ALND:
5/297
ALND: 4/
310
After 5
years:
no ALND:
0/297
ALND: 8/
310
NA NA NA NA NA Not
included in
meta-
analysis
Institut
Bergonie
Metastatic
event
Within 5
years:
no ALND:
4/297
ALND: 1/
310
After 5
years:
no ALND:
2/297
ALND: 2/
310
NA NA NA NA NA Not
included in
meta-
analysis
Institut
Bergonie
Contralat-
eral breast
cancer
Within 5
years:
no ALND:
2/297
ALND: 1/
310
After 5
years:
no ALND:
2/297
NA NA NA NA NA Not
included in
meta-
analysis
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Table 1. Summary time-to-event statistics (Continued)
ALND: 1/
310
Institut
Bergonie
Other site
cancer
Within 5
years:
no ALND:
5/297
ALND: 5/
310
After 5
years:
no ALND:
5/297
ALND: 4/
310
NA NA NA NA NA Not
included in
meta-
analysis
Institut
Curie
Overall
survival
RT: 43/
331;
ALND:
29/326
o-e = 7 17.3 1.50 (0.94 to 2.
40)
NA Taken from
Clarke
2005 (Ap-
pendix web
figure 10a),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
Institut
Curie
Isolated lo-
cal recur-
rence
RT: 39/
2045
women-
years;
ALND:
34/2126
women-
years
o-e = 1.6 17.5 1.10 (0.69 to 1.
75)
NA Taken from
Clarke
2005 (Ap-
pendix web
figure 10a),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
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Table 1. Summary time-to-event statistics (Continued)
Institut
Curie
Axilla
recurrence
RT: 12/
332;
ALND: 5/
326
o-e = 3.86 3.53 3.93 - 0.04 Table
2 in Louis-
Sylvestre
(2004)
, method 7
in Tierney
2007
Institut
Curie
Disease-
free
survival
RT:
5 years :
82 (SD =
2.1)%
10 years :
72 (SD =
2.5)%
15 years :
65.5 (SD
= 2.7)%
ALND:
5 years: 83.
3 (SD 2)%
10
years: 72.6
(SD 2.5)%
15
years: 64.
3 (SD 2.9)
%.
NA NA NA NA o-e can-
not be ex-
tracted be-
cause P val-
ues not re-
ported past
NS in Table
2 in Louis-
Sylvestre
(2004).
Not
included in
meta-
analysis
Institut
Curie
Metastases RT:
5 years: 12.
8 (SD 1.9)
%
10 years:
21 (SD 2.
3)%
15
years: 24.9
(SD 2.5)%
ALND: 5
years: 10.8
(SD 1.7)%
10
years: 18.3
(SD 2.2)%
15
years: 25.8
(SD 2.6)%
NA NA NA NA O-e cannot
be extracted
be-
cause P val-
ues not re-
ported past
NS in Table
2 in Louis-
Sylvestre
(2004).
Not
included in
meta-
analysis
Malmo Overall
survival
ALND
+ RT: ?/97
Mastec-
tomy
alone:
?/98 (total
event rate
= 91)
o-e = -4.19 22.75 0.83 (0.55 to 1.
25)
0.38 15-20 years Using P
= 0.38
reported on
page 558 of
Borgstrom
(1994) and
Tierney
2007
method 8.
The o-e is
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Table 1. Summary time-to-event statistics (Continued)
calculated
on the basis
of a total
event rate
of N = 91,
and total N
= 97 in the
ALND +
RT group
and N = 98
in mastec-
tomy alone
group (i.
e. intent-
to-treat
numbers),
and using
the only
P value
reported,
which was
for per-
protocol
analysis
that study
authors
stated
did not
differ from
intention-
to-treat
analyses
Malmo Chest wall
recurrence
ALND
+ RT: 2/97
Mastec-
tomy
alone: 11/
98
NA NA NA NA NA 15-20 years Cannot cal-
culate o-e.
Not
included in
meta-
analysis
Manch-
ester
Overall
survival
Radical:
126/149
Simple
+ RT: 140/
159
o-e = 5.4 58.6 1.10 (0.85 to 1.
42)
NA 15 years Taken from
Clarke
2005 (Ap-
pendix web
figure 10b),
then
inverted to
reflect that
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Table 1. Summary time-to-event statistics (Continued)
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
Manch-
ester
Death
from
breast can-
cer
Radical:
100/149
Simple
+ RT: 112/
159
o-e = 2.8 46 1.06 (0.80 to 1.
42)
NA 15 years Taken from
Clarke
2005 (Ap-
pendix web
figure 10b),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
Manch-
ester
Local
recurrence
Radical:
48 events/
997
women-
years
Sim-
ple + RT:
41 events/
1113
women-
years
o-e = -5.7 19.9 0.75 (0.48 to 1.
17)
NA 15 years Taken from
Clarke
2005 (Ap-
pendix web
figure 10b),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
Milan Death
from any
cause (OS)
ALND =
23/257
SLNB =
15/259
o-e = -4.34 9.08 0.62 (0.32 to 1.
19)
0.15 10 years Log-rank P
(Tierney
2007
method 7)
; ALND is
control
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Table 1. Summary time-to-event statistics (Continued)
Milan Breast can-
cer recur-
rence (lo-
cal recur-
rence, re-
gional
lymph
node
metas-
tases, dis-
tant metas-
tases)
ALND =
26/257
SLNB =
23/259
o-e = -2.25 12.02 0.83 (0.47 to 1.
46)
0.52 10 years Log-rank P
(Tierney
2007
method 7)
; ALND is
control
Milan Distant
metastasis
ALND =
20/257
SLNB =
17/259
o-e = -2.04 9.19 0.80 (0.42 to 1.
53)
0.50 10 years Log-rank P
from table
4 Veronesi
(2010)
(Tierney
2007
method 7)
; ALND is
control
Milan Axillary
metastasis
ALND =
0/257
SLNB = 2/
259
o-e = 0.97 0.50 6.96 (0.44 to
111.3)
0.17 10 years Log-rank P
from table
4 Veronesi
(2010)
(Tierney
2007
method
8 and 9)
; ALND is
control
Milan Local
recurrence
ALND =
4/257
SLNB = 4/
259
o-e = -0.12 2.00 0.94 (0.24 to 3.
76)
0.93 10 years Log-rank P
from table
4 Veronesi
(2010)
(Tierney
2007
method 7)
; ALND is
control
Milan Supraclav-
icular
metastasis
ALND =
2/257
SLNB = 0/
259
o-e = -1.02 0.50 0.13 (0.01 to 2.
09)
0.15 10 years Log-rank P
from table
4 Veronesi
(2010)
(Tierney
183Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Summary time-to-event statistics (Continued)
2007
method 8,
9); ALND
is control
Milan Contralat-
eral breast
cancer
ALND =
10/257
SLNB = 9/
259
o-e = -0.81 4.47 0.84 (0.34 to 2.
07)
0.71 10 years Log-rank P
from table
4 Veronesi
(2010)
(Tierney
2007
method 7)
; ALND is
control
Milan 2 Overall
survival
ALND =
31/109
No ALND
= 35/110
o-e = -2.72 16.43 0.85 (0.52 to 1.
37)
Me-
dian = 150
months
HR
reported on
page 922 of
Martelli
(2012). Us-
ing Tierney
2007
method 3 o
Please note,
the curves
cross;
also the HR
used for ex-
traction of
o-e and its
variance is
adjusted for
tu-
mour grade
and oestro-
gen-recep-
tor status
Milan 2 Breast can-
cer deaths
ALND: 8/
109
No
ALND:
10/110
o-e = 1.33 4.06 1.39 - - Me-
dian = 150
months
HR
reported in
Table 3 of
Martelli
(2012)
. Tierney
2007
method 3 o
Please note,
the curves
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Table 1. Summary time-to-event statistics (Continued)
cross;
also the HR
used for ex-
traction of
o-e and its
variance is
adjusted for
tu-
mour grade
and oestro-
gen-
receptor
status. Not
included in
meta-
analysis
Milan 2 Axillary re-
lapse
ALND: 0/
109
No
ALND: 4/
110
NA NA NA NA NA Me-
dian = 150
months
Table 2 of
Martelli
(2012),
cannot cal-
culate o-e
Milan 2 Recur-
rence (ipsi-
lat-
eral breast
tumour)
ALND: 4/
109
No
ALND: 7/
110
NA NA NA NA NA Me-
dian = 150
months
Table 2 of
Martelli
(2012),
cannot cal-
culate o-e
Milan 2 Distant
metastases
ALND: 9/
109
No
ALND: 9/
110
o-e = -2.68 5.93 0.64 (0.28 to 1.
42)
NA Me-
dian = 150
months
HR
reported in
Table 3 of
Martelli
(2012)
. Tierney
2007
method 3
Please note,
the curves
cross;
also the HR
used for ex-
traction of
o-e and its
variance is
adjusted for
tu-
185Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Summary time-to-event statistics (Continued)
mour grade
and oestro-
gen-recep-
tor status
Milan 3 Overall
survival
10-year
ALND:
93.
3% (95%
CI 89.4-
95.8)
no ALND:
91.
5% (95%
CI 87-94.
4)
o-e = 1.76 12.33 1.15 (0.66 to 2.
02)
P = .436 Me-
dian = 127.
5 months
Agresti
(2014) Fig-
ure 3A and
Tierney
2007
method 11
Please note,
the curves
cross at the
very end,
also HR
used for ex-
traction of
o-e
Milan 3 Death
from
breast can-
cer
ALND:
17/272
no ALND:
15/245
NA NA NA NA P = 1.00 Me-
dian = 127.
5 months
Not
included in
meta-
analysis
Milan 3 Disease-
free
survival
10-year
ALND:
92.
4% (95%
CI 88.5-
95.1)
no ALND:
91.
3% (95%
CI 86.7-
94.3)
o-e= -0.13 10.7 0.99 (0.54 to 1.
8)
P = .97 Me-
dian = 127.
5 months
Agresti
(2014) Fig-
ure 3A and
Tierney
2007
method 11
Please note,
the curves
cross at the
very end;
also the HR
used for ex-
traction of
o-e
Milan 3 Distant
metastases
ALND:
23/272
no ALND:
20/245
NA NA NA NA P = 1.00 Me-
dian = 127.
5 months
Not
included in
meta-
analysis
Milan 3 Axillary re-
currence
ALND: 0/
272;
no ALND:
22/245
NA NA NA NA NA Me-
dian = 127.
5 months
Not
included in
meta-
analysis
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Table 1. Summary time-to-event statistics (Continued)
Milan 3 Local
recurrence
ALND:
14/272
no ALND:
11/245
NA NA NA NA P = .839 Me-
dian = 127.
5 months
Not
included in
meta-
analysis
Milan 3 Contralat-
eral breast
cancer
ALND:
13/272
no ALND:
14/245
‘NA NA NA NA P = .695 Me-
dian = 127.
5 months
Not
included in
meta-
analysis
NSABP B-
04
Over-
all survival:
node nega-
tive:
ALND vs
no ALND
ALND =
259/389
No ALND
= 256/384
o-e = -5 117.3 0.96 (0.80 to 1.
15)
NA 15 years? Taken from
Clarke
2005
Lancet (Ap-
pendix web
figure 9a),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
NSABP B-
04
Over-
all survival:
node nega-
tive:
ALND vs
no ALND
+ RT
ALND =
259/389
No ALND
+ RT =
271/386
o-e = 8.6 122.2 1.07 (0.90 to 1.
28)
NA 15 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10a),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
NSABP B-
04
Over-
all survival:
node posi-
tive:
ALND =
244/301
No ALND
+ RT =
o-e = 8.3 109.4 1.08 (0.89 to 1.
30)
NA 15 years? Taken from
Clarke
2005 (Ap-
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Table 1. Summary time-to-event statistics (Continued)
ALND vs
no ALND
+ RT
244/305 pendix web
figure 10b),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
NSABP B-
04
Lo-
cal isolated
recurrence:
node nega-
tive:
ALND vs
no ALND
ALND =
35 events/
3949
women-
years
No ALND
=
94 events/
3335
women-
years
o-e = 31.5 29.2 2.94 (2.05 to 4.
23)
NA 5 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 9a),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
NSABP B-
04
Lo-
cal isolated
recurrence:
node nega-
tive:
ALND vs
no ALND
+ RT
ALND =
35 events/
3949
women-
years
No ALND
+ RT = 18
events/
3896
women-
years
o-e = -8.7 13 0.51 (0.30 to 0.
88)
NA 5 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10a),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
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Table 1. Summary time-to-event statistics (Continued)
NSABP B-
04
Lo-
cal isolated
recurrence:
node posi-
tive:
ALND vs
no ALND
+ RT
ALND =
45 events/
2268
women-
years
No ALND
+ RT = 42
events/
2025
women-
years
o-e = -0.5 20.8 0.98 (0.64 to 1.
50)
NA 5 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10b),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
NSABP B-
04
Disease-
free sur-
vival: node
negative:
ALND vs
no ALND
ALND =
281/362
No ALND
+ RT =
287/365
o-e = 9.36 138.3 1.07 (0.91 to 1.
27)
0.39 25 years FIsher
(2008)
page 568
(radical vs
total mas-
tectomy)
Tierney
2007
method 3,
calculated
from the
date of
mastec-
tomy,
events
considered
in determi-
nation of
disease-free
survival
were the
first local,
regional
or distant
recurrence
of tumour;
contralat-
eral breast
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Table 1. Summary time-to-event statistics (Continued)
cancer or
a second
primary
tumour
other than
a tumour in
the breast;
and death
with no
evidence of
cancer
NSABP B-
04
Disease-
free sur-
vival: node
negative:
ALND vs
no ALND
+ RT
ALND =
281/362
No ALND
+ RT =
292/352
o-e = 8.3 142.39 1.06 (0.90 to 1.
25)
0.49 25 years FIsher
(2008)
page 568
(radical
vs total
mastec-
tomy + RT)
Tierney
2007
method 3,
calculated
from the
date of
mastec-
tomy,
events
considered
in determi-
nation of
disease-free
survival
were the
first local,
regional
or distant
recurrence
of tumour;
contralat-
eral breast
cancer or
a second
primary
tumour
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Table 1. Summary time-to-event statistics (Continued)
other than
a tumour in
the breast;
and death
with no
evidence of
cancer
NSABP B-
04
Disease-
free sur-
vival: node
positive:
ALND vs
no ALND
+ RT
ALND =
254/292
No ALND
+ RT =
258/294
o-e = 14.46 127.57 1.12 (0.94 to 1.
33)
0.20 25 years FIsher
(2008)
page 568,
Tierney
2007
method 3,
calculated
from the
date of
mastec-
tomy,
events
considered
in determi-
nation of
disease-free
survival
were the
first local,
regional
or distant
recurrence
of tumour;
contralat-
eral breast
cancer or
a second
primary
tumour
other than
a tumour in
the breast;
and death
with no
evidence of
cancer
NSABP B-
04
Relapse-
free sur-
vival: node
negative:
ALND vs
ALND =
154/362
No ALND
+ RT =
182/365
o-e = 10.17 77.61 1.14 (0.91 to 1.
42)
0.27 25 years FIsher
(2008)
page 568
Tierney
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Table 1. Summary time-to-event statistics (Continued)
no ALND 2007
method 3;
calculated
from the
date of
mastec-
tomy,
events
considered
in determi-
nation of
relapse-free
survival
were the
first local,
regional
or distant
recurrence;
or an event
in the con-
tralateral
breast
NSABP B-
04
Relapse-
free sur-
vival: node
negative:
ALND vs
no ALND
+ RT
ALND =
154/362
No ALND
+ RT =
163/352
o-e = -2.9 71.05 0.96 (0.76 to 1.
21)
0.74 25 years FIsher
(2008)
page 568,
Tierney
2007
method 3,
calculated
from the
date of
mastec-
tomy,
events
considered
in determi-
nation of
relapse-free
survival
were the
first local,
regional
or distant
recurrence;
or an event
in the con-
tralateral
breast
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Table 1. Summary time-to-event statistics (Continued)
NSABP B-
04
Relapse-
free sur-
vival: node
positive:
ALND vs
no ALND
+ RT
ALND =
178/292
No ALND
+ RT =
183/294
o-e = 7.63 88.52 1.09 (0.89 to 1.
35)
0.40 25 years FIsher
(2008)
page 568,
Tierney
2007
method 3,
calculated
from the
date of
mastec-
tomy,
events
considered
in determi-
nation of
relapse-free
survival
were the
first local,
regional
or distant
recurrence;
or an event
in the con-
tralateral
breast
NSABP B-
04
Time to
dis-
tant metas-
tasis: node
negative:
ALND vs
no ALND
ALND =
101/362
No ALND
+ RT =
107/365
o-e = 8.44 88.52 1.1 (0.89 to 1.
35)
0.39 25 years FIsher
(2008)
page 569,
Tierney
2007
method 3
NSABP B-
04
Time to
dis-
tant metas-
tasis: node
negative:
ALND vs
no ALND
+ RT
ALND =
101/362
No ALND
+ RT =
111/352
o-e = 6.69 86.9 1.08 (0.88 to 1.
34)
0.44 25 years FIsher
(2008)
page 569,
Tierney
2007
method 3
NSABP B-
04
Time to
dis-
tant metas-
tasis: node
positive:
ALND =
120/292
No ALND
+ RT =
127/294
o-e = 5.98 88.41 1.07 (0.87 to 1.
32)
0.51 25 years FIsher
(2008)
page 569,
Tierney
2007
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Table 1. Summary time-to-event statistics (Continued)
ALND vs
no ALND
+ RT
method 3
NSABP B-
32
Over-
all survival
(all ran-
domised
partic-
ipants, i.e.
node+ and
node-)
ALND =
228
(deaths)/
2807
SLN= 252
(deaths)/
2804
10.32 119.7 1.09 (0.91 to 1.
3)
0.35 10 years From Julian
(2013) us-
ing Tierney
2007
method 4.
Contacted
au-
thor (Krag)
to confirm
direction of
effect
NSABP B-
32
Disease-
free
survival
(all ran-
domised
partic-
ipants, i.e.
node+ and
node-)
ALND =
455/2807
SLN =
475/2804
4.6 232.39 1.02 (0.9 to 1.
16)
0.72 10 years From Julian
(2013) us-
ing Tierney
2007
method 4.
Contacted
au-
thor (Krag)
to confirm
direction of
effect
NSABP B-
32
Local/
regional re-
currence
(all ran-
domised
partic-
ipants, i.e.
node+ and
node-)
ALND =
121/2807
SLN =
112/2804
-2.37 58.16 0.96 (0.74 to 1.
24)
0.77 10 years From Julian
(2013) us-
ing Tierney
2007
method 4.
Contacted
au-
thor (Krag)
to confirm
direction of
effect
NSABP B-
32
Axillary re-
currence
(all ran-
domised
partic-
ipants, i.e.
node+ and
node-)
ALND =
6/2807
SLN = 14/
2804
NA NA NA NA NA 10 years o-e cannot
be calcu-
lated. Not
included in
meta-
analysis
194Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Summary time-to-event statistics (Continued)
NSABP B-
32
Over-
all survival
(for SLN-
neg)
ALND =
219
(dead)/
1975
SLN= 245
(dead)/
2011
o-e = 12.07 115.64 1.11 (0.93 to 1.
33)
0.27 10 years From Julian
(2013) us-
ing Tierney
2007
method 4
NSABP B-
32
Disease-
free sur-
vival (for
SLN-neg)
ALND
= 456 (dis-
eased)/
1975
SLN = 465
(diseased)/
2011
o-e = 2.29 230.23 1.01 (0.89 to 1.
15)
0.92 10 years From Julian
(2013) us-
ing Tierney
2007
method 4
NSABP B-
32
Local
regional re-
currence
ALND =
85
(events)/
1975
SLN = 80
(events)/
2011
o-e = -2.11 41.21 0.95 (0.7 to 1.
29)
0.77 10 years From Julian
(2013) us-
ing Tierney
2007
method 4
NSABP B-
32
Local re-
currence in
SLN-nega-
tive partic-
ipants
ALND =
54
(events)/
1975
SLN = 49
(events)/
2011
o-e = -3.03 25.69 0.89 (0.6 to 1.
31)
0.55 Mean = 95.
6 months
From Krag
(2010)
page 930
using lo-
grank P = 0.
55 Tierney
2007
method 7
NSABP B-
32
Re-
gional re-
currence in
SLN-nega-
tive partic-
ipants
ALND =
8 (events)/
1975
SLN = 14
(events)/
2011
o-e = 2.77 5.09 1.72 (0.72 to 4.
11)
0.22 Mean = 95.
6 months
From Krag
(2010)
page 930
using log
rank P = 0.
22 Tierney
2007
method 7
NSABP B-
32
Distant re-
currence in
SLN-
negative
patients
ALND =
55
(events)/
1975
SLN = 64
(events)/
2011
o-e = 3.91 29.82 1.14 (0.8 to 1.
64)
Mean = 95.
6 months
From Krag
(2010) Fig-
ure
4 Tierney
2007
method 3
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Table 1. Summary time-to-event statistics (Continued)
Ostersund Re-
currence in
the axilla
ALND: 0/
57
Sampling:
1/54
NA NA NA NA NA Median: 30
(range, 5-
76) months
From
Borup-
Chiste-
sen (1993)
table
IV. Recur-
rence is re-
ported only
out of N =
111 (57 +
54) partic-
ipants who
did not
have metas-
tases in axil-
lary lymph
nodes after
dissection
or biopsy.
Cannot cal-
culate o-
e on the ba-
sis of avail-
able data
Ostersund Local
recurrence
ALND: 4/
57
Sampling:
1/54
NA NA NA NA NA Median: 30
(range, 5-
76) months
From
Borup-
Chiste-
sen (1993)
table
IV. Recur-
rence is re-
ported only
out of N =
111 (57 +
54) partic-
ipants who
did not
have metas-
tases in axil-
lary lymph
nodes after
dissection
or biopsy.
Cannot cal-
culate o-
e on the ba-
sis of avail-
able data
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Table 1. Summary time-to-event statistics (Continued)
Ostersund Distant re-
currence
ALND: 1/
57
Sampling:
4/54
NA NA NA NA NA Median: 30
(range, 5-
76) months
From
Borup-
Chiste-
sen (1993)
table
IV. Recur-
rence is re-
ported only
out of N =
111 (57 +
54) partic-
ipants who
did not
have metas-
tases in axil-
lary lymph
nodes after
dissection
or biopsy.
Cannot cal-
culate o-
e on the ba-
sis of avail-
able data
SE
Scotland
Over-
all survival:
node nega-
tive:
ALND
vs Simple +
RT
ALND =
143/199
Simple +
RT = 143/
180
o-e = 17.5 65.7 1.31 (1.02 to 1.
66)
NA 15 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10a),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
SE
Scotland
Over-
all survival:
node posi-
tive:
ALND
vs Simple +
RT
ALND =
72/89
Simple +
RT = 77/
93
o-e = 6.3 34.1 1.20 (0.86 to 1.
68)
NA 15 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10b),
then
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Table 1. Summary time-to-event statistics (Continued)
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
SE
Scotland
Lo-
cal isolated
recurrence:
node nega-
tive:
ALND vs
no ALND
+ RT
ALND =
26 events/
2880
women-
years
Sim-
ple + RT =
21 events/
2204
women-
years
o-e = -0.5 11.3 0.96 (0.53 to 1.
71)
NA 5 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10a),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
SE
Scotland
Lo-
cal isolated
recurrence:
node posi-
tive:
ALND vs
no ALND
+ RT
ALND =
24 events/
943
women-
years
Sim-
ple + RT =
17 events/
878
women-
years
o-e = -2.9 9.8 0.74 (0.40 to 1.
39)
NA 5 years? Taken from
Clarke
2005 (Ap-
pendix web
figure 10b),
then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
WSSA
Glasgow
Over-
all survival
- node neg-
ative
ALND:
56/101
Sim-
ple + RT
to chest
o-e = -5.5 21.4 0.77 (0.51 to 1.
18)
NA 15 years? CAU-
TION:
same con-
trol group
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Table 1. Summary time-to-event statistics (Continued)
wall & ax-
illa: 42/85
used twice
for these
data
Taken from
Clarke
2005 (Ap-
pendix web
fig-
ures 9a and
10a), then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
WSSA
Glasgow
Over-
all survival
- node pos-
itive
ALND:
13/17
Sim-
ple + RT
to chest
wall & ax-
illa: 7/9
o-e = -0.5 3.3 0.86 (0.29 to 2.
53)
NA 15 years? CAU-
TION:
same con-
trol group
used twice
for these
data
Taken from
Clarke
2005 (Ap-
pendix web
fig-
ures 9b and
10b). then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
WSSA
Glasgow
Isolated lo-
cal re-
currence -
node nega-
ALND:
15/510 py
Simple
+ RT to
o-e = 0.0 6.7 1.00 (0.47 to 2.
13)
NA 5 years? CAU-
TION:
same con-
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Table 1. Summary time-to-event statistics (Continued)
tive chest wall
& axilla:
13/483 py
trol group
used twice
for these
data
Taken from
Clarke
2005 (Ap-
pendix web
fig-
ures 9a and
10a), then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
WSSA
Glasgow
Isolated lo-
cal re-
currence -
node posi-
tive
ALND: 3/
69 py
Simple
+ RT to
chest wall
& axilla:
1/41 py
o-e = -0.5 0.9 0.57 (0.07 to 4.
53)
NA 5 years? CAU-
TION:
same con-
trol group
used twice
for these
data
Taken from
Clarke
2005 (Ap-
pendix web
fig-
ures 9b and
10b), then
inverted to
reflect that
more
surgery is
our
control and
less surgery
is our re-
search con-
dition
Xu 2003 10-
year overall
survival
Level I
clearance:
75/93
NA NA NA NA NA 10 years o-
e could not
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Table 1. Summary time-to-event statistics (Continued)
ALND:
71/88
be calcu-
lated as no
P values re-
ported. Not
included in
meta-
analysis
Xu 2003 10-year
disease-
free
survival
Level I
clearance:
72/93
ALND:
68/88
NA NA NA NA NA 10 years o-
e could not
be calcu-
lated as no
P values re-
ported. Not
included in
meta-
analysis
Xu 2003 Breast can-
cer recur-
rence
Level I
clearance:
19/93
ALND:
17/88
NA NA NA NA NA 10 years? o-
e could not
be calcu-
lated as no
P values re-
ported. Not
included in
meta-
analysis
Xu 2003 Local
recurrence
Level I
clearance:
3.2%
ALND: 2.
3%
NA NA NA NA NA 10 years? o-
e could not
be calcu-
lated as no
P values re-
ported. Not
included in
meta-
analysis
Xu 2003 Distant
metastasis
Level I
clearance:
19/93
ALND:
15/88
NA NA NA NA NA 10 years? o-
e could not
be calcu-
lated as no
P values re-
ported. Not
included in
meta-
analysis
Figures in bold were reported in the original publication; others were derived (see Notes column).
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Table 2. Morbidity definitions
Study Oedema Shoulder
function
Skin graft Delayed
healing
Activity Attitude Other Notes
Guy’s Slight: 0-2.5
cm
Moderate:
2.5-4.5 cm
Severe > 4.5
cm
Circumfer-
ence of both
arms mea-
sured 7.5 cm
below the
acromion,
18 cm above
and 10 cm
be-
low the ole-
cranon and
at the wrist
Pre-
sumably dif-
ference be-
tween
arm circum-
ference
Arm
function:
Good: uses
arm freely
Fair: can-
not do usual
tasks
Poor:
very unsat-
isfactory use
of arm
Appears to
be as-
sessed by pa-
tient ques-
tionnaire
Good: nor-
mal activity,
back at work
or resumed
usual activi-
ties
Fair: light
work
only because
of opera-
tion; not re-
sumed usual
activities
Poor: inac-
tive.
As-
sessed by pa-
tient ques-
tionnaire
Good: no
complaints
Fair: some
complaints
Poor: very
un-
happy about
experience
As-
sessed by pa-
tient ques-
tionnaire
ACOSOG
Z0011
Lym-
pheoedema
(subjective)
-
according to
patient self-
report
or physician
diagnosis
Lym-
pheoedema
(objec-
tive): 2 cm
or greater
postop
increase
in ipsilateral
arm circum-
ference
Axillary
paraesthesia
- patient re-
ported
Brachial
plexus
injury - de-
termined by
physician on
examining
the patient
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Table 2. Morbidity definitions (Continued)
Adden-
brookes
1. Mild
oedema
2. Gross
oedema (es-
timated
by measur-
ing the cir-
cumference
of each arm
with the arm
extended
at points 11
inches and
22 inches
from the tips
of the mid-
dle finger.
An increase
of 1 inch in
the circum-
ference
of the arm
on the side
of the oper-
ation at ei-
ther or both
points
was taken to
indicate
some degree
of oedema)
Stiff shoul-
der
Need for
skin graft
Sufficient to
cause post-
ponement
of radiother-
apy
until at least
2 months af-
ter the op-
eration. Al-
though inci-
dence of de-
layed heal-
ing varied
between sur-
geons, each
showed the
same trend
of higher in-
cidence fol-
lowing a
radical oper-
ation
Adden-
brookes
2
Sub-
jective lym-
phoedema:
patient
reported
Ob-
jective lym-
phoedema:
circum-
ferential arm
mea-
surement at
4 cm inter-
vals from the
wrist (ap-
proximately
10 measure-
Range of
movement
measured
by recording
degrees of
flexion, ab-
duction and
internal and
external ro-
tation using
goniometer
Sensory
function
tested using
pinprick,
light touch
Global
Severity
Index (GSI;
low values
better)
, Beck’s De-
pression In-
ventory,
Spielberger’s
State-Trait
anx-
iety, MAC,
SF-36 (mea-
sured
psycholog-
ical morbid-
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Table 2. Morbidity definitions (Continued)
ments) used
to calculate
arm volume.
Volume cor-
rected us-
ingmeasure-
ments from
contralateral
arm
ity and qual-
ity of life)
ALMANAC Change in
ipsilateral
arm volume
at each
follow-up
visit was
expressed
as a % in-
crease from
pretreat-
ment value.
Ratios of
presurgery
to post-
surgery
arm vol-
umes were
compared
on a log-
transformed
scale. The
contralateral
arm was
used as a
control for
evaluations
of arm
volume
Also pa-
tient rated as
mild, mod-
erate or se-
vere
Assessed by
gonio-
metric mea-
surement of
arm move-
ment (flex-
ion, abduc-
tion, inter-
nal rotation
and external
rotation).
Changes be-
tween
visits calcu-
lated by sub-
traction
The
contralat-
eral arm was
used
as a control
for arm and
shoulder
function
QoL:
Fact-B+4
Anxiety:
Spielberger
STAI
Cardiff - Lo-
cal
No morbid-
ity data
Cardiff - St
Mary’s
Oedema of
arm 72 cm
Re-
stricted ele-
vation 720
Measured
but not re-
Axillary
pain; numb-
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Table 2. Morbidity definitions (Continued)
degrees ported ness or
paraes-
thesia on op-
erated sides;
aesthetic ap-
pearance of
axillary scar
Edinburgh 1 Arm
swelling
measured by
wa-
ter displace-
ment, cir-
cumference
15 cm above
and be-
low the ole-
cranon pro-
cess
Shoul-
der mobility
assessed by
mea-
suring eleva-
tion through
flexion, ab-
duction,
medial and
lateral rota-
tion
Shoulder
mus-
cle power as-
sessed using
grad-
uated spring
to measure
flexion, ex-
tension, ab-
duction and
adduction of
the shoulder
joint
E’dburgh
Sample/
Clear
Arm welling
(arm cir-
cumference
15 cm above
and
10 cm below
olecranon)
Objective
assessment
via adduc-
tion with
internal
rotation;
abduction
with exter-
nal rotation,
difference
in height
reached
between
treated and
non-treated
arms by
stretching
above head,
measure-
ment of an
abduction
movement
without
shoulder
rotation
whilst lying
Power (cm/
kg) of pec-
toralis major
by repeated
lifting of a 3.
5 kg weight
as fast as pos-
sible over 45
seconds,
comparing
treated and
untreated
arm
Sample
from study
only, level B
evidence
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Table 2. Morbidity definitions (Continued)
on a flat,
hard surface
GIVOM
Sentinella
Lym-
pheodema
was assessed
by compar-
ing the cir-
cumference
of the oper-
ated vs the
non-oper-
ated arm at
15 cm above
the
epicondyle
Unclear
what differ-
ence in cir-
cumfer-
ence consti-
tuted lym-
phoedema
Assessed by
the surgeon
by eval-
uating active
and passive
flexion, ab-
duction,
internal and
external ro-
tation, and
classified on
a
scale 0 (nor-
mal mobil-
ity) to 3 (se-
vere mobil-
ity) restric-
tion
Winged
scapula
reported as
present/
absent
Axillary and
arm pain re-
ported by
patients on
a scale from
0 (absent) to
3 (continu-
ous/severe)
Numbness
assessed by
the surgeon
by compar-
ing skin sen-
sitivity
in operated
and non-op-
erated arms.
Rated 0 (ab-
sent) to 3
(severe)
Guy’s Reports
lym-
phoedema;
categorised
as none,
slight, mod-
erate and se-
vere
Reports arm
function as
good, fair or
poor
Reports ac-
tivity as
good, fair or
poor
Reports atti-
tude as
good, fair or
poor
Pts in no ax-
il-
lary surgery
+ RT arm re-
portedfibro-
sis of breast
and some-
times “mar-
bling” of the
overlying
skin. Both
occurred in
<5% of cases
Hammer-
smith
Impairted
function of
the shoulder
joint
and swollen
arm: no def-
initions
given, but it
is stated that
Impairted
function of
the shoulder
joint
and swollen
arm: no def-
initions
given, but it
is stated that
In evaluat-
ing morbid-
ity, attempts
made to ally
objective
measure-
ments with
patient’s
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Table 2. Morbidity definitions (Continued)
the method-
ology in-
cluded volu-
met-
ric measure-
ment of the
upper limb
and that an
attempt was
made to ally
objective
measure-
ments with
the patient’s
subjec-
tive expres-
sion of dis-
comfort or
disability
the method-
ology in-
cluded volu-
met-
ric measure-
ment of the
upper limb
and that an
attempt was
made to ally
objective
measure-
ments with
the patient’s
subjec-
tive expres-
sion of dis-
comfort or
disability
subjective
expression
of disability
or dis-
comfort.
Expectation
that after
RM, slight
increase in
volume of
ipsilateral
arm, or after
RT, some
discomfort
and stiffness
to shoulder,
but these do
not amount
tomorbidity
IBCSG-10-
93
≥ 5% in-
crease in
arm circum-
ference from
baseline
QOL: A
core ques-
tionnaire
plus a surgi-
cal module
specific to
this trial.
Four linear
analogue
scales on the
core ques-
tionnaire
were used:
well-being,
mood,
appetite and
perceived
adjustment/
coping.
After 1993,
6 additional
scales were
added:
tiredness,
hot flashes,
nausea/
vomiting,
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Table 2. Morbidity definitions (Continued)
perceived
social sup-
port, arm
restriction
and subjec-
tive health
estimation
Sur-
gicalmodule
measured
swelling,
numbness,
weakness,
pain, stiff-
ness, perfor-
mance
of daily ac-
tivities and
global mea-
sure of arm/
hand/
shoulder/
chest bother
IBCSG-23-
01
No def-
initions for
functional
outcomes
reported
Institut
Bergonie
No def-
initions for
functional
outcomes
reported
IPO-P An increase
in arm vol-
ume was de-
fined as an
increase > 2
cm, compar-
ing the cir-
cumfer-
ence of the
operated up-
per limb (at
3 points: the
wrist, the
Patients
were asked
to lift their
operated
arm (maxi-
mum pos-
sible abduc-
tion):
abduction≥
90° was con-
sidered ade-
quate;
abduction <
Patients
were asked:
Is your arm
painful in a
resting posi-
tion (yes/
no)?
Does the in-
side of your
arm feel
more numb
(yes/no)?
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Table 2. Morbidity definitions (Continued)
midpoint of
the forearm
and themid-
point of the
upper arm)
with its non-
operated
counterpart
90° was con-
sidered ab-
normal
Manchester
Milan Arm
swelling was
assessed by
comparing
the circum-
ference of
treated and
un-
treated arms
15 cm above
the lateral
epicondyle
Arm mobil-
ity
was judged
by ask-
ing the pa-
tient to rate
restriction in
movement
on a scale 0
to 100
Numb-
ness assessed
by compar-
ing skin sen-
sitiv-
ity on inside
and outside
of the upper
arm - classi-
fied as yes/
no
Aesthetic
ap-
pearance of
scar judged
by patient
(rated good
or bad)
Postopera-
tive pain was
evaluated as
contin-
uous (> 50%
of the day)
, sporadic or
absent
NSABP B-
04
Ipsilat-
eral and con-
tralateral
mea-
surement of
arm circum-
ference at 15
cm below
the
acromion
process and
15 cm below
the olecra-
non: An in-
crease in arm
circumfer-
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Table 2. Morbidity definitions (Continued)
ence≥ 2 cm
in ipsilateral
arm (below
or above the
elbow) indi-
cated arm
oedema
NSABP B-
32
Arm volume
measured
using vol-
ume of wa-
ter displaced
determined
by the dif-
ference be-
tween
treated and
un-
treated arms
(relative arm
volume
difference =
[ipsilateral-
contralat-
eral]/[con-
tralateral] ×
100%)
Arm mo-
bility in
degrees
was deter-
mined by
measuring
the straight
lateral ab-
duction of
both ipsi-
lateral and
contralateral
arms using
a standard
orthopaedic
goniometer
to deter-
mine the an-
gle between
lateral chest
wall and
humerus
(relative
shoulder
abduction
deficit =
[ipsilateral-
contralat-
eral]/[con-
tralateral] ×
100%)
Numb-
ness and tin-
gling were
assessed by
self-re-
port by ask-
ing patients
if they were
currently ex-
periencing
any numb-
ness or any
tingling any-
where in ip-
silateral and
contralateral
arms. OR of
SLN
compared
with ALND
Ad-
verse events:
no details re-
ported
Ostersund Arm volume
measured
using vol-
ume of wa-
ter
displaced. A
cutoff
of 10% in-
crease in vol-
Shoul-
der mobility
(flexion, ab-
duction and
rotation)
was deter-
mined with
the help of
a 360° scale
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Table 2. Morbidity definitions (Continued)
ume
was used as
the arbitrary
cut point
placed on a
wall with the
cen-
tre at shoul-
der height
SNAC Arm volume
was esti-
mated using
6
measures of
arm circum-
ference at 10
cm intervals
starting
10 cm from
the tip of the
index finger.
Upper limb
swelling was
expressed as
percent-
age change
in volume
from
baseline
Ab-
duction and
flexion mea-
sured using
goniometer
Arm mor-
bidity mea-
sured using
the 15-item
SSSS
scale devel-
oped for the
study, with
each
rated from 0
(no trouble
at all) to 10
(worst I can
imag-
ine) and av-
eraged to
obtain over-
all score
SE Scotland Increase in
circumfer-
ence of fore-
arm by at
least 3 cm
Failure to
abduct
the arm be-
yond a right
angle
Xu 2003 Postopera-
tive
swelling:
middle
grade (diam-
eter is 3-6
cm enlarge-
ment on the
involved up-
per arm or
forearm
compared
with the
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Table 2. Morbidity definitions (Continued)
contralateral
part)
Table 3. Morbidity data at each time point
Study Outcome Measurement Follow-upperiod 1 Follow-upperiod 2 Notes
ACOSOG Z0011 Wound infection Determined by
treating physician
SLND:
11/371; SLND +
ALND: 31/373
ACOSOG Z0011 Axillary seroma Determined by
treating physician
SLND:
21/371; SLND +
ALND: 53/373
ACOSOG Z0011 Brachial plexus in-
jury
Determined by
treating physician
At 6 months:
SLND: 3/415;
SLND + ALND: 5/
406
At 1
year: SLND: 0/415;
SLND + ALND: 1/
406
ACOSOG Z0011 Axillary paraesthesia Patient reported 30 days: SLND: 43/
371; SLND +
ALND: 174/373
6 months: SLND:
35/288; SLND +
ALND: 146/335
ACOSOG Z0011 Axillary paraesthesia Patient reported 12 months: SLND:
24/268; SLND +
ALND: 113/287
ACOSOG Z0011 Lymphoedema (ob-
jective)
Arm measurement 30 days: SLND: 17/
272; SLND +
ALND: 23/255
6 months: SLND:
21/271; SLND +
ALND: 29/270
ACOSOG Z0011 Lymphoedema (ob-
jective)
Arm measurement 12 months: SLND:
14/226; SLND +
ALND: 26/242
ACOSOG Z0011 Lymphoedema
(subjective)
Patient reported/
physician diagnosis
6 months: SLND:
19/339; SLND +
ALND: 27/327
12 months: SLND:
12/268; SLND +
ALND: 37/288
ACOSOG Z0011 Lymphoedema
(subjective)
Patient reported/
physician diagnosis
>
12 months: SLND:
14/253; SLND +
ALND: 52/272
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Table 3. Morbidity data at each time point (Continued)
Addenbrookes Mild oedema Follow-up was at
least 12 months in
most cases.
ALND= 7/91; Sim-
ple = 5/113
Addenbrookes Stiff shoulder ALND= 6/91; Sim-
ple = 8/113
Addenbrookes Skin graft Need for skin graft ALND= 4/91; Sim-
ple = 2/113
Addenbrookes Delayed healing Need to delay post-
operative RT
ALND = 18/91;
Simple = 7/113
Addenbrookes Gross oedema Arm measurement ALND= 0/91; Sim-
ple = 0/113
ALND = 12/45;
Simple = 6/53
Addenbrookes 2 Seroma ALND: 33/155;
SLNB: 20/143
Addenbrookes 2 Lymphoedema (ob-
jective)
Arm volume
changes
12 months: ALND:
mean (SE) = 56.
4 (10.9); SLNB:
mean (SE) = 18.
6 (13.8), difference
mean (SE) = 37.8
(17.6)
Mean
(1, 3, 6, 12 months)
: ALND: mean (SE)
= 53.1 (8.1); SLNB:
mean (SE) =17.7 (9.
2), difference mean
(SE) = 35.4 (12.2)
Max: ALND: mean
(SE) = 113.7 (9.7);
SLNB: mean (SE) =
78.4 (12), difference
mean (SE) = 35.3
(15.3)
Addenbrookes 2 Lymphoedema
(subjective)
Patient reported 1 month: OR = 0.
34 (95% CI 0.11 to
0.9); 3 months: OR
= 0.4 (95% CI 0.16
to 0.94); 6 months:
OR = 0.25 (95% CI
0.08 to 0.66)
12 months: OR = 0.
36 (95% CI 0.15 to
0.86); mean: OR =
0.3 (95%CI 0.18 to
0.68)
Odds ratios: SLNB/
ALND; i.e. lower
favours SLNB
Addenbrookes 2 Paraesthesia ALND: 130/155;
SLNB: 92/140
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Table 3. Morbidity data at each time point (Continued)
Addenbrookes 2 Numbness ALND: 115/155;
SLNB: 68/143
Addenbrookes 2 Loss of pinprick ALND: 118/155;
SLNB: 77/140
Addenbrookes 2 Loss of light touch ALND: 121/155;
SLNB: 81/140
Addenbrookes 2 QOL (immediate
postop)
Study authors note
QOL scores were
usually higher (bet-
ter) in the SLND
group and signifi-
cantly so in the im-
mediate postopera-
tive period (P < 0.
01). No significant
effect of node posi-
tive/negative
Addenbrookes 2 MAC scale (12
months)
Study authors
no significant differ-
ence in MAC scores
during 1 year fol-
low-up. No signifi-
cant effect of node
positive/negative
Addenbrookes 2 BSI - somatisation
(immediate postop)
SLND group scored
lower (better) than
ALND in the im-
mediate postopera-
tive period (P < 0.
001)
Addenbrookes 2 Quality of life GSI level 12 months: ALND:
mean (SE, N) = 49.
7 (1.1, 143); SLNB:
mean (SE, N) = 48.
4 (0.9, 134), differ-
ence mean (SE) = 1.
3 (1.4)
OR formorbidGSI:
study/control (95%
CI) 0.55 (0.08 to 2.
94)
Addenbrookes 2 Quality of life SF-36 (immediate
postoperative)
Physical combined:
ALND: mean (SD,
N) = 38.6 (8.2,
143); SLNB: mean
(SD, N) = 42.3 (10.
Vitality:
ALND: mean (SD,
N) = 48.2 (10.2,
143); SLNB: mean
(SD, N) = 51.8 (9.
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Table 3. Morbidity data at each time point (Continued)
4, 134), difference
mean (95% CI) = 3.
7 (1.2 to 6.1)
Physical function-
ing: ALND: mean
(SD, N) = 41.3 (9,
143); SLNB: mean
(SD, N) = 44.5 (8.
1, 134), difference
mean (95% CI) = 3.
2 (1.1 to5.4)
8, 134), difference
mean (95% CI) = 3.
7 (1.1 to 6.2)
Addenbrookes 2 Shoulder move-
ment (mean reduc-
tion)
Flexion, exten-
sion, abduction, in-
ternal rotation, ex-
ternal rotation
Flexion:
ALND: mean (SD,
N) = 13 (32.9, 141)
; SLNB: mean (SD,
N) = 6.7 (15.6, 134)
, difference mean
(95% CI) = 6.3 (0.1
to 12.6); Extension:
ALND: mean (SD,
N) = -1.5 (10.7,
139); SLNB: mean
(SD, N) = -2.2 (8.
1, 134), difference
mean (95% CI) =
0.7 (-1.5 to 3.3);
Abduction: ALND:
mean (SD, N) = 6.3
(11.5, 138); SLNB:
mean (SD, N) = 3.
1 (15.7, 132), dif-
ference mean (95%
CI) = 3.2 (-0.5 to 6.
3)
Internal rotation:
ALND: mean (SD,
N) = 1.7 (12.7, 139)
; SLNB: mean (SD,
N) = 0.3 (12, 134)
, difference mean
(95% CI) = 1.4 (-
1.5 to 4.4); External
rotation: ALND:
mean (SD, N) = 2.9
(12.3, 139); SLNB:
mean (SD, N) = 1.5
(11, 134), difference
mean (95% CI) = 1.
4 (-1.5 to 4.4)
ALMANAC Axillary drain usage ALND: 359/453;
SLNB: 75/449
ALMANAC Infection rate of sur-
gical wounds
ALND: 72/476;
SLNB: 52/478
ALMANAC Lymphoedema Patient-assessed;
moderate/severe
1month: ALND: 7/
419; SLNB: 1/428
3 months: ALND:
12/395; SLNB: 4/
417
6 months: ALND:
13/414; SLNB: 2/
432
12 months: ALND:
10/403 SLNB: 4/
412
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Table 3. Morbidity data at each time point (Continued)
ALMANAC Lymphoedema Mean (95%
CI) change in arm
vol compared with
pretreatment
1 month: ALND
= 1.022 (1.013-1.
032); SLNB=1.003
(0.997-1.01)
3 months: ALND
= 1.044 (1.035-1.
053); SLNB=1.019
(1.01-1.028)
6 months: ALND
= 1.058 (1.048-1.
069); SLNB=1.022
(1.011-1.032)
12 months: ALND
= 1.061 (1.048-1.
074); SLNB=1.028
(1.016-1.039)
ALMANAC Sensory loss Median area
of sensory loss (cm2;
range)
1 month: ALND =
40 (1-489); SLNB =
32 (2-254)
3 months: ALND =
47 (0-1139); SLNB
= 48 (0-327)
6 months: ALND
= 39 (0.4-2827);
SLNB = 32 (0-201)
12 months: ALND
= 35 (0.8-1013);
SLNB = 59 (0.2-
342)
Event rates for self-
assessed sensory loss
also
reported in Mansel
2006 for these fol-
low-up periods, but
not extracted
ALMANAC Intercostobrachial
nerve damage
Clinician
assessment; severe
1 month: ALND:
10/392; SLNB: 6/
409
3 months: ALND:
10/373; SLNB: 4/
397
6 months: ALND:
10/394; SLNB: 4/
410
12 months: ALND:
5/384 SLNB: 5/400
ALMANAC Shoulder function Mean change
in shoulder function
(degrees): flexion
1 month: ALND =
9.8; SLNB = 5.8
3 months: ALND =
3.7; SLNB = 2
6 months: ALND =
1.6; SLNB = 2
12 months: ALND
= 0.1; SLNB = 2.7
95% CI can also be
extracted
ALMANAC Shoulder function Mean
change in shoulder
function (degrees):
abduction
1 month: ALND =
12.9; SLNB = 6.5
3 months: ALND =
4.2; SLNB = 1.9
6 months: ALND =
2.3; SLNB = 1.5
12 months: ALND
= 1.9; SLNB = 2.5
95% CI can also be
extracted
ALMANAC Shoulder function Mean
change in shoulder
function (degrees):
external rotation
1 month: ALND =
1.2; SLNB = 0.7
3 months: ALND =
1.2; SLNB = 0.2
6 months: ALND =
1; SLNB = 0.6
12 months: ALND
= 0.7; SLNB = 0.6
95% CI can also be
extracted
ALMANAC Shoulder function Mean
change in shoulder
function (degrees):
internal rotation
1 month: ALND =
0.9; SLNB = 0.4
3 months: ALND =
0.7; SLNB = 1
6 months: ALND =
0.8; SLNB = 0.2
12 months: ALND
= 0.4; SLNB = 1.7
95% CI can also be
extracted
ALMANAC Quality of life Measures:
mean trial outcome
index; trial outcome
index reduced by ≥
5 points from base-
Means (95% CI)
and event rates can
be extracted for each
time point (base-
line, 1, 3, 6 and 12
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Table 3. Morbidity data at each time point (Continued)
line (n/N); mean
arm functioning
subscale score; sub-
stantial arm swelling
or tenderness (n/N)
; substantial numb-
ness on ipsilateral
side (n/N); mean
FACT-B+4 score
months)
ALMANAC State and trait anxi-
ety
Mean and 95%
CI can be extracted
for each time point
(baseline, 1, 3, 6 and
12 months)
Cardiff Morbidity Objective com-
plaints: restricted el-
evation 720 degrees
Not stated: full ax-
illary surgery, neg
nodes = 25% (×2
= 7.47, P < 0.01)
; no axilary surgery,
neg nodes = 0%;
full axillary surgery
+ radical RT, posi-
tive nodes = 67%;
no axillary surgery +
local RT = 37%
Sample
of 85 patients only
from Cardiff site
Cardiff Morbidity Objective
complaints: oedema
of arm, 72 cm
Not stated: full ax-
illary surgery, neg
nodes = 46% (×2
= 6.02, P < 0.03);
no axillary surgery,
neg nodes = 15%;
full axillary surgery
+ radical RT, posi-
tive nodes = 58%;
no axillary surgery +
local RT = 37%
Sample
of 85 patients only
from Cardiff site
Cardiff Morbidity Subjective com-
plaints: limited arm
movement
Not stated: full ax-
illary surgery, neg
nodes = 21%; no
axillary surgery, neg
nodes = 8%; full
axillary surgery +
radical RT, positive
nodes = 8%; no ax-
illary surgery + local
RT = 21%
Sample
of 85 patients only
from Cardiff site
217Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Morbidity data at each time point (Continued)
Cardiff Morbidity Subjective
complaints: swollen
arm
Not stated: full ax-
illary surgery, neg
nodes = 43%; no
axillary surgery, neg
nodes = 23%; full
axillary surgery +
radical RT, positive
nodes = 58%; no ax-
illary surgery + local
RT = 37%
Sample
of 85 patients only
from Cardiff site
Edinburgh 1 Morbidity Lateral shoulder ro-
tation
(mean (SE) differ-
ence (cm) from pre-
operative value (N))
6months: Sampling
+ RT: 1.91 (SE = 0.
56) (N = 64), sam-
pling - RT: 0.34 (SE
= 0.59) (N = 59);
ALND: 0.13 (SE =
0.39) (N = 132)
12 months: Sam-
pling +RT: 1.75 (SE
= 0.56) (N = 66),
Sampling - RT: 0.72
(SE = 0.62) (N =55)
; ALND: 0.77 (0.4)
(N = 128)
Figure 4, Chetty
2000 paper
Edinburgh 1 Morbidity Lateral shoulder ro-
tation
(mean (SE) differ-
ence (cm) from pre-
operative value (N))
24 months: Sam-
pling +RT: 1.57 (SE
= 0.6) (N = 60),
Sampling - RT: -0.
48 (SE = 0.65) (N
= 52); ALND: 0.38
(SE = 0.43) (N =
117)
36 months: Sam-
pling +RT: 2.19 (SE
= 0.59) (N = 59),
Sampling - RT: 0.43
(SE = 0.64) (N =50)
; ALND: 0.24 (SE =
0.43) (N = 110)
Figure 4, Chetty
2000 paper
Edinburgh 1 Morbidity Arm volume (mean
(SE) percentage
of preoperative arm
volume (N))
6months: Sampling
+ RT: 100.69 (SE
= 0.779) (N = 56),
Sampling - RT: 102.
04 (SE = 0.766) (N
= 58); ALND: 103.
57 (SE = 0.519) (N
= 126)
12 months: Sam-
pling + RT: 100.95
(SE = 0.81) (N =
59), Sampling - RT:
102.47 (SE = 0.85)
(N = 54); ALND:
103.74 (SE = 0.57)
(N = 119)
Figure 5, Chetty
2000 paper
Edinburgh 1 Morbidity Arm volume (mean
(SE) percentage
of preoperative arm
volume (N))
24 months: Sam-
pling + RT: 100.84
(SE = 1.03) (N =
54), Sampling - RT:
100.81 (SE = 1.06)
(N = 51); ALND:
104.37 (SE = 0.73)
(N = 108)
36 months: Sam-
pling + RT: 100.01
(SE = 1.03) (N =
52), Sampling - RT:
101.28 (SE = 1.07)
(N = 48); ALND:
104.07 (SE = 0.73)
(N = 103)
Figure 5, Chetty
2000 paper
E’dburgh
Sample/Clear
Morbidity Subjective arm Not stated; full ax-
illary surgery, pos-
itive node (Nil 8/
Morbidity data to
be included in dis-
cussion only; sam-
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12; intermittent 1/
12; persistent 3/12);
full axillary surgery,
-negative node (nil
22/28; intermittent
1/28; persistent 5/
28); Sample + RT,
positive node (nil
17/28; intermittent
2/28; persistent 9/
28); Sample, nega-
tive node (nil 23/
26; intermittent 1/
26; persistent 2/26)
ple chosen from al-
phabetical pt list of
patients free of local
or systemic disease
E’dburgh
Sample/Clear
Morbidity Subjective mobility Not stated; full axil-
lary surgery, positive
node (normal 12/
12; reduced 0/12);
full axillary surgery,
negative node (nor-
mal 22/28; reduced
6/28); Sample + RT,
negative node (nor-
mal 12/28; reduced
16/28); Sample,
negative node (nor-
mal 24/26; reduced
2/26)
See comments in
Aitken paper
E’dburgh
Sample/Clear
Morbidity Subjective interfer-
ence with daily ac-
tivities
Not stated; full ax-
illary surgery, posi-
tive node (nil 12/12;
occasional 0/12; se-
vere 0/12); full ax-
illary surgery, neg-
ative node (nil 24/
28; occasional 4/28;
severe 0/28); Sam-
ple + RT, positive
node (nil 16/28; oc-
casional 8/28; severe
4/28); Sample, neg-
ative node (nil 24/
26; occasional 4/26;
severe 0/26)
See comments in
Aitken paper
E’dburgh
Sample/Clear
Morbidity Objective as-
sessment - shoulder
See comments in
Aitken paper
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Table 3. Morbidity data at each time point (Continued)
joint mobility
WSSA Glasgow Psychological mor-
bidity
Use in discussion
only
GIVOM Sentinella Lymphoedema Assessed by physi-
cian, reported as
odds ratio (95%CI)
: SLNB/ALND
6 months: 0.37 (0.2
to 0.7)
12 months: 0.48 (0.
2 to 0.9)
18 months: 0.59 (0.
3 to 1.2)
24 months: 0.52 (0.
2 to 1.1)
GIVOM Sentinella Shoulder move-
ment restriction
Assessed by physi-
cian, reported as
odds ratio (95%CI)
: SLNB/ALND
6 months: 0.47 (0.3
to 0.8)
12 months: 0.73 (0.
4 to 1.4)
12months: raw data
extracted
from graph (SLNB
17/336, ALND 23/
341)
18 months: 0.62 (0.
3 to 1.3)
24 months: 0.44 (0.
2 to 1.0)
GIVOM Sentinella Axillary/arm pain Assessed by physi-
cian, reported as
odds ratio (95%CI)
: SLNB/ALND
6 months: 0.52 (0.3
to 0.8)
12 months: 0.76 (0.
5 to 1.3)
12months: raw data
extracted
from graph (SLNB
30/336, ALND 39/
341)
18 months: 0.84 (0.
5 to 1.5)
24 months: 0.90 (0.
5 to 1.6)
GIVOM Sentinella Numbness Assessed by physi-
cian, reported as
odds ratio (95%CI)
: SLNB/ALND
6 months: 0.64 (0.4
to 0.9)
12 months: 0.53 (0.
3 to 0.8)
12months: raw data
extracted
from graph (SLNB
41/336, ALND 71/
341)
18 months: 0.37 (0.
2 to 0.6)
24 months: 0.54 (0.
3 to 0.9)
GIVOM Sentinella Winged scapula Assessed by physi-
cian
Study authors re-
port rate too low to
analyse
GIVOM Sentinella Health-related qual-
ity of life: SF-36 -
physical component
Assessed by patients
using validated
questionnaires
No significant dif-
ferences found be-
tween group means
of SF-36
physical component
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(Del Bianco, 2008)
GIVOM Sentinella Health-related qual-
ity of life: SF-36 -
mental component
Assessed by patients
using validated
questionnaires
No significant dif-
ferences found be-
tween group means
of SF-36 men-
tal component (Del
Bianco, 2008)
GIVOM Sentinella Health-related qual-
ity of life: SF-36
HRQOL domains
Assessed by patients
using validated
questionnaires
No significant dif-
ferences found be-
tween groups on all
HRQOL domains
of SF-36 (Zavagno,
2008)
GIVOM Sentinella Health-related qual-
ity of life: psycho-
logical general well-
being index
Assessed by patients
using validated
questionnaires
6,
12 months: signifi-
cantly better PGWB
general and anxi-
ety domain scores in
SLNBgroup than in
ALND group (Del
Bianco, 2008)
24 months: no sig-
nif-
icant differences be-
tween PGWB gen-
eral and anxiety do-
main scores of both
groups.(Del Bianco,
2008)
Guy’s Morbidity Arm function 3 months: ALND:
Good: 44/90, Fair:
41/90, Poor: 5/90;
No ALND: Good:
59/77, Fair: 18/77,
Poor: 0/77
15 months: ALND:
Good: 83/100, Fair:
14/100, Poor: 3/
100; No ALND:
Good: 70/88, Fair:
17/88, Poor: 1/88
Sample only
Guy’s Morbidity Lymphoedema 3 months: ALND:
None:
18/93, Slight: 66/
93, Moderate: 6/
93, Severe: 3/93;No
ALND: None: 36/
81, Slight: 43/81,
Moderate: 0/81, Se-
vere: 2/81
15 months: ALND:
None:
27/104, Slight: 71/
104 Moderate: 6/
104, Severe: 0/104;
No ALND: None:
39/91, Slight: 52/
91, Moderate: 0/91,
Severe: 0/91
Sample only
Guy’s Morbidity Activity 3 months: ALND:
Good: 45/92, Fair:
46/92, Poor: 1/92;
No ALND: Good:
62/80, Fair: 16/80,
Poor: 2/80
15 months: ALND:
Good: 85/101, Fair:
14/101, Poor: 2/
101; No ALND:
Good: 78/92, Fair:
13/92, Poor: 1/92
Sample only
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Guy’s Morbidity Attitude 3 months: ALND:
Good: 81/92, Fair:
9/92, Poor: 2/92;
No ALND: Good:
71/80, Fair: 7/80,
Poor: 2/80
15 months: ALND:
Good: 91/101, Fair:
8/101, Poor: 2/101;
No ALND: Good:
87/92, Fair: 5/92,
Poor: 0/92
Sample only
Hammersmith Postoperative
deaths
Radical: 0/95; Sim-
ple: 0/100
Hammersmith Morbidity Shoulder function At 4-year minimum
follow-up in sur-
vivors: Radical: 6/
95; Simple =18/100
Consequential mor-
bid-
ity, at time of pub-
lication Methodol-
ogy not reported, all
patients included
Hammersmith Morbidity Arm swelling (in-
cluding volumetric
measurement of up-
per limb)
At 4-year minimum
follow-up in sur-
vivors: Radical: 7/
95; Simple = 3/100
Consequential mor-
bid-
ity, at time of pub-
lication Methodol-
ogy not reported, all
patients included
IBCSG-10-93 Lymphoedema Physician reported Not signif-
icantly different be-
tween treatments
IBCSG-10-93 Arm circumference Physician reported Not signif-
icantly different be-
tween treatments
IBCSG-10-93 Performance of
daily activities
Physician reported Not signif-
icantly different be-
tween treatments
IBCSG-10-93 Arm pain Physician reported Baseline: ALND 5/
175, surgery 8/194;
1st postoperative:
ALND 38/164,
surgery 12/168; 3
months: ALND 16/
161, surgery 9/171;
6 months: ALND
17/174, surgery 11/
177
9 months: ALND
21/160, surgery 8/
164;
12 months: ALND
13/189, surgery 8/
190;
18 months: ALND
14/173, surgery 7/
183;
24 months: ALND
12/165, surgery 8/
164
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IBCSG-10-93 Restricted arm
movement
Physician reported Baseline: ALND 9/
174, surgery 6/194;
1st postop-
erative: ALND 64/
163, surgery
25/168; 3 months:
ALND 23/161,
surgery 10/170; 6
months: ALND 21/
176, surgery 9/176
9 months: ALND
21/160, surgery 7/
163;
12 months: ALND
19/188, surgery 6/
187;
18 months: ALND
10/171, surgery 7/
182;
24 months: ALND
12/165, surgery 7/
164
IBCSG-10-93 QOL - bothered
scores
Patient reported No significant dif-
ferences at any time
point (baseline, 1st
postoperative, 3, 6,
9, 12, 18 and 24
months)
IBCSG-10-93 QOL - arm move-
ment scores
Patient reported At 1st postoperative
surgery alone, re-
ported less restric-
tion in use of their
arm than ALND
(P < .0001). Other-
wise, no significant
differences
IBCSG-10-93 QOL - numbness
scores
Patient reported At 1st postopera-
tive surgery alone,
reported less severe
postsurgery numb-
ness than ALND
(P < .0001). Other-
wise, no significant
differences
IBCSG-10-93 QOL - coping
scores
Patient reported No significant dif-
ferences at any time
point (baseline, 1st
postoperative, 3, 6,
9, 12, 18 and 24
months)
IBCSG-23-01 Postoperative infec-
tion
Physician assessed Surgery alone: 0/
467
ALND: 1/464
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IBCSG-23-01 Sensory neuropathy Physician assessed Any:
Surgery alone: 55/
453
ALND: 82/447
Grade 3-4:
Surgery alone: 0/
453
ALND: 1/447
IBCSG-23-01 Lymphoedema Physician assessed Defined as long
term:
Any:
Surgery alone: 15/
453
ALND: 59/447
Grade 3-4:
Surgery alone: 0/
453
ALND: 3/447
IBCSG-23-01 Motor neuropathy Physician assessed Any:
Surgery alone: 13/
453
ALND: 37/447
Grade 3-4:
Surgery alone: 1/
453
ALND: 3/447
Institut Bergonie Arm fatigue Unclear Moderate/severe: no
ALND: N = 4/258;
ALND: N = 24/273
Institut Bergonie Shoulder mobility Unclear Restricted some-
what or severely: no
ALND: N = 5/257;
ALND: N = 21/271
Institut Bergonie Parasthesia Unclear Moderate/severe: no
ALND: N = 6/258;
ALND: N = 41/274
Institut Bergonie Lymphoedema Unclear Minor/major differ-
ence: no ALND: N
= 3/258; ALND: N
= 29/275
Institut Bergonie Other functional
impairments
Unclear Minor/ma-
jor: no ALND: N =
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12/263; ALND: N
= 16/276
Institut Bergonie Number of patients
with functional im-
pairments
Unclear Mi-
nor: no ALND: N =
23/265; ALND: N
= 78/278
IPO-P Upper limb circum-
ference > 2 cm
Measured as per def-
inition
6 months: Obs: 6/
57; ALND: 10/49
12 months: Obs: 8/
57; ALND: 15/49
24 months: Obs: 8/
57; ALND: 14/49
48 months: Obs: 4/
57; ALND: 19/49
IPO-P Pain at rest Patient reported 6 months: Obs: 9/
57; ALND: 9/49
12 months: Obs:
11/57; ALND: 14/
49
24 months: Obs: 9/
57; ALND: 10/49
48 months: Obs: 3/
57; ALND: 7/49
IPO-P Parasthesias Patient reported? 6 months: Obs: 10/
57; ALND: 28/49
12 months: Obs: 6/
57; ALND: 29/49
24 months: Obs: 5/
57; ALND: 34/49
48 months: Obs: 6/
57; ALND: 30/49
IPO-P Shoulder dysfunc-
tion
Measured as per def-
inition
6 months: Obs: 5/
57; ALND: 5/49
12 months: Obs: 4/
57; ALND: 8/49
24 months: Obs: 0/
57; ALND: 6/49
48 months: Obs: 2/
57; ALND: 11/49
Milan Morbidity Axillary pain (spo-
radic/continuous)
6 months: ALND:
91/100; SNLB =
16/100
24 months: ALND:
39/100; SNLB = 8/
100
Milan Morbidity Numbness/
Parasthesia on oper-
ated side
6 months: ALND:
85/100; SNLB = 2/
100
24 months: ALND:
68/100; SNLB = 1/
100
Milan Morbidity Armmobility, 80%-
100%
6 months: ALND:
73/100; SNLB =
100/100
24 months: ALND:
79/100; SNLB =
100/100
Milan Morbidity Armmobility, 60%-
79%
6 months: ALND:
22/100; SNLB = 0/
100
24 months: ALND:
18/100; SNLB = 0/
100
Milan Morbidity Armmobility, 40%-
59%
6 months: ALND:
5/100; SNLB = 0/
100
24 months: ALND:
2/100; SNLB = 0/
100
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Milan Morbidity Armmobility, 20%-
39%
6 months: ALND:
0/100; SNLB = 0/
100
24 months: ALND:
1/100; SNLB = 0/
100
Milan Morbidity Arm mobility, <
20%
6 months: ALND:
0/100; SNLB = 0/
100
24 months: ALND:
0/100; SNLB = 0/
100
Milan Morbidity Aesthetic appear-
ance of axillary scar:
bad
6 months: ALND:
9/100; SNLB = 2/
100
24 months: ALND:
15/100; SNLB = 0/
100
Milan Morbidity Arm swelling < 1
cm difference in cir-
cumference
6 months: ALND:
44/100; SNLB =
11/100
24 months: ALND:
38/100; SNLB = 6/
100
Milan Morbidity Arm swelling 1-2
cm difference in cir-
cumference
6 months: ALND:
17/100; SNLB = 0/
100
24 months: ALND:
25/100; SNLB = 1/
100
Milan Morbidity Arm swelling >2 cm
difference in cir-
cumference
6 months: ALND:
8/100; SNLB = 0/
100
24 months: ALND:
12/100; SNLB = 0/
100
Milan Morbidity Arm swelling, any 6 months: ALND:
69/100; SNLB =
11/100
24 months: ALND:
75/100; SNLB = 7/
100
NSABP B-04 Arm oedema Arm swelling ≥ 2
cm difference in cir-
cumference
No. of patients with
data:
ALND:N= 577; no
ALND + RT: N =
568 no ALND: N
= 312 both node +
and node- patients.
Final measurement
was 2 to 5 years after
surgery
Arm
oedema recorded at
least once: ALND:
58.1%; no ALND
+ RT: 38.2%; no
ALND: 39.1% (P <
0.001)
Oedema al-
ways: ALND: 3.6%;
no ALND + RT: 0.
9%; no ALND: 1%
Oedema once, then
resolution: ALND:
15.9%; no ALND
+ RT: 15.3%; no
ALND: 16.7%
Intermit-
tent, final measure-
ment no oedema:
ALND: 11.4%; no
ALND + RT: 8.1%;
no ALND: 7.1%
Total with
no oedema on final
measurement (after
at least 1 measure-
ment of oedema):
ALND: 27.3%; no
ALND + RT: 23.
4%; no ALND: 23.
8
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Nomeasurement af-
ter first oedema:
ALND: 9.2%; no
ALND + RT: 5.8%;
no ALND: 3.2%
Oedema always af-
ter first oedema:
ALND: 6.1%; no
ALND + RT: 3.2%;
no ALND: 2.6%
Inter-
mittent, final mea-
surement oedema:
ALND: 11.8%; no
ALND + RT: 4.9%;
no ALND: 8.6%;
To-
tal with oedema on
final measurement:
ALND: 30.7%; no
ALND + RT: 14.
8%; no ALND: 15.
4% (P < 0.001)
Arm oedema ≥ 4
cm difference in cir-
cum-
ference recorded at
least once: ALND:
21.5%; no ALND
+ RT: 11.4%; no
ALND: 13.1%
NSABP B-32 Ad-
verse events (grade 3
or greater surgery re-
lated)
No details reported ALND: 14/2788
SLN: 12/2800
Must include most
of SLN positive and
negative patients
Peri-surgery
NSABP B-32 Arm mobility/
shoulder abduction
deficit (objective)
Physician assessed 6 months:
< 5%:
ALND: 1299/1667;
SLN: 1468/1744
5%-10%:
ALND: 218/1667;
SLN: 176/1744
≥ 10%:
ALND: 150/1667;
SLN: 99/1744
NSABP B-32 Arm volume differ-
ence (objective)
Physician assessed 6 months:
< 5%:
ALND: 1187/1677;
SLN: 1363/1759
5%-10%:
ALND: 277/1677;
SLN: 236/1759
≥ 10%:
12 months:
< 5%:
ALND: 1170/1639;
SLN: 1345/1705
5%-10%:
ALND: 252/1639;
SLN: 215/1705
≥ 10%:
These data are also
available for 18 and
30 months
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ALND: 211/1677;
SLN: 158/1759
ALND: 216/1639;
SLN: 147/1705
NSABP B-32 Arm volume differ-
ence (objective)
Physician assessed 24 months:
< 5%:
ALND: 1062/1517;
SLN: 1184/1504
5%-10%:
ALND: 243/1517;
SLN: 197/1504
≥ 10%:
ALND: 212/1517;
SLN: 123/1504
36 months:
< 5%: ALND: 990/
1421; SLN: 1156/
1459
5%-10%:
ALND: 227/1421;
SLN: 194/1459
≥ 10%:
ALND: 203/1421;
SLN: 109/1459
These data are also
available for 18 and
30 months
NSABP B-32 Tingling
(subjective)
Self-reported 6 months: ALND
(N = 388/1693),
SLN (N = 184/
1766)
12 months: ALND
(N = 305/1640),
SLN (N = 158/
1713)
18 months: ALND
(N = 272/1566),
SLN (N = 138/
1638)
24 months: ALND
(N = 236/1521),
SLN (N = 137/
1588)
30 months: ALND
(N = 219/1448),
SLN (N = 116/
1502)
36 months: ALND
(N = 193/1431),
SLN (N = 110/
1463)
NSABP B-32 Numbness (subjec-
tive)
Self-reported 6 months: ALND
(N = 821/1693),
SLN (N = 257/
1769)
12 months: ALND
(N = 679/1641),
SLN (N = 216/
1713)
18 months: ALND
(N = 592/1567),
SLN (N = 174/
1638)
24 months: ALND
(N = 554/1523),
SLN (N = 157/
1587)
30 months: ALND
(N = 473/1450),
SLN (N = 137/
1504)
36 months: ALND
(N = 445/1430),
SLN (N = 119/
1463)
NSABP B-32 Shoulder abduction
deficit ≥ 5% (in
those with < 5% at
baseline)
Physician assessed 6 months: ALND
(N = 275/1449),
SLN (N = 201/
1519)
NSABP B-32 Shoulder abduction
deficit ≥ 5% (in
those with < 5% at
baseline)
Physician assessed 36 months: ALND
(N = 314/1136),
SLN (N = 192/
1151)
228Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Morbidity data at each time point (Continued)
NSABP B-32 Numbness (in those
with none at base-
line)
Self-reported 36 months: ALND
(N = 407/1336),
SLN (N = 103/
1371)
NSABP B-32 Tingling (in those
with none at base-
line)
Self-reported 36 months: ALND
(N = 175/1329),
SLN (N = 90/1343)
Ostersund Seroma Patients with percu-
taneous
aspiration in outpa-
tient department
ALND: 17/50; sam-
pling: 10/50
Adverse events re-
ported only for the
1987-89 sample; i.e.
for N = 100/200
Ostersund Postopera-
tive discharge (mL),
median (range)
ALND: 250 (25-
1610); sampling:
130 (0-1785)
Adverse events re-
ported only for the
1987-89 sample; i.e.
for N = 100/200
Ostersund Duration of postop
drainage (days) (me-
dian, range)
ALND: 4 (1-11);
sampling: 2.1 (1 -
11)
Adverse events re-
ported only for the
1987-89 sample; i.e.
for N = 100/200
Ostersund Arm volume
increase
≥ 10% ALND: 14/47; sam-
pling: 0/48
Adverse events re-
ported only for the
1987-89 sample; i.e.
for ca N = 100/200
Ostersund Subjective sensation
of swelling
in women without
objective increase in
arm volume
Any ALND: 12/33; sam-
pling: 9/48
Adverse events re-
ported only for the
1987-89 sample; i.e.
for ca N = 100/200
Ostersund Shoul-
der mobility (mean
decrease compared
with baseline)
7.5° decrease for
whole sample of 95
patients
Adverse events re-
ported only for the
1987-89 sample; i.e.
for ca N = 100/200
Ostersund Axillary paraesthesia
(impairment of sen-
sibility in the axilla)
ALND: 17/48; sam-
pling: 19/48
Adverse events re-
ported only for the
1987-89 sample; i.e.
for ca N = 100/200
Ostersund Inner up-
per arm paraesthesia
(impairment of sen-
sibility in the inner
ALND: 24/48; sam-
pling: 4/48
Adverse events re-
ported only for the
1987-89 sample; i.e.
for ca N = 100/200
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upper arm)
SE Scotland Delayed healing ALND: 27/100;
Simple + RT: 8/100
SE Scotland Haematoma ALND: 24/100;
Simple + RT: 6/100
SE Scotland Infection ALND: 9/100; Sim-
ple + RT: 6/100
SE Scotland DVT ALND: 4/100; Sim-
ple + RT: 1/100
SE Scotland Pulmonary
embolism
ALND: 1/100; Sim-
ple + RT: 1/100
SE Scotland Chest infection ALND: 6/100; Sim-
ple + RT: 3/100
SE Scotland Severe skin reaction ALND: 0/100; Sim-
ple + RT: 5/100
SE Scotland Nausea and vomit-
ing
ALND: 0/100; Sim-
ple + RT: 2/100
SE Scotland Tracheitis ALND: 0/100; Sim-
ple + RT: 2/100
SE Scotland Skin grafts ALND: 10/100;
Simple + RT: 0/100
SE Scotland Arm oedema ALND: 10/100;
Simple + RT: 5/100
SE Scotland Limitation of shoul-
der movement
ALND: 4/100; Sim-
ple + RT: 14/100
SNAC Haematoma Any ALND: 30/539;
SLNB: 38/544
SNAC Seroma Any ALND: 195/539;
SLNB: 93/544
SNAC Infection Any ALND: 73/539;
SLNB: 48/544
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Table 3. Morbidity data at each time point (Continued)
SNAC Arm morbidity Mean changes in
arm morbidity (pa-
tient reported, over-
all summary aver-
age score of 15
items; unclear if it
is SEM or SD re-
ported) from base-
line
Node+ and node-
patients: average of
measures taken at 6
and 12 months:
ALND: 7 (N = 457)
; SLNB: 4.4 (N =
456)
1 month: ALND: 2.
2 (0.2); SLNB: 1.4
(0.15)
6 months: ALND:
1.1 (0.2); SLNB: 0.
8 (0.15)
12 months: ALND:
1.05 (0.2); SLNB:
0.8 (0.15)
24 months: ALND:
1.05 (0.2); SLNB:
0.75 (0.15)
36 months: ALND:
1.05 (0.2); SLNB:
0.7 (0.15)
SNAC Arm symptoms Mean changes in
arm symptoms (pa-
tient reported, aver-
age of 7 items; un-
clear if it is SEM or
SD reported) from
baseline
Node+ and node-
patients: average of
measures taken at 6
and 12 months:
ALND: 9.7 (N =
457); SLNB: 5.5 (N
= 456)
1 month: ALND: 2.
1 (0.2); SLNB: 1.2
(0.1)
6 months: ALND:
1.3 (0.15); SLNB:
0.8 (0.1)
12 months: ALND:
1.25 (0.15); SLNB:
0.7 (0.1)
24 months: ALND:
1.25 (0.15); SLNB:
0.7 (0.1)
36 months: ALND:
1.2 (0.2); SLNB: 0.
65 (0.15)
SNAC Arm swelling Mean changes in
arm
swelling (patient re-
ported, 1 item; un-
clear if it is SEM or
SD reported) from
baseline
Node+ and node-
patients: average of
measures taken at 6
and 12 months:
ALND: 7.3 (N =
457); SLNB: 3.4 (N
= 456)
1 month: ALND: 1.
25 (0.2); SLNB: 0.
75 (0.15)
6 months: ALND:
0.9 (0.15); SLNB:
0.55 (0.1)
12 months: ALND:
24 months: ALND:
1 (0.2); SLNB: 0.55
(0.15)
36 months: ALND:
1 (0.2); SLNB: 0.55
(0.15)
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Table 3. Morbidity data at each time point (Continued)
0.95 (0.15); SLNB:
0.45 (0.1)
SNAC Arm dysfunctions Mean arm dysfunc-
tions change (pa-
tient reported, aver-
age of 3 items; un-
clear if it is SEM or
SD reported) from
baseline
Node+ and node-
patients: average of
measures taken at 6
and 12 months:
ALND: 5.5 (N =
457); SLNB: 3.6 (N
= 456)
1 month: ALND: 1.
9 (0.15); SLNB: 1.
35 (0.15)
6 months: ALND:
0.8 (0.1); SLNB: 0.
65 (0.1)
12 months: ALND:
0.75 (0.1); SLNB:
0.6 (0.1)
24 months: ALND:
0.7 (0.1); SLNB: 0.
55 (0.1)
36 months: ALND:
0.8 (0.1); SLNB: 0.
5 (0.1)
SNAC Arm disabilities Mean arm
disabilities (patient-
reported change, av-
erage of 4 items; un-
clear if it is SEM or
SD reported) from
baseline
Node+ and node-
patients: average of
measures taken at 6
and 12 months:
ALND: 3.4 (N =
457); SLNB: 2.9 (N
= 456)
1 month: ALND: 2.
2 (0.2); SLNB: 1.4
(0.15)
6 months: ALND:
0.75 (0.1); SLNB:
0.55 (0.1)
12 months: ALND:
0.65 (0.1); SLNB:
0.45 (0.1)
24 months: ALND:
0.6 (0.1); SLNB: 0.
5 (0.1)
36 months: ALND:
0.7 (0.1); SLNB: 0.
45 (0.1)
SNAC Arm volume Increase in arm vol-
ume
(percentage change
from clinician rat-
ings from baseline;
unclear if it is SEM
or SD reported)
Average of measures
taken at 6 and 12
months:
ALND: 4.2% (N =
509); SLNB: 2.8%
(N = 519)
All patients:
1 month: ALND: 0.
8% (0.4); SLNB: 0.
9% (0.4), P = 0.67
6 months: ALND:
3.5% (0.8); SLNB:
All patients:
24 months: ALND:
5.8% (1); SLNB: 3.
9% (0.7), P = 0.006
36 months: ALND:
5.8% (1); SLNB: 4.
0% (1), P = 0.02
Node-negative pa-
tients:
24 months: ALND:
5.8% (1); SLNB:
3% (0.7), P = 0.001
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Table 3. Morbidity data at each time point (Continued)
2.4% (0.7), P = 0.02
12 months: ALND:
4.6% (0.8); SLNB:
3% (0.8), P = 0.001
Node-negative pa-
tients:
1 month: ALND: 0.
8% (0.4); SLNB: 0.
3% (0.4), P = 0.16
6 months: ALND:
3.5% (0.8); SLNB:
1.9% (0.5), P = 0.
004
12 months: ALND:
4.6% (0.8); SLNB:
2.2% (0.7), P = 0.
001
36 months: ALND:
5.8% (1); SLNB: 3.
1% (1), P= 0.004
SNAC Arm volume Number with an in-
crease in arm vol-
ume ≥ 15% (per-
centage change
from clinician rat-
ings from baseline)
All patients:
1 month: ALND: 5/
544; SLNB: 3/544
6 months: ALND:
29/544; SLNB:21/
544
12 months: ALND:
47/544; SLNB: 29/
544 (P = 0.02)
Node-negative pa-
tients only:
1 month: ALND: 4/
363; SLNB: 1/356
6 months: ALND:
16/363; SLNB: 9/
356
12 months: ALND:
28/363; SLNB: 13/
356 (P = 0.02)
All patients:
24 months: ALND:
81/544; SLNB: /
544 (P = 0.001)
36 months: ALND:
82/544; SLNB: /
544 (P = 0.01)
Node-negative pa-
tients only:
24 months: ALND:
47/363; SLNB: 25/
356 (P = 0.01)
36 months: ALND:
49/363; SLNB: 25/
356 (P = 0.006)
SNAC Lateral abduction Lateral
abduction (change
from clinician rat-
ings from baseline;
degrees; unclear if it
is SEM or SD re-
ported - have as-
sumed it is SEM for
calculations)
Average of measures
taken at 6 and 12
months (percentage
change from base-
line:
ALND: 4.4% (N =
509); SLNB: 2.5%
(N = 519)
Node+ and node-
patients (read off
graph):
Node+ and node-
patients (read off
graph):
24 months: ALND:
151 (1); SLNB: 152
(1)
36 months: ALND:
150 (1); SLNB: 151
(1)
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Table 3. Morbidity data at each time point (Continued)
Baseline: ALND:
158 (1); SLNB: 157
(1)
1 month: ALND:
131 (2); SLNB: 144
(2)
6 months: ALND:
150 (1); SLNB: 151
(1)
12 months: ALND:
150 (1); SLNB: 151
(1)
SNAC Forward flexion Forward flexion (de-
grees; unclear if it
is SEM or SD re-
ported - have as-
sumed it is SEM for
calculations)
Node+ and node-
patients (read off
graph):
Baseline: ALND:
157 (1); SLNB: 158
(1)
1 month: ALND:
137 (2); SLNB: 148
(1.5)
6 months: ALND:
150 (1); SLNB: 152
(1)
12 months: ALND:
151 (1); SLNB: 151
(1)
Node+ and node-
patients (read off
graph):
24 months: ALND:
152 (1); SLNB: 152
(1)
36 months: ALND:
152 (1); SLNB: 151
(1)
Xu 2003 Postoperative
swelling (oedema)
Measurement of
arm diameter
Level I clearance: 3/
93
ALND: 7/88
Xu 2003 Involved upper limb
disorder
Unclear Level I clearance: 0/
93
ALND: 0/88
Xu 2003 Cerebrovascular ac-
cident
Unclear Level I clearance: 0/
93
ALND: 2/88
Xu 2003 Cardiovascular
events
Unclear Level I clearance: 2/
93
ALND: 1/88
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Breast Neoplasms] explode all trees
#2 breast near cancer*
#3 breast near neoplasm*
#4 breast near carcinoma*
#5 breast near tumour*
#6 breast near tumor*
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Sentinel Lymph Node Biopsy] explode all trees
#9 sentinel lymph node biopsy or SLNB or SNB or SLN or (sentinel near node)
#10 MeSH descriptor: [Axilla] explode all trees
#11 axilla* near (surg* or sampl* or stag*)
#12 MeSH descriptor: [Neoplasm Staging] explode all trees
#13 MeSH descriptor: [Lymph Node Excision] explode all trees
#14 lymphadenectomy
#15 (block or lymph node or axillary) near dissection
#16 (block or lymph node or axillary) near clearance
#17 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #7 and #17
Appendix 2. MEDLINE search strategy
MEDLINE via OVIDSp
1 exp Breast Neoplasms/
2 exp “Neoplasms, Ductal, Lobular, and Medullary”/
3 exp Fibrocystic Breast Disease/
4 or/1-3
5 exp Breast/
6 breast.tw.
7 5 or 6
8 (breast adj milk).ti,ab,sh.
9 (breast adj tender$).ti,ab,sh.
10 8 or 9
11 7 not 10
12 exp Neoplasms/
13 11 and 12
14 exp Lymphedema/
15 14 and 11
16 (breast adj25 neoplasm$).ti,ab,sh.
17 (breast adj25 cancer$).ti,ab,sh.
18 (breast adj25 tumour$).ti,ab,sh.
19 (breast adj25 tumor$).ti,ab,sh.
20 (breast adj25 carcinoma$).ti,ab,sh.
21 (breast adj25 adenocarcinoma$).ti,ab,sh.
22 (breast adj25 sarcoma$).ti,ab,sh.
23 (breast adj50 dcis).ti,ab,sh.
24 (breast adj25 ductal).ti,ab,sh.
25 (breast adj25 infiltrating).ti,ab,sh.
26 (breast adj25 intraductal).ti,ab,sh.
27 (breast adj25 lobular).ti,ab,sh.
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28 (breast adj25 medullary).ti,ab,sh.
29 or/16-28
30 4 or 13 or 15 or 29
31 exp Mastectomy/
32 30 or 31
33 (mammary adj25 neoplasm$).ti,ab,sh.
34 (mammary adj25 cancer$).ti,ab,sh.
35 (mammary adj25 tumour$).ti,ab,sh.
36 (mammary adj25 tumor$).ti,ab,sh.
37 (mammary adj25 carcinoma$).ti,ab,sh.
38 (mammary adj25 adenocarcinoma$).ti,ab,sh.
39 (mammary adj25 sarcoma$).ti,ab,sh.
40 (mammary adj50 dcis).ti,ab,sh.
41 (mammary adj25 ductal).ti,ab,sh.
42 (mammary adj25 infiltrating).ti,ab,sh.
43 (mammary adj25 intraductal).ti,ab,sh.
44 (mammary adj25 lobular).ti,ab,sh.
45 (mammary adj25 medullary).ti,ab,sh.
46 or/33-45
47 32 or 46
48 exp Breast Self-Examination/
49 (breast adj25 self$).ti,ab,sh.
50 (breast adj25 screen$).ti,ab,sh.
51 exp Mammography/
52 or/47-51
53 mammograph$.tw.
54 53 and 11
55 52 or 54
56 randomized controlled trial.pt.
57 controlled clinical trial.pt.
58 randomized controlled trials.sh.
59 random allocation.sh.
60 double-blind method.sh.
61 single-blind method.sh.
62 or/56-61
63 clinical trial.pt.
64 exp Clinical Trials/
65 (clin$ adj25 trial$).ti,ab.
66 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
67 placebos.sh.
68 placebo$.ti,ab.
69 random$.ti,ab.
70 research design.sh.
71 or/63-70
72 62 or 71
73 55 and 72
74 (animals not humans).sh.
75 73 not 74
76 exp Sentinel Lymph Node Biopsy/
77 (sentinel adj2 node).mp.
78 (SN or SNB or SLN or SLNB).mp.
79 exp Axilla/
80 exp Neoplasm Staging/
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81 exp Lymph Node Excision/
82 lymphadenectomy.mp.
83 (axill$ adj3 (surg$ or sampl$ or stag$)).mp.
84 ((block or lymph node or axillary) adj dissection).mp.
85 ((block or lymph node or axillary) adj clearance).mp.
86 or/76-85
87 75 and 86
Appendix 3. WHO ICTRP search strategy
Basic search
1. Axillary staging for operable primary breast cancer
2. Breast cancer AND (axillary sampling OR axillary staging OR axillary surgery OR sentinel node biopsy OR sentinel lymph node
biopsy)
Advanced search
1. Title: Axillary staging for operable primary breast cancer
Recruitment status: ALL
2. Condition: Breast cancer
Intervention: axillary sampling OR axillary staging OR axillary surgery OR sentinel node biopsy OR sentinel lymph node biopsy
Recruitment status: ALL
Appendix 4. ClinicalTrials.gov search strategy
Basic search
1. Axillary staging for operable primary breast cancer
2. Breast cancer AND (axillary sampling OR axillary staging OR axillary surgery OR sentinel node biopsy OR sentinel lymph node
biopsy)
Advanced search
1. Search terms: Axillary staging for operable primary breast cancer
Recruitment: all studies
Study results: all studies
Study type: all studies
Gender: all studies
2. Conditions: breast cancer
Interventions: axillary sampling OR axillary staging OR axillary surgery OR sentinel node biopsy OR sentinel lymph node biopsy
Recruitment: all studies
Study results: all studies
Study type: all studies
Gender: all studies
H I S T O R Y
Protocol first published: Issue 2, 2004
Review first published: Issue 1, 2017
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Date Event Description
24 February 2009 Amended Changed from protocol to full review
15 October 2008 Amended Converted to new review format
C O N T R I B U T I O N S O F A U T H O R S
NB, MSH and MA screened literature searches and extracted and analysed data.
MWR interpreted results and prepared the discussion and implications for practice.
EH designed and carried out literature searches.
MWR, LW and DH conceived of the protocol.
LW, DH, EW and CB drafted the protocol.
MWR and Professor RE Coleman commented on the content of the protocol.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• North Trent Cancer Research Network, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• We searched trial registries to comply with new Cochrane methodological standards
• We analysed breast cancer recurrence separately for local recurrence, locoregional recurrence and distant metastasis
• The protocol states that when the eligibility of a trial is judged, the results section of the publication would be masked, but
results were not masked when review authors judged eligibility
• The protocol predates the current Cochrane risk of bias tool, which we used for the review
• With the exception of Prof Malcolm W Reed, the review authors are different from those listed in the protocol
• We have updated the background section of the review
• We used the GRADE approach to interpret review findings
• We included an additional comparison of less surgery versus ALND, which combines comparisons 1, 2, 3 and 7 (see Types of
interventions section)
238Axillary treatment for operable primary breast cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
N O T E S
We have added a new review author, Eifiona Wood, to the protocol (10/05/2004).
We have added a new comparison to the protocol along with the following text added to the section titled “Criteria for considering
studies for this review” (10/05/2004).
7) Full axillary surgery with no radiotherapy versus no axillary surgery with radiotherapy.
No subgroups.
We added comparison ’7’ to the original protocol in response to retrieval of large numbers of trial reports pertaining to this question.
The review authors recognise that, unlike comparisons 1 through 6, comparison 7 does not address the effectiveness of axillary surgery.
A regimen in comparison 1 - full axillary surgery plus radiotherapy - was standard practice but has been largely discontinued because
of the illogic of irradiating the axilla subsequent to removal of the lymph nodes. The regimen in comparison 7 - no axillary surgery
with radiotherapy - reflects more current practice; although it is considered irrelevant to a younger, fitter population, some clinicians
still consider it a viable treatment option for older women.
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